CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: steroid ester
Accession: CHEBI:47880
browse the term
Synonyms: related_synonym: steroid esters
alt_id: CHEBI:26762
xref: KEGG:C15506
G
Gsta1
glutathione S-transferase alpha 1
multiple interactions
ISO
estradiol 3,17-disulfate binds to and results in decreased activity of GSTA1 protein
CTD
PMID:12206662
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
G
Srd5a2
steroid 5 alpha-reductase 2
decreases abundance
ISO
SRD5A2 gene SNP results in decreased abundance of androstane-3,17-diol glucuronide
CTD
PMID:17136762
NCBI chr 6:21,426,225...21,465,727
Ensembl chr 6:21,426,215...21,462,112
G
Ccl2
C-C motif chemokine ligand 2
decreases expression
ISO
alclometasone dipropionate results in decreased expression of CCL2 protein
CTD
PMID:20116850
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
G
Ccl3
C-C motif chemokine ligand 3
increases expression
ISO
alclometasone dipropionate results in increased expression of CCL3 protein
CTD
PMID:20116850
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
G
Ccl4
C-C motif chemokine ligand 4
increases expression
ISO
alclometasone dipropionate results in increased expression of CCL4 protein
CTD
PMID:20116850
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
G
Csf2
colony stimulating factor 2
decreases expression
ISO
alclometasone dipropionate results in decreased expression of CSF2 protein
CTD
PMID:11407316
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
G
Ifng
interferon gamma
decreases expression
ISO
alclometasone dipropionate results in decreased expression of IFNG protein
CTD
PMID:11407316
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
G
Il2
interleukin 2
decreases expression
ISO
alclometasone dipropionate results in decreased expression of IL2 protein
CTD
PMID:11407316
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
G
Il3
interleukin 3
decreases expression
ISO
alclometasone dipropionate results in decreased expression of IL3 protein
CTD
PMID:11407316
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
G
Il4
interleukin 4
decreases expression
ISO
alclometasone dipropionate results in decreased expression of IL4 protein
CTD
PMID:11407316
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
G
Il5
interleukin 5
decreases expression
ISO
alclometasone dipropionate results in decreased expression of IL5 protein
CTD
PMID:11407316
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
G
Vegfa
vascular endothelial growth factor A
decreases expression
ISO
alclometasone dipropionate results in decreased expression of VEGFA protein
CTD
PMID:20116850
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
G
Ahr
aryl hydrocarbon receptor
increases abundance multiple interactions
ISO
AHR protein results in increased abundance of androstane-3,17-diol dipropionate AHR protein affects the reaction [Tetrachlorodibenzodioxin results in decreased abundance of androstane-3,17-diol dipropionate]
CTD
PMID:12151645
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
G
Gstp1
glutathione S-transferase pi 1
multiple interactions
ISO
betamethasone-17,21-dipropionate inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]
CTD
PMID:23769903
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
G
Cd40
CD40 molecule
decreases expression
ISO
Betamethasone Valerate results in decreased expression of CD40 protein
CTD
PMID:15940147
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
G
Cd83
CD83 molecule
decreases expression
ISO
Betamethasone Valerate results in decreased expression of CD83 protein
CTD
PMID:15940147
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
G
Cd86
CD86 molecule
decreases expression
ISO
Betamethasone Valerate results in decreased expression of CD86 protein
CTD
PMID:15940147
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
G
Csf2
colony stimulating factor 2
decreases expression
ISO
Betamethasone Valerate results in decreased expression of CSF2 protein
CTD
PMID:11407316
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
G
Ifng
interferon gamma
decreases expression
ISO
Betamethasone Valerate results in decreased expression of IFNG protein
CTD
PMID:11407316
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
G
Il2
interleukin 2
decreases expression
ISO
Betamethasone Valerate results in decreased expression of IL2 protein
CTD
PMID:11407316
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
G
Il3
interleukin 3
decreases expression
ISO
Betamethasone Valerate results in decreased expression of IL3 protein
CTD
PMID:11407316
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
G
Il4
interleukin 4
decreases expression
ISO
Betamethasone Valerate results in decreased expression of IL4 protein
CTD
PMID:11407316
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
G
Il5
interleukin 5
decreases expression
ISO
Betamethasone Valerate results in decreased expression of IL5 protein
CTD
PMID:11407316
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
G
Cyp11a1
cytochrome P450, family 11, subfamily a, polypeptide 1
decreases expression
ISO
cholesteryl sulfate results in decreased expression of CYP11A1 mRNA
CTD
PMID:18490834
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
G
Star
steroidogenic acute regulatory protein
decreases expression
ISO
cholesteryl sulfate results in decreased expression of STAR mRNA; cholesteryl sulfate results in decreased expression of STAR protein
CTD
PMID:18490834
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
G
Sult2b1
sulfotransferase family 2B member 1
increases abundance
ISO
SULT2B1 protein results in increased abundance of cholesteryl sulfate
CTD
PMID:27052460
NCBI chr 1:96,200,155...96,261,295
Ensembl chr 1:96,200,156...96,261,295
G
Lipc
lipase C, hepatic type
multiple interactions
ISO
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate
CTD
PMID:24777581
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
G
Lipg
lipase G, endothelial type
multiple interactions decreases abundance
ISO
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate LIPG gene mutant form results in decreased abundance of cholesteryl arachidonate
CTD
PMID:24777581
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
G
Lipc
lipase C, hepatic type
multiple interactions
ISO
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate
CTD
PMID:24777581
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
G
Lipg
lipase G, endothelial type
multiple interactions affects abundance
ISO
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate LIPG gene mutant form affects the abundance of cholesteryl linoleate
CTD
PMID:24777581
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
G
Lipc
lipase C, hepatic type
multiple interactions
ISO
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linolenate
CTD
PMID:24777581
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
G
Lipg
lipase G, endothelial type
multiple interactions increases abundance
ISO
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linolenate LIPG gene mutant form results in increased abundance of cholesteryl linolenate
CTD
PMID:24777581
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
G
Lipc
lipase C, hepatic type
multiple interactions
ISO
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl myristate
CTD
PMID:24777581
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
G
Lipg
lipase G, endothelial type
affects abundance multiple interactions
ISO
LIPG gene mutant form affects the abundance of cholesteryl myristate [LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl myristate
CTD
PMID:24777581
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
G
Lipc
lipase C, hepatic type
multiple interactions
ISO
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl oleate
CTD
PMID:24777581
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
G
Lipg
lipase G, endothelial type
multiple interactions increases abundance
ISO
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl oleate LIPG gene mutant form results in increased abundance of cholesteryl oleate
CTD
PMID:24777581
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
G
Lipc
lipase C, hepatic type
multiple interactions
ISO
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl palmitate
CTD
PMID:24777581
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
G
Lipg
lipase G, endothelial type
multiple interactions increases abundance
ISO
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl palmitate LIPG gene mutant form results in increased abundance of cholesteryl palmitate
CTD
PMID:24777581
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
G
Lipg
lipase G, endothelial type
decreases abundance
ISO
LIPG gene mutant form results in decreased abundance of cholesterol stearate
CTD
PMID:24777581
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
G
Adipoq
adiponectin, C1Q and collagen domain containing
multiple interactions
ISO
Cyproterone Acetate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]
CTD
PMID:29782964
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
G
Apoa1
apolipoprotein A1
affects expression
ISO
Cyproterone Acetate affects the expression of APOA1 protein
CTD
PMID:16323982
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
G
Apoa2
apolipoprotein A2
affects expression
ISO
Cyproterone Acetate affects the expression of APOA2 protein
CTD
PMID:16323982
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
G
Ar
androgen receptor
multiple interactions increases response to substance affects localization decreases activity affects binding increases expression decreases expression
ISO EXP
[AR protein mutant form results in increased susceptibility to Cyproterone Acetate] which results in increased activity of AR protein mutant form; [Cyproterone Acetate binds to and affects the folding of AR protein] affects the reaction [AR protein modified form binds to NFKBIB protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] affects the reaction [AR protein modified form binds to NR0B1 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to HELZ2 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to MEN1 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to NCOR1 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to NRIP1 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to PELP1 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to PGR protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to PPRC1 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to TGFB1I1 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to TRERF1 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to UBE3A protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to AR protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to BLOC1S1 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to BRD8 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to CHD9 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to CNOT1 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to CREBBP protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to DHX30 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to EP300 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to GNAQ protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to ITGB3BP protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to KIF11 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to MED1 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to MTA1 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to NCOA2 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to NCOA3 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to NR0B2 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to NRBF2 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to PNRC2 protein modified form]; [Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to PRAME protein modified form]; [Cyproterone Acetate binds to AR protein] promotes the reaction [CREBBP protein binds to KLK3 enhancer]; [Cyproterone Acetate binds to AR protein] promotes the reaction [CREBBP protein binds to KLK3 promoter]; [Cyproterone Acetate binds to AR protein] promotes the reaction [NCOA2 protein binds to KLK3 enhancer]; [Cyproterone Acetate binds to AR protein] promotes the reaction [NCOA2 protein binds to KLK3 promoter]; [Cyproterone Acetate binds to AR protein] promotes the reaction [NCOR1 protein binds to KLK3 promoter]; Cyproterone Acetate binds to and affects the folding of AR protein; Cyproterone Acetate binds to and results in decreased activity of AR protein; Cyproterone Acetate binds to and results in increased activity of AR protein; Cyproterone Acetate inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; Cyproterone Acetate inhibits the reaction [[Dihydrotestosterone binds to and results in increased activity of AR protein] which results in increased expression of KLK3 protein]; Cyproterone Acetate inhibits the reaction [[Metribolone binds to and results in increased activity of AR protein] which results in increased expression of KLK3 protein]; Cyproterone Acetate inhibits the reaction [Cadmium Chloride results in decreased expression of AR protein]; Cyproterone Acetate inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; Cyproterone Acetate inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; Cyproterone Acetate inhibits the reaction [Metribolone results in increased activity of AR protein]; Cyproterone Acetate promotes the reaction [Metribolone results in increased expression of AR mRNA]; NCOA1 protein results in increased activity of [Cyproterone Acetate binds to AR protein]; PA2G4 protein inhibits the reaction [Cyproterone Acetate promotes the reaction [Metribolone results in increased expression of AR mRNA]]; PA2G4 protein inhibits the reaction [Cyproterone Acetate results in increased expression of AR mRNA] Cyproterone Acetate affects the localization of AR protein Cyproterone Acetate results in decreased activity of AR protein [Cyproterone Acetate binds to AR protein] which binds to KLK3 enhancer; [Cyproterone Acetate binds to AR protein] which binds to KLK3 promoter; Cyproterone Acetate binds to AR protein Cyproterone Acetate results in decreased expression of AR mRNA
CTD
PMID:10053169 PMID:11751618 PMID:14565775 PMID:14751673 PMID:15084347 PMID:15110108 PMID:15308689 PMID:15336702 PMID:15483189 PMID:15994225 PMID:17505938 PMID:17804755 PMID:18324785 PMID:21543282 PMID:23562765 PMID:27473015 PMID:28751236 PMID:33049310 More...
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Bloc1s1
biogenesis of lysosomal organelles complex-1, subunit 1
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to BLOC1S1 protein modified form]
CTD
PMID:28751236
NCBI chr 7:1,347,495...1,351,103
Ensembl chr 7:1,340,934...1,351,558
G
Brd8
bromodomain containing 8
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to BRD8 protein modified form]
CTD
PMID:28751236
NCBI chr18:26,204,892...26,229,999
Ensembl chr18:26,181,732...26,229,884
G
Ccr1
C-C motif chemokine receptor 1
multiple interactions
ISO
[Ethinyl Estradiol co-treated with Cyproterone Acetate] results in increased expression of CCR1 protein
CTD
PMID:10770211
NCBI chr 8:123,556,286...123,561,841
G
Ccr5
C-C motif chemokine receptor 5
multiple interactions
ISO
[Ethinyl Estradiol co-treated with Cyproterone Acetate] results in increased expression of CCR5 protein
CTD
PMID:10770211
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
G
Chd9
chromodomain helicase DNA binding protein 9
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to CHD9 protein modified form]
CTD
PMID:28751236
NCBI chr19:15,941,535...16,146,220
Ensembl chr19:15,942,687...16,164,556
G
Cnot1
CCR4-NOT transcription complex, subunit 1
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to CNOT1 protein modified form]
CTD
PMID:28751236
NCBI chr19:9,255,190...9,346,574
Ensembl chr19:9,255,194...9,346,574
G
Crebbp
CREB binding protein
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to CREBBP protein modified form]; [Cyproterone Acetate binds to AR protein] promotes the reaction [CREBBP protein binds to KLK3 enhancer]; [Cyproterone Acetate binds to AR protein] promotes the reaction [CREBBP protein binds to KLK3 promoter]
CTD
PMID:15308689 PMID:28751236
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
G
Crp
C-reactive protein
multiple interactions
ISO
[Ethinyl Estradiol co-treated with Cyproterone Acetate] results in increased expression of CRP protein
CTD
PMID:14557435
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
G
Cxcr3
C-X-C motif chemokine receptor 3
multiple interactions
ISO
[Ethinyl Estradiol co-treated with Cyproterone Acetate] results in increased expression of CXCR3 protein
CTD
PMID:10770211
NCBI chr X:66,844,318...66,846,969
Ensembl chr X:66,844,318...66,846,969
G
Cyp1a1
cytochrome P450, family 1, subfamily a, polypeptide 1
decreases activity
ISO
Cyproterone Acetate results in decreased activity of CYP1A1 protein
CTD
PMID:34181028
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
G
Cyp2b3
cytochrome P450, family 2, subfamily b, polypeptide 3
increases expression
ISO
Cyproterone Acetate results in increased expression of CYP2B10 mRNA
CTD
PMID:28541575
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
G
Cyp2c24
cytochrome P450, family 2, subfamily c, polypeptide 24
increases expression
ISO
Cyproterone Acetate results in increased expression of CYP2C55 mRNA
CTD
PMID:28541575
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
G
Cyp3a2
cytochrome P450, family 3, subfamily a, polypeptide 2
increases expression
ISO
Cyproterone Acetate results in increased expression of CYP3A4 mRNA
CTD
PMID:12505310
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
G
Dhx30
DExH-box helicase 30
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to DHX30 protein modified form]
CTD
PMID:28751236
NCBI chr 8:110,064,751...110,096,954
Ensembl chr 8:110,064,752...110,097,381
G
Egf
epidermal growth factor
multiple interactions
EXP
[EGF protein co-treated with Cyproterone Acetate] results in increased expression of MYC mRNA
CTD
PMID:12632255
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
G
Ep300
E1A binding protein p300
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to EP300 protein modified form]
CTD
PMID:28751236
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
G
Esr1
estrogen receptor 1
multiple interactions
ISO
Cyproterone Acetate binds to and results in increased activity of ESR1 protein
CTD
PMID:33049310
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Esr2
estrogen receptor 2
multiple interactions
ISO
Cyproterone Acetate binds to and results in increased activity of ESR2 protein
CTD
PMID:33049310
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
G
Fabp4
fatty acid binding protein 4
multiple interactions
ISO
[Cyproterone Acetate co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein; Cyproterone Acetate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]
CTD
PMID:29782964
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
G
Fshb
follicle stimulating hormone subunit beta
multiple interactions decreases expression
ISO
[Ethinyl Estradiol co-treated with Cyproterone Acetate] results in decreased expression of FSHB protein Cyproterone Acetate results in decreased expression of FSHB protein
CTD
PMID:11994349 PMID:16002536
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
G
Gnaq
G protein subunit alpha q
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to GNAQ protein modified form]
CTD
PMID:28751236
NCBI chr 1:213,425,631...213,671,947
Ensembl chr 1:213,424,465...213,667,672
G
Greb1
growth regulating estrogen receptor binding 1
multiple interactions
ISO
Cyproterone Acetate inhibits the reaction [Testosterone results in increased expression of GREB1 mRNA]
CTD
PMID:16496412
NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633
G
Helz2
helicase with zinc finger 2
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to HELZ2 protein modified form]
CTD
PMID:28751236
NCBI chr 3:168,338,813...168,353,219
Ensembl chr 3:168,338,813...168,353,159
G
Igf1
insulin-like growth factor 1
multiple interactions
ISO
[Ethinyl Estradiol co-treated with Cyproterone Acetate] results in decreased expression of IGF1 protein
CTD
PMID:16002536
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
G
Ins2
insulin 2
multiple interactions
ISO
[Cyproterone Acetate co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein; Cyproterone Acetate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; Cyproterone Acetate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]
CTD
PMID:29782964
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
G
Itgb3bp
integrin subunit beta 3 binding protein
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to ITGB3BP protein modified form]
CTD
PMID:28751236
NCBI chr 5:114,460,217...114,525,538
Ensembl chr 5:114,460,221...114,525,704
G
Kif11
kinesin family member 11
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to KIF11 protein modified form]
CTD
PMID:28751236
NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766
G
Klk1c10
kallikrein 1-related peptidase C10
affects binding decreases expression multiple interactions
ISO
[Cyproterone Acetate binds to AR protein] which binds to KLK3 enhancer; [Cyproterone Acetate binds to AR protein] which binds to KLK3 promoter Cyproterone Acetate results in decreased expression of KLK3 protein [Cyproterone Acetate binds to AR protein] promotes the reaction [CREBBP protein binds to KLK3 enhancer]; [Cyproterone Acetate binds to AR protein] promotes the reaction [CREBBP protein binds to KLK3 promoter]; [Cyproterone Acetate binds to AR protein] promotes the reaction [NCOA2 protein binds to KLK3 enhancer]; [Cyproterone Acetate binds to AR protein] promotes the reaction [NCOA2 protein binds to KLK3 promoter]; [Cyproterone Acetate binds to AR protein] promotes the reaction [NCOR1 protein binds to KLK3 promoter]; [Cyproterone Acetate co-treated with Estradiol] results in decreased expression of KLK3 protein; [Cyproterone Acetate co-treated with Ethinyl Estradiol] results in decreased expression of KLK3 protein; Cyproterone Acetate inhibits the reaction [[Dihydrotestosterone binds to and results in increased activity of AR protein] which results in increased expression of KLK3 protein]; Cyproterone Acetate inhibits the reaction [[Metribolone binds to and results in increased activity of AR protein] which results in increased expression of KLK3 protein]
CTD
PMID:10687981 PMID:15308689 PMID:15336702
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
G
Kpna1
karyopherin subunit alpha 1
increases expression
EXP
Cyproterone Acetate results in increased expression of KPNA1 mRNA
CTD
PMID:16906019
NCBI chr11:64,715,844...64,774,647
Ensembl chr11:64,717,563...64,774,623
G
Kpna2
karyopherin subunit alpha 2
decreases expression increases expression
EXP
Cyproterone Acetate results in decreased expression of KPNA2 mRNA Cyproterone Acetate results in increased expression of KPNA2 mRNA
CTD
PMID:16906019
NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150
G
Kpna3
karyopherin subunit alpha 3
increases expression
EXP
Cyproterone Acetate results in increased expression of KPNA3 mRNA
CTD
PMID:16906019
NCBI chr15:35,536,310...35,610,066
Ensembl chr15:35,536,316...35,610,419
G
Kpna4
karyopherin subunit alpha 4
decreases expression
EXP
Cyproterone Acetate results in decreased expression of KPNA4 mRNA
CTD
PMID:16906019
NCBI chr 2:153,319,380...153,381,085
Ensembl chr 2:153,324,273...153,381,081
G
Kpna5
karyopherin subunit alpha 5
decreases expression
EXP
Cyproterone Acetate results in decreased expression of KPNA5 mRNA
CTD
PMID:16906019
NCBI chr20:30,822,925...30,888,080
Ensembl chr20:30,822,935...30,888,078
G
Lhb
luteinizing hormone subunit beta
decreases expression multiple interactions increases expression
ISO EXP
Cyproterone Acetate results in decreased expression of LHB protein Cyproterone Acetate inhibits the reaction [testosterone enanthate results in decreased expression of LHB protein] Cyproterone Acetate results in increased expression of LHB protein [Ethinyl Estradiol co-treated with Cyproterone Acetate] results in decreased expression of LHB protein
CTD
PMID:11994349 PMID:16002536 PMID:20463352 PMID:23085480
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
G
Med1
mediator complex subunit 1
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to MED1 protein modified form]
CTD
PMID:28751236
NCBI chr10:83,145,538...83,189,260
Ensembl chr10:83,145,568...83,189,299
G
Men1
menin 1
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to MEN1 protein modified form]
CTD
PMID:28751236
NCBI chr 1:203,638,905...203,644,871
Ensembl chr 1:203,639,000...203,644,871
G
Mta1
metastasis associated 1
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to MTA1 protein modified form]
CTD
PMID:28751236
NCBI chr 6:132,178,608...132,217,641
Ensembl chr 6:132,178,853...132,217,641
G
Myc
MYC proto-oncogene, bHLH transcription factor
multiple interactions
EXP
[EGF protein co-treated with Cyproterone Acetate] results in increased expression of MYC mRNA
CTD
PMID:12632255
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
G
Ncoa1
nuclear receptor coactivator 1
multiple interactions
ISO
NCOA1 protein results in increased activity of [Cyproterone Acetate binds to AR protein]
CTD
PMID:17804755
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
G
Ncoa2
nuclear receptor coactivator 2
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to NCOA2 protein modified form]; [Cyproterone Acetate binds to AR protein] promotes the reaction [NCOA2 protein binds to KLK3 enhancer]; [Cyproterone Acetate binds to AR protein] promotes the reaction [NCOA2 protein binds to KLK3 promoter]
CTD
PMID:15308689 PMID:28751236
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
G
Ncoa3
nuclear receptor coactivator 3
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to NCOA3 protein modified form]
CTD
PMID:28751236
NCBI chr 3:154,738,566...154,821,395
Ensembl chr 3:154,738,581...154,818,594
G
Ncor1
nuclear receptor co-repressor 1
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to NCOR1 protein modified form]; [Cyproterone Acetate binds to AR protein] promotes the reaction [NCOR1 protein binds to KLK3 promoter]
CTD
PMID:15308689 PMID:28751236
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
G
Nfe2l2
NFE2 like bZIP transcription factor 2
increases activity
ISO
Cyproterone Acetate results in increased activity of NFE2L2 protein
CTD
PMID:30203046
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
G
Nfkbib
NFKB inhibitor beta
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] affects the reaction [AR protein modified form binds to NFKBIB protein modified form]
CTD
PMID:28751236
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
G
Nos2
nitric oxide synthase 2
multiple interactions decreases expression
EXP
Cyproterone Acetate inhibits the reaction [testosterone enanthate results in increased expression of NOS2 mRNA]; Cyproterone Acetate inhibits the reaction [testosterone enanthate results in increased expression of NOS2 protein] Cyproterone Acetate results in decreased expression of NOS2 mRNA
CTD
PMID:20463352 PMID:23085480
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
G
Nr0b1
nuclear receptor subfamily 0, group B, member 1
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] affects the reaction [AR protein modified form binds to NR0B1 protein modified form]
CTD
PMID:28751236
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
G
Nr0b2
nuclear receptor subfamily 0, group B, member 2
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to NR0B2 protein modified form]
CTD
PMID:28751236
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
G
Nr1i2
nuclear receptor subfamily 1, group I, member 2
multiple interactions
ISO
Cyproterone Acetate binds to and results in increased activity of NR1I2 protein
CTD
PMID:33049310
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
G
Nr1i3
nuclear receptor subfamily 1, group I, member 3
increases activity
ISO
Cyproterone Acetate results in increased activity of NR1I3 protein
CTD
PMID:30203046
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
G
Nrbf2
nuclear receptor binding factor 2
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to NRBF2 protein modified form]
CTD
PMID:28751236
NCBI chr20:21,308,555...21,326,881
Ensembl chr20:21,308,576...21,326,818
G
Nrip1
nuclear receptor interacting protein 1
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to NRIP1 protein modified form]
CTD
PMID:28751236
NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761
G
Pa2g4
proliferation-associated 2G4
multiple interactions
ISO
PA2G4 protein inhibits the reaction [Cyproterone Acetate promotes the reaction [Metribolone results in increased expression of AR mRNA]]; PA2G4 protein inhibits the reaction [Cyproterone Acetate results in increased expression of AR mRNA]
CTD
PMID:15994225
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
G
Pde5a
phosphodiesterase 5A
multiple interactions
EXP
Cyproterone Acetate inhibits the reaction [testosterone enanthate results in increased expression of PDE5A mRNA]
CTD
PMID:20463352
NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701
G
Pelp1
proline, glutamate and leucine rich protein 1
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to PELP1 protein modified form]
CTD
PMID:28751236
NCBI chr10:55,094,798...55,111,833
Ensembl chr10:55,094,796...55,111,994
G
Pgr
progesterone receptor
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to PGR protein modified form]; Cyproterone Acetate binds to and results in increased activity of PGR protein
CTD
PMID:20599585 PMID:28751236
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
G
Pnrc2
proline-rich nuclear receptor coactivator 2
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to PNRC2 protein modified form]
CTD
PMID:28751236
NCBI chr 5:148,103,966...148,106,950
Ensembl chr 5:148,095,699...148,107,242 Ensembl chr 5:148,095,699...148,107,242
G
Pparg
peroxisome proliferator-activated receptor gamma
multiple interactions
ISO
Cyproterone Acetate binds to and results in increased activity of PPARG protein
CTD
PMID:33049310
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
G
Pprc1
PPARG related coactivator 1
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to PPRC1 protein modified form]
CTD
PMID:28751236
NCBI chr 1:244,901,985...244,918,587
Ensembl chr 1:244,902,179...244,918,587
G
Pramex1
PRAME like, X-linked 1
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] promotes the reaction [AR protein modified form binds to PRAME protein modified form]
CTD
PMID:28751236
NCBI chr X:98,567,994...98,574,654
Ensembl chr X:98,569,415...98,572,096
G
Prl
prolactin
multiple interactions
ISO EXP
[Cyproterone Acetate co-treated with Ethinyl Estradiol] results in decreased expression of PRL protein Cyproterone Acetate inhibits the reaction [Testosterone results in decreased expression of PRL mRNA]
CTD
PMID:3157511 PMID:25603467
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
G
Prlr
prolactin receptor
multiple interactions increases expression
EXP
[Cyproterone Acetate co-treated with Testosterone] results in increased expression of PRLR mRNA Cyproterone Acetate results in increased expression of PRLR mRNA
CTD
PMID:25603467
NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718
G
Tfrc
transferrin receptor
multiple interactions
ISO
[Ethinyl Estradiol co-treated with Cyproterone Acetate] results in decreased expression of TFRC protein
CTD
PMID:16002536
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
G
Tgfb1i1
transforming growth factor beta 1 induced transcript 1
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to TGFB1I1 protein modified form]
CTD
PMID:28751236
NCBI chr 1:182,828,553...182,835,465
Ensembl chr 1:182,828,544...182,837,080
G
Trerf1
transcriptional regulating factor 1
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to TRERF1 protein modified form]
CTD
PMID:28751236
NCBI chr 9:13,631,619...13,858,326
Ensembl chr 9:13,634,126...13,857,029
G
Ube3a
ubiquitin protein ligase E3A
multiple interactions
ISO
[Cyproterone Acetate binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to UBE3A protein modified form]
CTD
PMID:28751236
NCBI chr 1:110,070,260...110,161,675
Ensembl chr 1:110,070,480...110,157,250
G
Abcb11
ATP binding cassette subfamily B member 11
decreases activity multiple interactions
ISO
Dehydroepiandrosterone Sulfate results in decreased activity of ABCB11 protein Dehydroepiandrosterone Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
CTD
PMID:24014644
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
G
Acox1
acyl-CoA oxidase 1
increases expression multiple interactions
ISO
Dehydroepiandrosterone Sulfate results in increased expression of ACOX1 mRNA PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of ACOX1 mRNA]
CTD
PMID:8700121
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
G
Bcl2
BCL2, apoptosis regulator
increases expression multiple interactions
EXP
Dehydroepiandrosterone Sulfate results in increased expression of BCL2 protein Pertussis Toxin inhibits the reaction [Dehydroepiandrosterone Sulfate results in increased expression of BCL2 protein]
CTD
PMID:16407456
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
G
Bcl2l1
Bcl2-like 1
increases expression multiple interactions
EXP
Dehydroepiandrosterone Sulfate results in increased expression of BCL2L1 protein Pertussis Toxin inhibits the reaction [Dehydroepiandrosterone Sulfate results in increased expression of BCL2L1 protein]
CTD
PMID:16407456
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
G
Cpt1a
carnitine palmitoyltransferase 1A
multiple interactions increases expression
EXP
[Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CPT1A protein Dehydroepiandrosterone Sulfate results in increased expression of CPT1A protein
CTD
PMID:25786523
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
G
Cyp2c11
cytochrome P450, subfamily 2, polypeptide 11
multiple interactions
EXP
[Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CYP2C11 protein
CTD
PMID:25786523
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
G
Cyp2c6
cytochrome P450, family 2, subfamily C, polypeptide 6
multiple interactions
EXP
[Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CYP2C6 protein
CTD
PMID:25786523
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
G
Cyp3a2
cytochrome P450, family 3, subfamily a, polypeptide 2
multiple interactions affects metabolic processing
EXP ISO
[Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CYP3A2 protein CYP3A4 protein affects the metabolism of Dehydroepiandrosterone Sulfate
CTD
PMID:2271712 PMID:25786523
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
G
Cyp4a1
cytochrome P450, family 4, subfamily a, polypeptide 1
increases expression multiple interactions
EXP
Dehydroepiandrosterone Sulfate results in increased expression of CYP4A1 mRNA; Dehydroepiandrosterone Sulfate results in increased expression of CYP4A1 protein [Dehydroepiandrosterone Sulfate co-treated with Phenobarbital] results in increased expression of CYP4A1 protein
CTD
PMID:8700121 PMID:25786523
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
G
Cyp4a3
cytochrome P450, family 4, subfamily a, polypeptide 3
increases expression
EXP
Dehydroepiandrosterone Sulfate results in increased expression of CYP4A3 mRNA
CTD
PMID:8700121
NCBI chr 5:129,097,571...129,115,488
Ensembl chr 5:129,097,926...129,115,463
G
Ehhadh
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase
increases expression multiple interactions
ISO
Dehydroepiandrosterone Sulfate results in increased expression of EHHADH mRNA PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of EHHADH mRNA]
CTD
PMID:8700121
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
G
Fabp1
fatty acid binding protein 1
increases expression multiple interactions
ISO
Dehydroepiandrosterone Sulfate results in increased expression of FABP1 mRNA PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of FABP1 mRNA]
CTD
PMID:8700121
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
G
Fos
Fos proto-oncogene, AP-1 transcription factor subunit
multiple interactions
ISO
[Morphine co-treated with Dehydroepiandrosterone Sulfate] results in decreased expression of FOS protein
CTD
PMID:15196791
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
G
Il1b
interleukin 1 beta
multiple interactions increases abundance
ISO
Dexamethasone inhibits the reaction [IL1B protein results in increased abundance of Dehydroepiandrosterone Sulfate]
CTD
PMID:12548226
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Mapk1
mitogen activated protein kinase 1
multiple interactions
ISO
[Morphine co-treated with Dehydroepiandrosterone Sulfate] results in decreased phosphorylation of MAPK1 protein
CTD
PMID:15196791
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
G
Nat1
N-acetyltransferase 1
multiple interactions
ISO
Dehydroepiandrosterone Sulfate inhibits the reaction [NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid]; Dehydroepiandrosterone Sulfate promotes the reaction [NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid]
CTD
PMID:11470991
NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520
G
Pomc
proopiomelanocortin
increases abundance
ISO
POMC results in increased abundance of Dehydroepiandrosterone Sulfate
CTD
PMID:2161262
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
G
Ppara
peroxisome proliferator activated receptor alpha
multiple interactions increases response to substance
ISO
PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of ACOX1 mRNA]; PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of CYP4A1 mRNA]; PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of CYP4A3 mRNA]; PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of EHHADH mRNA]; PPARA protein affects the reaction [Dehydroepiandrosterone Sulfate results in increased expression of FABP1 mRNA] PPARA protein results in increased susceptibility to Dehydroepiandrosterone Sulfate
CTD
PMID:8700121
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
G
Prl
prolactin
increases abundance
ISO
PRL protein results in increased abundance of Dehydroepiandrosterone Sulfate
CTD
PMID:2943108
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
G
Sirt1
sirtuin 1
increases expression
EXP
Dehydroepiandrosterone Sulfate results in increased expression of SIRT1 protein
CTD
PMID:25786523
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
G
Sirt6
sirtuin 6
increases expression
EXP
Dehydroepiandrosterone Sulfate results in increased expression of SIRT6 protein
CTD
PMID:25786523
NCBI chr 7:8,082,312...8,087,776
Ensembl chr 7:8,082,364...8,098,914
G
Slc10a6
solute carrier family 10 member 6
increases transport
ISO
SLC10A6 protein results in increased transport of Dehydroepiandrosterone Sulfate
CTD
PMID:23562556
NCBI chr14:6,080,716...6,102,902
Ensembl chr14:6,080,717...6,103,037
G
Slc22a12
solute carrier family 22 member 12
multiple interactions
ISO
Potassium promotes the reaction [SLC22A12 protein results in increased uptake of Dehydroepiandrosterone Sulfate]
CTD
PMID:15284287
NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555
G
Slc22a25
solute carrier family 22, member 25
increases uptake affects transport multiple interactions
EXP ISO
SLC22A9 protein results in increased uptake of Dehydroepiandrosterone Sulfate SLC22A19 protein affects the transport of Dehydroepiandrosterone Sulfate Dehydroepiandrosterone Sulfate inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]
CTD
PMID:16079298 PMID:17132213 PMID:18441515
NCBI chr 1:205,338,698...205,498,486
Ensembl chr 1:205,338,699...205,433,085
G
Slc22a7
solute carrier family 22 member 7
increases transport
ISO
SLC22A7 protein results in increased transport of Dehydroepiandrosterone Sulfate
CTD
PMID:15901346
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
G
Slc22a8
solute carrier family 22 member 8
affects transport increases uptake
ISO
SLC22A8 protein affects the transport of Dehydroepiandrosterone Sulfate SLC22A8 protein results in increased uptake of Dehydroepiandrosterone Sulfate
CTD
PMID:11306713 PMID:16098483 PMID:17255469
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
G
Slco1b2
solute carrier organic anion transporter family member 1B2
multiple interactions
ISO
Dehydroepiandrosterone Sulfate inhibits the reaction [SLCO1B3 protein results in increased susceptibility to cyanoginosin LR]; Dehydroepiandrosterone Sulfate inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Okadaic Acid]
CTD
PMID:26134461
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
G
Src
SRC proto-oncogene, non-receptor tyrosine kinase
increases phosphorylation
EXP
Dehydroepiandrosterone Sulfate results in increased phosphorylation of SRC protein
CTD
PMID:16407456
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
G
Sts
steroid sulfatase
affects metabolic processing
ISO
STS protein affects the metabolism of Dehydroepiandrosterone Sulfate
CTD
PMID:16054388
NCBI chr X:42,225,131...42,233,403
Ensembl chr X:42,225,372...42,233,402
G
Acta2
actin alpha 2, smooth muscle
multiple interactions
ISO
eplerenone inhibits the reaction [Aldosterone results in increased expression of ACTA2 mRNA]; eplerenone inhibits the reaction [Aldosterone results in increased expression of ACTA2 protein]
CTD
PMID:17596522
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
G
Agt
angiotensinogen
multiple interactions
ISO
eplerenone inhibits the reaction [AGT protein results in increased phosphorylation of OSR1 protein]; eplerenone inhibits the reaction [AGT protein results in increased phosphorylation of SLC12A3 protein]
CTD
PMID:20175999
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
G
Cat
catalase
increases expression
EXP
eplerenone results in increased expression of CAT protein
CTD
PMID:17324946
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
G
Cd80
Cd80 molecule
multiple interactions
EXP
Eplerenone inhibits the reaction [[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of CD80 mRNA]
CTD
PMID:27773435
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
G
Cdh1
cadherin 1
multiple interactions
ISO
eplerenone inhibits the reaction [Aldosterone results in decreased expression of CDH1 mRNA]; eplerenone inhibits the reaction [Aldosterone results in decreased expression of CDH1 protein]
CTD
PMID:17596522
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
G
Col1a1
collagen type I alpha 1 chain
multiple interactions
EXP
Eplerenone inhibits the reaction [[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of COL1A1 mRNA]
CTD
PMID:27773435
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
G
Col3a1
collagen type III alpha 1 chain
multiple interactions
EXP
Eplerenone inhibits the reaction [[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of COL3A1 mRNA]
CTD
PMID:27773435
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
G
Col4a1
collagen type IV alpha 1 chain
multiple interactions decreases expression
EXP
[eplerenone co-treated with Enalapril] inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]]; [eplerenone co-treated with Enalapril] results in decreased expression of COL4A1 mRNA; [eplerenone co-treated with Enalapril] results in decreased expression of COL4A1 protein; eplerenone inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]] eplerenone results in decreased expression of COL4A1 mRNA; eplerenone results in decreased expression of COL4A1 protein
CTD
PMID:18682491
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
G
Cyba
cytochrome b-245 alpha chain
decreases expression multiple interactions
EXP
eplerenone results in decreased expression of CYBA mRNA [trandolapril co-treated with eplerenone] results in decreased expression of CYBA mRNA
CTD
PMID:17324946
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
G
Cyp3a2
cytochrome P450, family 3, subfamily a, polypeptide 2
increases abundance increases metabolic processing
ISO
CYP3A4 protein results in increased abundance of Eplerenone metabolite CYP3A4 protein results in increased metabolism of Eplerenone
CTD
PMID:31408697
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
G
Cyp3a9
cytochrome P450, family 3, subfamily a, polypeptide 9
increases abundance increases metabolic processing
ISO
CYP3A5 protein results in increased abundance of Eplerenone metabolite CYP3A5 protein results in increased metabolism of Eplerenone
CTD
PMID:31408697
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
G
Fn1
fibronectin 1
multiple interactions
EXP
[trandolapril co-treated with eplerenone] results in decreased expression of FN1 protein
CTD
PMID:17324946
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
G
Il18
interleukin 18
multiple interactions
EXP
eplerenone inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]
CTD
PMID:18660453
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
G
Il1b
interleukin 1 beta
decreases expression
EXP
eplerenone decreases expression of protein in hippocampus of post-surgical rats
RGD
PMID:33390808
RGD:401965467
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Il6
interleukin 6
decreases expression
EXP
eplerenone decreases expression of protein in hippocampus of post-surgical rats
RGD
PMID:33390808
RGD:401965467
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Mapk1
mitogen activated protein kinase 1
multiple interactions
ISO
eplerenone inhibits the reaction [Aldosterone results in increased phosphorylation of and results in increased activity of MAPK1 protein]
CTD
PMID:17596522
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
G
Mapk3
mitogen activated protein kinase 3
multiple interactions
ISO
eplerenone inhibits the reaction [Aldosterone results in increased phosphorylation of and results in increased activity of MAPK3 protein]
CTD
PMID:17596522
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
G
Ncf1
neutrophil cytosolic factor 1
decreases expression multiple interactions
EXP
eplerenone results in decreased expression of NCF1 mRNA; eplerenone results in decreased expression of NCF1 protein [trandolapril co-treated with eplerenone] results in decreased expression of NCF1 mRNA; [trandolapril co-treated with eplerenone] results in decreased expression of NCF1 protein
CTD
PMID:17324946
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
G
Nos3
nitric oxide synthase 3
multiple interactions increases activity increases expression decreases expression
EXP
[Enalapril co-treated with eplerenone] results in decreased expression of NOS3 mRNA eplerenone results in increased activity of NOS3 protein eplerenone results in increased expression of NOS3 mRNA Eplerenone results in decreased expression of NOS3 mRNA; Eplerenone results in decreased expression of NOS3 protein
CTD
PMID:15974890 PMID:20571278
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
G
Nr3c2
nuclear receptor subfamily 3, group C, member 2
multiple interactions decreases expression
EXP
eplerenone binds to and results in decreased activity of NR3C2 protein eplerenone decreases expression of protein in hippocampus of post-surgical rats
CTD RGD
PMID:15974890 PMID:33390808
RGD:401965467
NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885
G
Osr1
odd-skipped related transcription factor 1
multiple interactions
ISO
eplerenone inhibits the reaction [AGT protein results in increased phosphorylation of OSR1 protein]
CTD
PMID:20175999
NCBI chr 6:32,369,561...32,380,822
Ensembl chr 6:32,373,816...32,380,817
G
Oxsr1
oxidative stress responsive kinase 1
multiple interactions
ISO
[eplerenone co-treated with Sodium Chloride, Dietary] results in decreased phosphorylation of OXSR1 protein
CTD
PMID:22949526
NCBI chr 8:118,972,754...119,062,102
Ensembl chr 8:118,972,754...119,062,027
G
Serpine1
serpin family E member 1
multiple interactions decreases expression
EXP
[eplerenone co-treated with Enalapril] inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 mRNA]; [eplerenone co-treated with Enalapril] inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 protein]; [eplerenone co-treated with Enalapril] results in decreased expression of SERPINE1 mRNA; [eplerenone co-treated with Enalapril] results in decreased expression of SERPINE1 protein; eplerenone inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 mRNA]; eplerenone inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 protein] eplerenone results in decreased expression of SERPINE1 mRNA; eplerenone results in decreased expression of SERPINE1 protein
CTD
PMID:18682491
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
G
Slc12a3
solute carrier family 12 member 3
multiple interactions
ISO
[eplerenone co-treated with Sodium Chloride, Dietary] results in decreased phosphorylation of SLC12A3 protein; eplerenone inhibits the reaction [AGT protein results in increased phosphorylation of SLC12A3 protein]
CTD
PMID:20175999 PMID:22949526
NCBI chr19:10,630,651...10,679,250
Ensembl chr19:10,631,393...10,669,091
G
Slc9a1
solute carrier family 9 member A1
multiple interactions
EXP
eplerenone inhibits the reaction [Aldosterone results in increased expression of SLC9A1 mRNA]
CTD
PMID:16373419
NCBI chr 5:145,576,341...145,629,630
Ensembl chr 5:145,576,334...145,629,624
G
Snai1
snail family transcriptional repressor 1
multiple interactions
ISO
eplerenone inhibits the reaction [Aldosterone results in increased expression of SNAI1 mRNA]
CTD
PMID:17596522
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
G
Sod1
superoxide dismutase 1
increases expression
EXP
eplerenone results in increased expression of SOD1 protein
CTD
PMID:17324946
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
G
Sod2
superoxide dismutase 2
increases expression
EXP
eplerenone results in increased expression of SOD2 protein
CTD
PMID:17324946
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
G
Stk39
serine threonine kinase 39
multiple interactions
ISO
[eplerenone co-treated with Sodium Chloride, Dietary] results in decreased phosphorylation of STK39 protein
CTD
PMID:22949526
NCBI chr 3:52,913,583...53,179,060
Ensembl chr 3:52,913,585...53,179,060
G
Tbx1
T-box transcription factor 1
decreases expression
EXP
Eplerenone decreases expression of Tbx1 mRNA and protein in infarcted heart
RGD
PMID:27422448
RGD:155882497
NCBI chr11:82,409,275...82,419,058
Ensembl chr11:82,409,275...82,418,380
G
Tgfb1
transforming growth factor, beta 1
multiple interactions decreases expression
EXP
[Eplerenone co-treated with Enalapril] inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased secretion of TGFB1 protein]; [Eplerenone co-treated with Enalapril] inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of TGFB1 mRNA]]; [Eplerenone co-treated with Enalapril] results in decreased expression of TGFB1 mRNA; [Eplerenone co-treated with Enalapril] results in decreased expression of TGFB1 protein; Eplerenone inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased secretion of TGFB1 protein]; Eplerenone inhibits the reaction [[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of TGFB1 mRNA]; Eplerenone inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of TGFB1 mRNA]] eplerenone results in decreased expression of TGFB1 mRNA; eplerenone results in decreased expression of TGFB1 protein
CTD
PMID:18682491 PMID:27773435
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
G
Tgfbi
transforming growth factor, beta induced
decreases secretion multiple interactions
EXP
eplerenone results in decreased secretion of TGFBI protein [eplerenone co-treated with Enalapril] results in decreased secretion of TGFBI protein
CTD
PMID:18682491
NCBI chr17:7,955,603...7,984,903
Ensembl chr17:7,955,603...7,985,240
G
Tnf
tumor necrosis factor
multiple interactions decreases expression
EXP
Eplerenone inhibits the reaction [[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of TNF mRNA] eplerenone decreases expression of protein in hippocampus of post-surgical rats
CTD RGD
PMID:27773435 PMID:33390808
RGD:401965467
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Fshb
follicle stimulating hormone subunit beta
multiple interactions
EXP
estradiol 17 beta-cypionate promotes the reaction [[Tetrachlorodibenzodioxin co-treated with Gonadotropins, Equine] results in increased expression of FSHB protein]; estradiol 17 beta-cypionate promotes the reaction [[Tetrachlorodibenzodioxin co-treated with Gonadotropins, Equine] results in increased secretion of FSHB protein]
CTD
PMID:12606454
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
G
Gnrh1
gonadotropin releasing hormone 1
multiple interactions
EXP
estradiol 17 beta-cypionate affects the reaction [methylmercuric chloride affects the secretion of GNRH1 protein]
CTD
PMID:16406600
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
G
Gstp1
glutathione S-transferase pi 1
multiple interactions
ISO
estradiol 17 beta-cypionate inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]
CTD
PMID:23769903
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
G
Lhb
luteinizing hormone subunit beta
multiple interactions
EXP
estradiol 17 beta-cypionate affects the reaction [methylmercuric chloride affects the secretion of LHB protein]; estradiol 17 beta-cypionate promotes the reaction [[Tetrachlorodibenzodioxin co-treated with Gonadotropins, Equine] results in increased expression of LHB protein]; estradiol 17 beta-cypionate promotes the reaction [[Tetrachlorodibenzodioxin co-treated with Gonadotropins, Equine] results in increased secretion of LHB protein]
CTD
PMID:12606454 PMID:16406600
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
G
Ctnnb1
catenin beta 1
multiple interactions
ISO
[estradiol dipropionate co-treated with Butyrates] results in decreased expression of CTNNB1 protein; [estradiol dipropionate co-treated with trichostatin A] results in decreased expression of CTNNB1 protein
CTD
PMID:15930180
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
G
Esr1
estrogen receptor 1
multiple interactions
ISO
[estradiol dipropionate co-treated with Butyrates] results in decreased expression of ESR1 protein; [estradiol dipropionate co-treated with trichostatin A] results in decreased expression of ESR1 protein
CTD
PMID:15930180
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Pgr
progesterone receptor
multiple interactions
ISO
[estradiol dipropionate co-treated with Butyrates] results in decreased expression of PGR protein; [estradiol dipropionate co-treated with trichostatin A] results in decreased expression of PGR protein
CTD
PMID:15930180
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
G
Slc26a1
solute carrier family 26 member 1
decreases expression
EXP
estradiol dipropionate results in decreased expression of SLC26A1 protein
CTD
PMID:19002488
NCBI chr14:1,040,565...1,045,851
Ensembl chr14:1,040,243...1,045,849
G
Slc5a2
solute carrier family 5 member 2
increases expression
EXP
estradiol dipropionate results in increased expression of SLC5A2 protein
CTD
PMID:22262063
NCBI chr 1:182,847,185...182,853,309
Ensembl chr 1:182,847,106...182,853,306
G
Abca8
ATP binding cassette subfamily A member 8
affects transport
ISO
ABCA8 protein affects the transport of estrone sulfate
CTD
PMID:12379217
NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988
G
Abcc2
ATP binding cassette subfamily C member 2
affects export increases activity
ISO EXP
ABCC2 protein affects the export of estrone sulfate estrone sulfate results in increased activity of ABCC2 protein; estrone sulfate results in increased activity of ABCC2 protein modified form
CTD
PMID:15652233 PMID:15904671 PMID:16046661
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
G
Abcg2
ATP binding cassette subfamily G member 2
affects export increases export increases uptake multiple interactions affects transport
ISO
ABCG2 protein affects the export of estrone sulfate ABCG2 protein results in increased export of estrone sulfate ABCG2 protein results in increased uptake of estrone sulfate [Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate; Androstenedione inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate]; Estradiol inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate]; hippuric acid inhibits the reaction [ABCG2 protein results in increased export of estrone sulfate]; Indican inhibits the reaction [ABCG2 protein results in increased export of estrone sulfate]; Kynurenic Acid inhibits the reaction [ABCG2 protein results in increased export of estrone sulfate]; Progesterone inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate]; Risperidone inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate]; Sulfasalazine inhibits the reaction [[Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate]; Testosterone inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate] ABCG2 protein affects the transport of estrone sulfate
CTD
PMID:15901800 PMID:18834354 PMID:19505989 PMID:21483698 PMID:22581381 PMID:32003934 More...
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
G
Dhrs11
dehydrogenase/reductase 11
increases reduction
ISO
DHRS11 protein results in increased reduction of estrone sulfate
CTD
PMID:30926317
NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295
G
Esr2
estrogen receptor 2
affects binding
EXP
Estrone-3-sulfate binds to Esr2 protein
RGD
PMID:9048584
RGD:8694130
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
G
Il1a
interleukin 1 alpha
decreases expression
ISO
estrone sulfate results in decreased expression of IL1A mRNA
CTD
PMID:10731640
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
G
Il6
interleukin 6
decreases expression
ISO
estrone sulfate results in decreased expression of IL6 mRNA
CTD
PMID:10731640
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Pdgfa
platelet derived growth factor subunit A
decreases expression
ISO
estrone sulfate results in decreased expression of PDGFA mRNA
CTD
PMID:10731640
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
G
Slc10a1
solute carrier family 10 member 1
multiple interactions
ISO
daidzein metabolite inhibits the reaction [SLC10A1 protein results in increased transport of estrone sulfate]; daidzein metabolite promotes the reaction [SLC10A1 protein results in increased transport of estrone sulfate]; estrone sulfate inhibits the reaction [SLC10A1 protein results in increased transport of daidzein metabolite]
CTD
PMID:25319728
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
G
Slc10a6
solute carrier family 10 member 6
increases transport increases uptake increases response to substance multiple interactions
ISO
SLC10A6 protein results in increased transport of estrone sulfate SLC10A6 protein results in increased uptake of estrone sulfate SLC10A6 protein results in increased susceptibility to estrone sulfate daidzein inhibits the reaction [SLC10A6 protein results in increased transport of estrone sulfate]; daidzein metabolite inhibits the reaction [SLC10A6 protein results in increased transport of estrone sulfate]; estrone sulfate inhibits the reaction [SLC10A6 protein results in increased transport of daidzein metabolite]; Sodium promotes the reaction [SLC10A6 protein results in increased uptake of estrone sulfate]
CTD
PMID:23562556 PMID:25319728 PMID:30186172
NCBI chr14:6,080,716...6,102,902
Ensembl chr14:6,080,717...6,103,037
G
Slc17a3
solute carrier family 17 member 3
affects transport
ISO
SLC17A3 gene SNP affects the transport of estrone sulfate
CTD
PMID:21282933
NCBI chr17:41,270,804...41,300,132
Ensembl chr17:41,270,812...41,295,256
G
Slc22a12
solute carrier family 22 member 12
increases uptake
ISO
SLC22A12 protein results in increased uptake of estrone sulfate
CTD
PMID:35835357
NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555
G
Slc22a20
solute carrier family 22 member 20
multiple interactions increases uptake
ISO
2,4-Dichlorophenoxyacetic Acid inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; Glutarates promotes the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; ochratoxin A inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; p-Aminohippuric Acid inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; Penicillin G inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; Probenecid inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; Salicylates inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]; Uric Acid inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]
CTD
PMID:16478971
NCBI chr 1:203,257,374...203,273,854
Ensembl chr 1:203,257,374...203,273,822
G
Slc22a25
solute carrier family 22, member 25
affects transport multiple interactions increases import increases uptake
EXP ISO
SLC22A19 protein affects the transport of estrone sulfate; SLC22A9 protein affects the transport of estrone sulfate estrone sulfate inhibits the reaction [SLC22A19 protein results in increased uptake of ochratoxin A] SLC22A9 protein results in increased import of estrone sulfate candesartan cilexetil inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; candesartan inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; Dehydroepiandrosterone Sulfate inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; losartan carboxylic acid inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; Losartan inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; pranlukast inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; Probenecid inhibits the reaction [SLC22A9 protein results in increased import of estrone sulfate]; Probenecid inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]; Tobacco Smoke Pollution inhibits the reaction [SLC22A9 protein results in increased import of estrone sulfate]; Valsartan inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate] 4-methylumbelliferyl sulfate inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; 4-methylumbelliferyl sulfate inhibits the reaction [SLC22A9 protein affects the transport of estrone sulfate]; Bumetanide inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; Diclofenac inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; estradiol sulfate inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; Furosemide inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; Glutarates affects the reaction [SLC22A9 protein affects the transport of estrone sulfate]; Ibuprofen inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; naphthyl sulfate inhibits the reaction [SLC22A9 protein affects the transport of estrone sulfate]; Probenecid inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]; Succinic Acid affects the reaction [SLC22A19 protein affects the transport of estrone sulfate]; Succinic Acid inhibits the reaction [SLC22A9 protein affects the transport of estrone sulfate]; Sulfobromophthalein inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate]
CTD
PMID:15068970 PMID:16079298 PMID:17132213 PMID:18441515 PMID:28629854
NCBI chr 1:205,338,698...205,498,486
Ensembl chr 1:205,338,699...205,433,085
G
Slc22a6
solute carrier family 22 member 6
increases uptake
ISO
SLC22A6 protein results in increased uptake of estrone sulfate
CTD
PMID:16098483
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
G
Slc22a7
solute carrier family 22 member 7
multiple interactions increases uptake
ISO
Fumarates promotes the reaction [SLC22A7 protein results in increased uptake of estrone sulfate]; Succinates promotes the reaction [SLC22A7 protein results in increased uptake of estrone sulfate]
CTD
PMID:15901346
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
G
Slc22a8
solute carrier family 22 member 8
multiple interactions increases import affects transport increases uptake
ISO EXP
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; aristolochic acid I inhibits the reaction [SLC22A8 results in increased uptake of estrone sulfate]; bisphenol A inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; bisphenol F inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; bisphenol S inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Bumetanide inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Cefaclor inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Cefdinir inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; cefoselis inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Cefotiam inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Ceftibuten inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Ceftizoxime inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Cephaloridine inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Cholates inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Cimetidine inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; cyazofamid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Dehydroepiandrosterone inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Diclofenac inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; estrone sulfate inhibits the reaction [SLC22A8 protein results in increased uptake of Famotidine]; estrone sulfate promotes the reaction [SLC22A8 results in increased export of p-Aminohippuric Acid]; Famotidine inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Furosemide inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Ibuprofen inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Indomethacin inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Probenecid inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Probenecid inhibits the reaction [SLC22A8 protein results in increased import of estrone sulfate]; Probenecid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Quercetin inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; rhein inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; rhein metabolite inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; tetrabromobisphenol A inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Tobacco Smoke Pollution inhibits the reaction [SLC22A8 protein results in increased import of estrone sulfate] SLC22A8 protein results in increased uptake of estrone sulfate; SLC22A8 results in increased uptake of estrone sulfate 3,4-dihydroxymandelic acid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; 3,4-Dihydroxyphenylacetic Acid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; 5-methoxyindoleacetic acid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Bumetanide inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; estrone sulfate inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Furosemide inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; hexadecafluoro-nonanoic acid inhibits the reaction [SLC22A8 protein results in increased import of estrone sulfate]; Homovanillic Acid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Indocyanine Green inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; methoxytryptophol inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; perfluoro-n-heptanoic acid inhibits the reaction [SLC22A8 protein results in increased import of estrone sulfate]; perfluorodecanoic acid inhibits the reaction [SLC22A8 protein results in increased import of estrone sulfate]; perfluorooctanoic acid inhibits the reaction [SLC22A8 protein results in increased import of estrone sulfate]; Piroxicam inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Probenecid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Sulfobromophthalein inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Vanilmandelic Acid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]
CTD
PMID:10224140 PMID:11306713 PMID:15100168 PMID:15319347 PMID:15496291 PMID:16079298 PMID:16098483 PMID:16857889 PMID:17255469 PMID:19605544 PMID:19643159 PMID:19915082 PMID:21256917 PMID:27989701 PMID:28629854 PMID:28890383 PMID:32003934 PMID:32305507 More...
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
G
Slco1a4
solute carrier organic anion transporter family, member 1a4
affects uptake multiple interactions increases uptake increases transport increases import
ISO
SLCO1A4 protein affects the uptake of estrone sulfate 7-hydroxymethotrexate inhibits the reaction [SLCO1A2 mRNA results in increased import of estrone sulfate]; artemisinin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Chloroquine inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Mefloquine inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Methotrexate inhibits the reaction [SLCO1A2 mRNA results in increased import of estrone sulfate]; naringin inhibits the reaction [SLCO1A2 protein alternative form results in increased uptake of estrone sulfate]; naringin inhibits the reaction [SLCO1A2 protein results in increased transport of estrone sulfate]; perfluorodecanoic acid inhibits the reaction [SLCO1A2 protein results in increased import of estrone sulfate]; Pyrimethamine inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Quinine inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate] SLCO1A2 protein alternative form results in increased uptake of estrone sulfate; SLCO1A2 protein results in increased uptake of estrone sulfate SLCO1A2 mRNA results in increased import of estrone sulfate; SLCO1A2 protein results in increased import of estrone sulfate
CTD
PMID:16702441 PMID:20639259 PMID:21561886 PMID:25466967 PMID:27504015
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
G
Slco1b2
solute carrier organic anion transporter family member 1B2
multiple interactions increases uptake
ISO
cyazofamid inhibits the reaction [SLCO1B3 protein results in increased uptake of estrone sulfate]
CTD
PMID:32003934 PMID:34619012
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
G
Slco2b1
solute carrier organic anion transporter family, member 2b1
increases import multiple interactions increases uptake
ISO
SLCO2B1 protein results in increased import of estrone sulfate; SLCO2B1 results in increased import of estrone sulfate 2,2',4,4',5,6'-hexabromodiphenyl ether inhibits the reaction [SLCO2B1 results in increased import of estrone sulfate]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [SLCO2B1 results in increased import of estrone sulfate]; [icariin results in decreased activity of SLCO2B1 protein] which results in decreased uptake of estrone sulfate; daidzein inhibits the reaction [SLCO2B1 protein results in increased transport of estrone sulfate]; daidzein metabolite inhibits the reaction [SLCO2B1 protein results in increased transport of estrone sulfate]; estrone sulfate inhibits the reaction [SLCO2B1 protein results in increased transport of daidzein metabolite]; estrone sulfate inhibits the reaction [SLCO2B1 protein results in increased uptake of Quercetin]; Mefloquine affects the reaction [SLCO2B1 protein results in increased uptake of estrone sulfate]; pentabromodiphenyl ether inhibits the reaction [SLCO2B1 results in increased import of estrone sulfate]; Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of estrone sulfate]; Sulfobromophthalein inhibits the reaction [SLCO2B1 protein results in increased import of estrone sulfate]; Tobacco Smoke Pollution inhibits the reaction [SLCO2B1 protein results in increased import of estrone sulfate]
CTD
PMID:16714376 PMID:20176623 PMID:24265111 PMID:24285294 PMID:24947867 PMID:25319728 PMID:27450509 PMID:27504015 More...
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
G
Slco3a1
solute carrier organic anion transporter family, member 3a1
multiple interactions
ISO
estrone sulfate promotes the reaction [SLCO3A1 protein results in increased uptake of simvastatin acid]
CTD
PMID:28887287
NCBI chr 1:128,106,232...128,388,043
Ensembl chr 1:128,106,228...128,387,925
G
Sts
steroid sulfatase
affects metabolic processing decreases sulfation
ISO
STS protein affects the metabolism of estrone sulfate STS protein results in decreased sulfation of estrone sulfate
CTD
PMID:15597397 PMID:16054388
NCBI chr X:42,225,131...42,233,403
Ensembl chr X:42,225,372...42,233,402
G
Sult1e1
sulfotransferase family 1E member 1
multiple interactions
ISO
[[Oxygen deficiency co-treated with Oxygen] results in increased expression of SULT1E1 protein] which results in increased abundance of estrone sulfate
CTD
PMID:25922074
NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
G
Ar
androgen receptor
affects localization multiple interactions
ISO
Ethynodiol Diacetate affects the localization of AR protein Ethynodiol Diacetate binds to and results in increased activity of AR protein
CTD
PMID:28478275
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Abcb11
ATP binding cassette subfamily B member 11
decreases activity multiple interactions
EXP ISO
Fusidic Acid results in decreased activity of ABCB11 protein Fusidic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
CTD
PMID:12106615 PMID:20829430 PMID:23956101 PMID:24014644 PMID:27676153
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
G
Abcb1a
ATP binding cassette subfamily B member 1A
multiple interactions
ISO
Fusidic Acid inhibits the reaction [ABCB1 protein results in increased export of Digoxin]
CTD
PMID:26888941
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
G
Abcc2
ATP binding cassette subfamily C member 2
multiple interactions
EXP
Fusidic Acid results in decreased expression of and results in decreased activity of ABCC2 protein
CTD
PMID:12106615
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
G
Cyp3a2
cytochrome P450, family 3, subfamily a, polypeptide 2
multiple interactions
ISO
Fusidic Acid inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]
CTD
PMID:26888941
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
G
Slc10a1
solute carrier family 10 member 1
multiple interactions
ISO
Fusidic Acid inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]
CTD
PMID:27676153
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
G
Slco1a4
solute carrier organic anion transporter family, member 1a4
multiple interactions
EXP
Fusidic Acid inhibits the reaction [SLCO1A4 protein results in increased uptake of Rosuvastatin Calcium]
CTD
PMID:26888941
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
G
Slco1b2
solute carrier organic anion transporter family member 1B2
multiple interactions decreases activity
EXP ISO
Fusidic Acid inhibits the reaction [SLCO1B2 protein results in increased uptake of Rosuvastatin Calcium] Fusidic Acid inhibits the reaction [SLCO1B3 protein results in increased uptake of Rosuvastatin Calcium] Fusidic Acid results in decreased activity of SLCO1B3 protein
CTD
PMID:26888941 PMID:27676153
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
G
Ugt1a1
UDP glucuronosyltransferase family 1 member A1
multiple interactions
ISO
Fusidic Acid inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Estradiol]
CTD
PMID:27676153
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
G
Abcc1
ATP binding cassette subfamily C member 1
multiple interactions
ISO
sulfolithocholic acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein]
CTD
PMID:16101123
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
G
Gsta4
glutathione S-transferase alpha 4
multiple interactions
EXP
sulfolithocholic acid binds to and results in decreased activity of GSTA4 protein
CTD
PMID:3954743
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
G
Gstm1
glutathione S-transferase mu 1
multiple interactions
EXP
sulfolithocholic acid binds to and results in decreased activity of GSTM1 protein
CTD
PMID:3954743
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
G
Gstm2
glutathione S-transferase mu 2
multiple interactions
EXP
sulfolithocholic acid binds to and results in decreased activity of GSTM2 protein
CTD
PMID:3954743
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
G
Ar
androgen receptor
multiple interactions
ISO
Loteprednol Etabonate binds to and results in decreased activity of AR protein; Loteprednol Etabonate binds to and results in increased activity of AR protein
CTD
PMID:25752796
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Pgr
progesterone receptor
multiple interactions
ISO
Loteprednol Etabonate binds to and results in increased activity of PGR protein
CTD
PMID:25752796
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
G
Abcb11
ATP binding cassette subfamily B member 11
decreases activity
ISO
Medroxyprogesterone Acetate results in decreased activity of ABCB11 protein
CTD
PMID:23956101
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
G
Ackr1
atypical chemokine receptor 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of ACKR1 mRNA
CTD
PMID:20843944
NCBI chr13:85,782,396...85,784,015
Ensembl chr13:85,782,398...85,783,983
G
Acp3
acid phosphatase 3
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of ACP3 mRNA
CTD
PMID:20843944
NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
G
Acsl1
acyl-CoA synthetase long-chain family member 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of ACSL1 mRNA
CTD
PMID:18497975
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
G
Adamts1
ADAM metallopeptidase with thrombospondin type 1 motif, 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ADAMTS1 mRNA
CTD
PMID:20823114
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
G
Adora3
adenosine A3 receptor
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of ADORA3 mRNA
CTD
PMID:20843944
NCBI chr 2:193,352,759...193,392,946
Ensembl chr 2:193,388,713...193,392,357
G
Agt
angiotensinogen
multiple interactions
ISO
AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein]; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]; Losartan inhibits the reaction [AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]]
CTD
PMID:36682589
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
G
Ahr
aryl hydrocarbon receptor
multiple interactions
ISO
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA
CTD
PMID:32781018
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
G
Aif1
allograft inflammatory factor 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of AIF1 mRNA
CTD
PMID:20843944
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
G
Ak5
adenylate kinase 5
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of AK5 mRNA
CTD
PMID:20823114
NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458
G
Akr1c1
aldo-keto reductase family 1, member C1
decreases expression increases expression decreases activity
ISO
Medroxyprogesterone Acetate results in decreased expression of AKR1C1 mRNA Medroxyprogesterone Acetate results in increased expression of AKR1C1 mRNA Medroxyprogesterone Acetate results in decreased activity of AKR1C1 protein
CTD
PMID:12604236 PMID:18497975 PMID:21182831 PMID:23183084
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
G
Akr1c2
aldo-keto reductase family 1, member C2
decreases activity
ISO
Medroxyprogesterone Acetate results in decreased activity of AKR1C2 protein
CTD
PMID:12604236 PMID:22245609
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
G
Akr1c3
aldo-keto reductase family 1, member C3
multiple interactions decreases activity
ISO
[Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost] Medroxyprogesterone Acetate results in decreased activity of AKR1C3 protein
CTD
PMID:12604236 PMID:19997560 PMID:21182831 PMID:23261716
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
G
Alcam
activated leukocyte cell adhesion molecule
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of ALCAM mRNA
CTD
PMID:18497975 PMID:20843944
NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954
G
Alox5ap
arachidonate 5-lipoxygenase activating protein
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of ALOX5AP mRNA
CTD
PMID:20843944
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
G
Antxr1
ANTXR cell adhesion molecule 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ANTXR1 mRNA
CTD
PMID:20823114
NCBI chr 4:119,590,770...119,778,232
Ensembl chr 4:119,590,771...119,778,232
G
Anxa2
annexin A2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ANXA2 mRNA
CTD
PMID:20823114
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
G
Apod
apolipoprotein D
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of APOD mRNA
CTD
PMID:20843944
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
G
Aqp3
aquaporin 3 (Gill blood group)
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of AQP3 mRNA
CTD
PMID:18497975
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
G
Ar
androgen receptor
affects binding increases activity
ISO EXP
Medroxyprogesterone Acetate binds to AR protein Medroxyprogesterone Acetate results in increased activity of AR protein
CTD
PMID:11861974 PMID:14565775 PMID:14751673
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Arhgef19
Rho guanine nucleotide exchange factor 19
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of ARHGEF19 mRNA
CTD
PMID:20843944
NCBI chr 5:153,536,038...153,554,203
Ensembl chr 5:153,536,013...153,554,203
G
Arhgef2
Rho/Rac guanine nucleotide exchange factor 2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ARHGEF2 mRNA
CTD
PMID:20823114
NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355
G
Atp11a
ATPase phospholipid transporting 11A
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP11A mRNA
CTD
PMID:20823114
NCBI chr16:76,657,752...76,767,640
Ensembl chr16:76,657,752...76,767,640
G
Atp1a1
ATPase Na+/K+ transporting subunit alpha 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of ATP1A1 mRNA
CTD
PMID:15866426
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
G
Atp2b1
ATPase plasma membrane Ca2+ transporting 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ATP2B1 mRNA
CTD
PMID:20823114
NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295
G
Atp2b4
ATPase plasma membrane Ca2+ transporting 4
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of ATP2B4 mRNA
CTD
PMID:20843944
NCBI chr13:45,156,137...45,255,292
Ensembl chr13:45,156,146...45,255,246
G
Atp6v0c
ATPase H+ transporting V0 subunit C
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP6V0C mRNA
CTD
PMID:20823114
NCBI chr10:13,196,204...13,202,580
Ensembl chr10:13,196,204...13,201,500
G
Azgp1
alpha-2-glycoprotein 1, zinc-binding
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of AZGP1 mRNA
CTD
PMID:15866426
NCBI chr12:16,930,990...16,939,333
Ensembl chr12:16,931,024...16,939,091
G
Bax
BCL2 associated X, apoptosis regulator
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BAX protein
CTD
PMID:16709600
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
G
Bcat1
branched chain amino acid transaminase 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BCAT1 mRNA
CTD
PMID:20823114
NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597
G
Bckdk
branched chain ketoacid dehydrogenase kinase
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCKDK mRNA
CTD
PMID:20823114
NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633
G
Bcl2l11
Bcl2-like 11
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein
CTD
PMID:16709600
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
G
Bcl2l13
Bcl2-like 13
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCL2L13 mRNA
CTD
PMID:20823114
NCBI chr 4:154,056,116...154,112,890
Ensembl chr 4:154,056,127...154,108,985
G
Bdkrb1
bradykinin receptor B1
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of BDKRB1 mRNA
CTD
PMID:20843944
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
G
Bet1l
Bet1 golgi vesicular membrane trafficking protein-like
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BET1L mRNA
CTD
PMID:20823114
NCBI chr 1:195,931,407...195,935,072
Ensembl chr 1:195,931,411...195,935,040
G
Bicd1
BICD cargo adaptor 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BICD1 mRNA
CTD
PMID:20823114
NCBI chr 4:182,479,071...182,631,504
Ensembl chr 4:182,479,071...182,627,434
G
Bsnd
barttin CLCNK type accessory subunit beta
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BSND mRNA
CTD
PMID:20823114
NCBI chr 5:121,251,774...121,260,571
Ensembl chr 5:121,251,774...121,260,571
G
C1qa
complement C1q A chain
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of C1QA mRNA
CTD
PMID:20843944
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
G
C1qb
complement C1q B chain
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of C1QB mRNA
CTD
PMID:20843944
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
G
C1qc
complement C1q C chain
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of C1QC mRNA
CTD
PMID:20843944
NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017
G
C1r
complement C1r
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of C1R mRNA
CTD
PMID:20823114
NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484
G
C2cd4b
C2 calcium-dependent domain containing 4B
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of NLF2 mRNA
CTD
PMID:20843944
NCBI chr 8:68,372,793...68,396,477
Ensembl chr 8:68,384,847...68,396,328
G
C2h1orf162
similar to human chromosome 1 open reading frame 162
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of C1ORF162 mRNA
CTD
PMID:20843944
NCBI chr 2:193,410,730...193,420,824
Ensembl chr 2:193,412,971...193,420,030
G
C3
complement C3
multiple interactions
EXP
Medroxyprogesterone Acetate inhibits the reaction [Ethinyl Estradiol results in increased expression of C3 mRNA]; Mifepristone inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Ethinyl Estradiol results in increased expression of C3 mRNA]]
CTD
PMID:11566438 PMID:16806946
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
G
C3h15orf48
similar to human chromosome 15 open reading frame 48
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of C15ORF48 mRNA
CTD
PMID:20843944
NCBI chr 3:109,719,952...109,723,505
Ensembl chr 3:109,719,897...109,724,006 Ensembl chr 3:109,719,897...109,724,006
G
Calm1
calmodulin 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CALM1 mRNA
CTD
PMID:20823114
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
G
Capn2
calpain 2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAPN2 mRNA
CTD
PMID:20823114
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
G
Car2
carbonic anhydrase 2
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of CA2 mRNA
CTD
PMID:18497975
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
G
Car8
carbonic anhydrase 8
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of CA8 mRNA
CTD
PMID:20843944
NCBI chr 5:21,302,940...21,402,395
Ensembl chr 5:21,305,383...21,402,374
G
Cast
calpastatin
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CAST mRNA
CTD
PMID:20823114
NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659
G
Cat
catalase
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CAT mRNA
CTD
PMID:16709600
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
G
Cav2
caveolin 2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAV2 mRNA
CTD
PMID:20823114
NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244
G
Ccl2
C-C motif chemokine ligand 2
decreases expression decreases secretion
EXP
Medroxyprogesterone Acetate results in decreased expression of CCL2 mRNA; Medroxyprogesterone Acetate results in decreased expression of CCL2 protein Medroxyprogesterone Acetate results in decreased secretion of CCL2 protein
CTD
PMID:18606702
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
G
Ccn2
cellular communication network factor 2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CCN2 mRNA
CTD
PMID:20823114
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
G
Ccnb1
cyclin B1
multiple interactions
ISO
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CCNB1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CCNB1 protein
CTD
PMID:22534328
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
G
Ccnd1
cyclin D1
multiple interactions
ISO
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] affects the expression of CCND1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 protein
CTD
PMID:22534328
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
G
Cd163
CD163 molecule
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of CD163 mRNA
CTD
PMID:20843944
NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878
G
Cd40lg
CD40 ligand
multiple interactions decreases activity
ISO
[Bezafibrate co-treated with Medroxyprogesterone Acetate] results in decreased activity of CD40LG protein Medroxyprogesterone Acetate results in decreased activity of CD40LG protein
CTD
PMID:18923439
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
G
Cdc42bpa
CDC42 binding protein kinase alpha
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CDC42BPA mRNA
CTD
PMID:20823114
NCBI chr13:91,683,775...91,903,732
Ensembl chr13:91,684,007...91,903,732
G
Cdkn1a
cyclin-dependent kinase inhibitor 1A
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CDKN1A protein
CTD
PMID:20823114 PMID:22534328
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
G
Cdkn1b
cyclin-dependent kinase inhibitor 1B
multiple interactions increases expression
ISO
Estradiol promotes the reaction [Medroxyprogesterone Acetate results in increased expression of CDKN1B protein]; Mifepristone inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol] results in increased expression of CDKN1B protein]
CTD
PMID:17283133
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
G
Cebpz
CCAAT/enhancer binding protein zeta
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CEBPZ mRNA
CTD
PMID:20823114
NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600
G
Cflar
CASP8 and FADD-like apoptosis regulator
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CFLAR protein alternative form
CTD
PMID:16709600
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
G
Cilp
cartilage intermediate layer protein
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of CILP mRNA
CTD
PMID:20843944
NCBI chr 8:65,777,281...65,792,251
Ensembl chr 8:65,777,281...65,792,251
G
Cldn5
claudin 5
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of CLDN5 mRNA
CTD
PMID:20843944
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
G
Cngb1
cyclic nucleotide gated channel subunit beta 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CNGB1 mRNA
CTD
PMID:20823114
NCBI chr19:9,726,595...9,791,111
Ensembl chr19:9,726,595...9,791,173
G
Cnr1
cannabinoid receptor 1
increases expression multiple interactions
ISO
Medroxyprogesterone Acetate results in increased expression of CNR1 mRNA [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR1 mRNA
CTD
PMID:20843944 PMID:31154070
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
G
Cnr2
cannabinoid receptor 2
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR2 mRNA
CTD
PMID:31154070
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
G
Col6a2
collagen type VI alpha 2 chain
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A2 mRNA
CTD
PMID:20823114
NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564
G
Col6a3
collagen type VI alpha 3 chain
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A3 mRNA
CTD
PMID:20823114
NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
G
Cox6a2
cytochrome c oxidase subunit 6A2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of COX6A2 mRNA
CTD
PMID:20823114
NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274
G
Cplx1
complexin 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CPLX1 mRNA
CTD
PMID:20823114
NCBI chr14:1,184,677...1,216,392
G
Crebbp
CREB binding protein
multiple interactions
ISO
Medroxyprogesterone Acetate promotes the reaction [CREBBP protein binds to SOD2 promoter]
CTD
PMID:20685861
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
G
Crem
cAMP responsive element modulator
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CREM mRNA
CTD
PMID:20823114
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
G
Crp
C-reactive protein
multiple interactions
ISO
[Estrogens, Conjugated (USP) co-treated with Medroxyprogesterone Acetate] results in increased expression of CRP protein
CTD
PMID:15990257 PMID:17882670
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
G
Ctps2
CTP synthase 2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CTPS2 mRNA
CTD
PMID:20823114
NCBI chr X:31,645,873...31,786,733
Ensembl chr X:31,645,873...31,786,733
G
Ctsd
cathepsin D
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of CTSD mRNA
CTD
PMID:18497975
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
G
Cyb5d1
cytochrome b5 domain containing 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CYB5D1 mRNA
CTD
PMID:20823114
NCBI chr10:54,113,428...54,117,744
Ensembl chr10:54,113,438...54,117,911
G
Cybb
cytochrome b-245 beta chain
multiple interactions
EXP
[Medroxyprogesterone Acetate co-treated with Estradiol] results in increased expression of CYBB protein
CTD
PMID:21670166
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
G
Cyp19a1
cytochrome P450, family 19, subfamily a, polypeptide 1
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]
CTD
PMID:31953017
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
G
Cyp1a1
cytochrome P450, family 1, subfamily a, polypeptide 1
multiple interactions increases expression
ISO
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; Medroxyprogesterone Acetate inhibits the reaction [benzo(a)pyrene 7,8-dihydrodiol results in increased expression of CYP1A1 mRNA] Medroxyprogesterone Acetate results in increased expression of CYP1A1 mRNA
CTD
PMID:10706104 PMID:20843944 PMID:32781018
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
G
Cyp1b1
cytochrome P450, family 1, subfamily b, polypeptide 1
multiple interactions
ISO
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; CYP1B1 gene polymorphism affects the susceptibility to [Estrogens co-treated with Medroxyprogesterone Acetate]
CTD
PMID:15987428 PMID:32781018
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
G
Cyp27b1
cytochrome P450, family 27, subfamily b, polypeptide 1
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of CYP27B1 mRNA
CTD
PMID:20843944
NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241
G
Cyp3a2
cytochrome P450, family 3, subfamily a, polypeptide 2
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of CYP3A4 mRNA; Medroxyprogesterone Acetate results in increased expression of CYP3A4 protein
CTD
PMID:15650019
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
G
Dcn
decorin
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein]
CTD
PMID:20823114
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
G
Ddx27
DEAD-box helicase 27
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DDX27 mRNA
CTD
PMID:20823114
NCBI chr 3:155,744,182...155,763,380
Ensembl chr 3:155,744,150...155,763,372
G
Depp1
DEPP autophagy regulator 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of DEPP1 mRNA
CTD
PMID:20843944
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
G
Des
desmin
multiple interactions
EXP ISO
[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of DES mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA
CTD
PMID:19089455 PMID:20823114
NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
G
Dhx9
DExH-box helicase 9
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DHX9 mRNA
CTD
PMID:20823114
NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069
G
Dio2
iodothyronine deiodinase 2
decreases expression multiple interactions
ISO
Medroxyprogesterone Acetate results in decreased expression of DIO2 mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DIO2 mRNA
CTD
PMID:20823114 PMID:20843944
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
G
Dkk1
dickkopf WNT signaling pathway inhibitor 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of DKK1 mRNA
CTD
PMID:20843944
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
G
Dlg5
discs large MAGUK scaffold protein 5
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of DLG5 mRNA
CTD
PMID:18497975 PMID:19146866
NCBI chr15:75,786...209,735
Ensembl chr15:75,786...187,837
G
Dner
delta/notch-like EGF repeat containing
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of DNER mRNA
CTD
PMID:20843944
NCBI chr 9:85,586,985...85,902,461
Ensembl chr 9:85,586,987...85,902,637
G
Dtymk
deoxythymidylate kinase
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DTYMK mRNA
CTD
PMID:20823114
NCBI chr 9:94,315,552...94,324,386
Ensembl chr 9:94,315,552...94,324,870
G
Dusp23
dual specificity phosphatase 23
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of DUSP23 mRNA
CTD
PMID:20843944
NCBI chr13:85,097,899...85,100,054
Ensembl chr13:85,097,899...85,100,093
G
Eda
ectodysplasin-A
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EDA mRNA
CTD
PMID:20823114
NCBI chr X:65,078,454...65,480,172
Ensembl chr X:65,078,673...65,480,172
G
Eef1a1
eukaryotic translation elongation factor 1 alpha 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EEF1A1 mRNA
CTD
PMID:20823114
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
G
Efemp1
EGF containing fibulin extracellular matrix protein 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EFEMP1 mRNA
CTD
PMID:20823114
NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018
G
Efhd1
EF-hand domain family, member D1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of EFHD1 mRNA
CTD
PMID:20843944
NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917
G
Egr2
early growth response 2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EGR2 mRNA
CTD
PMID:20823114
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
G
Elf3
E74 like ETS transcription factor 3
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of ELF3 mRNA
CTD
PMID:18497975
NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481
G
Enpp2
ectonucleotide pyrophosphatase/phosphodiesterase 2
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of ENPP2 mRNA
CTD
PMID:20843944
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
G
Epb41l4a
erythrocyte membrane protein band 4.1 like 4A
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPB41L4A mRNA
CTD
PMID:20823114
NCBI chr18:25,405,461...25,615,392
Ensembl chr18:25,406,057...25,615,149
G
Epha3
Eph receptor A3
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPHA3 mRNA
CTD
PMID:20823114
NCBI chr11:1,138,485...1,474,102
Ensembl chr11:1,140,985...1,473,900
G
Ephx1
epoxide hydrolase 1
multiple interactions increases expression
ISO
ESR1 protein promotes the reaction [Medroxyprogesterone Acetate results in increased expression of EPHX1 protein] Medroxyprogesterone Acetate results in increased expression of EPHX1 mRNA; Medroxyprogesterone Acetate results in increased expression of EPHX1 protein
CTD
PMID:20383792
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
G
Esr1
estrogen receptor 1
multiple interactions decreases expression
ISO
ESR1 protein promotes the reaction [Medroxyprogesterone Acetate results in increased expression of EPHX1 protein] Medroxyprogesterone Acetate results in decreased expression of ESR1 mRNA
CTD
PMID:20383792 PMID:20843944
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Eya1
EYA transcriptional coactivator and phosphatase 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EYA1 mRNA
CTD
PMID:20823114
NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483
G
Ezh2
enhancer of zeste 2 polycomb repressive complex 2 subunit
multiple interactions decreases expression
ISO
[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 mRNA; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 protein; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA] Medroxyprogesterone Acetate results in decreased expression of EZH2 mRNA; Medroxyprogesterone Acetate results in decreased expression of EZH2 protein
CTD
PMID:21903722
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
G
F13a1
coagulation factor XIII A1 chain
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of F13A1 mRNA
CTD
PMID:20843944
NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700
G
F2
coagulation factor II, thrombin
multiple interactions increases expression
ISO EXP
Medroxyprogesterone Acetate promotes the reaction [F2 protein results in increased expression of F3 mRNA] Medroxyprogesterone Acetate results in increased expression of F2
CTD
PMID:1828463 PMID:11733402
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
G
F2r
coagulation factor II (thrombin) receptor
increases expression multiple interactions
ISO EXP
Medroxyprogesterone Acetate results in increased expression of F2R protein Mifepristone inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of F2R mRNA] Medroxyprogesterone Acetate results in increased expression of F2R mRNA; Medroxyprogesterone Acetate results in increased expression of F2R protein
CTD
PMID:11733402
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
G
F3
coagulation factor III, tissue factor
multiple interactions increases expression
ISO EXP
Medroxyprogesterone Acetate promotes the reaction [F2 protein results in increased expression of F3 mRNA] Medroxyprogesterone Acetate results in increased expression of F3 protein
CTD
PMID:11733402 PMID:16011840
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
G
F7
coagulation factor VII
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of F7
CTD
PMID:1828463
NCBI chr16:76,489,775...76,500,636
Ensembl chr16:76,489,717...76,500,610
G
F9
coagulation factor IX
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of F9
CTD
PMID:1828463
NCBI chr X:138,352,334...138,396,835
Ensembl chr X:138,352,298...138,396,835
G
Fads2
fatty acid desaturase 2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FADS2 mRNA
CTD
PMID:20823114
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
G
Fam107a
family with sequence similarity 107, member A
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of FAM107A mRNA
CTD
PMID:20843944
NCBI chr15:16,608,362...16,630,398
Ensembl chr15:16,607,205...16,630,396
G
Fas
Fas cell surface death receptor
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of FAS mRNA
CTD
PMID:18497975
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
G
Faslg
Fas ligand
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FASLG protein
CTD
PMID:16709600
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
G
Fbln1
fibulin 1
increases expression multiple interactions
ISO
Medroxyprogesterone Acetate results in increased expression of FBLN1 mRNA; Medroxyprogesterone Acetate results in increased expression of FBLN1 protein Mifepristone inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of FBLN1 mRNA]
CTD
PMID:15774544
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
G
Fbxo11
F-box protein 11
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXO11 mRNA
CTD
PMID:20823114
NCBI chr 6:6,486,761...6,562,664
Ensembl chr 6:6,486,015...6,562,662
G
Fbxw5
F-box and WD repeat domain containing 5
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXW5 mRNA
CTD
PMID:20823114
NCBI chr 3:8,322,543...8,327,092
Ensembl chr 3:8,322,543...8,327,092
G
Fcgbp
Fc gamma binding protein
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of FCGBP mRNA
CTD
PMID:20843944
NCBI chr 1:83,374,979...83,413,082
Ensembl chr 1:83,372,127...83,413,083
G
Fgd1
FYVE, RhoGEF and PH domain containing 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FGD1 mRNA
CTD
PMID:20823114
NCBI chr X:20,023,746...20,066,734
Ensembl chr X:20,023,746...20,066,566
G
Fgf7
fibroblast growth factor 7
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of FGF7 mRNA
CTD
PMID:20843944
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
G
Fibin
fin bud initiation factor homolog
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of FIBIN mRNA
CTD
PMID:20843944
NCBI chr 3:96,942,405...96,944,676
Ensembl chr 3:96,942,406...96,944,676
G
Filip1l
filamin A interacting protein 1-like
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FILIP1L mRNA
CTD
PMID:20823114
NCBI chr11:42,937,353...43,177,085
Ensembl chr11:42,940,467...43,177,415
G
Fkbp5
FKBP prolyl isomerase 5
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of FKBP5 mRNA
CTD
PMID:19146866 PMID:20843944
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
G
Fn1
fibronectin 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FN1 mRNA; [Medroxyprogesterone Acetate co-treated with Carbon Tetrachloride] results in increased expression of FN1 protein
CTD
PMID:1465320 PMID:20823114
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
G
Folr2
folate receptor beta
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of FOLR2 mRNA
CTD
PMID:20843944
NCBI chr 1:156,200,044...156,218,380
Ensembl chr 1:156,200,060...156,205,724
G
Foxo1
forkhead box O1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein; [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein]
CTD
PMID:16709600 PMID:20823114 PMID:31953017 PMID:36682589
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
G
Foxo3
forkhead box O3
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 mRNA]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA]
CTD
PMID:16709600
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
G
Fpr1
formyl peptide receptor 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of FPR1 mRNA
CTD
PMID:20843944
NCBI chr 1:58,745,019...58,756,776
Ensembl chr 1:58,747,246...58,756,559
G
Fscn2
fascin actin-bundling protein 2, retinal
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FSCN2 mRNA
CTD
PMID:20823114
NCBI chr10:105,634,783...105,641,322
Ensembl chr10:105,634,783...105,641,322
G
Fshb
follicle stimulating hormone subunit beta
multiple interactions
ISO
[Estrogens, Conjugated (USP) co-treated with Medroxyprogesterone Acetate] results in decreased expression of FSHB protein
CTD
PMID:16236362
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
G
Fxyd3
FXYD domain-containing ion transport regulator 3
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of FXYD3 mRNA
CTD
PMID:18497975
NCBI chr 1:86,305,531...86,312,455
G
Gadd45a
growth arrest and DNA-damage-inducible, alpha
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A protein
CTD
PMID:16709600
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
G
Galnt15
polypeptide N-acetylgalactosaminyltransferase 15
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of GALNT15 mRNA
CTD
PMID:20843944
NCBI chr16:7,227,232...7,267,002
Ensembl chr16:7,227,271...7,267,014
G
Gars1
glycyl-tRNA synthetase 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GARS1 mRNA
CTD
PMID:20823114
NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609
G
Gbe1
1,4-alpha-glucan branching enzyme 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GBE1 mRNA
CTD
PMID:20823114
NCBI chr11:8,734,806...9,000,226
Ensembl chr11:8,734,820...9,000,210
G
Gbp2
guanylate binding protein 2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GBP2 mRNA
CTD
PMID:20823114
NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
G
Gcnt2
glucosaminyl (N-acetyl) transferase 2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GCNT2 mRNA
CTD
PMID:20823114
NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611
G
Gdf10
growth differentiation factor 10
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of GDF10 mRNA
CTD
PMID:20843944
NCBI chr16:9,237,182...9,250,537
Ensembl chr16:9,237,261...9,249,343
G
Gipc1
GIPC PDZ domain containing family, member 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GIPC1 mRNA
CTD
PMID:20823114
NCBI chr19:24,474,291...24,487,083
Ensembl chr19:24,453,123...24,486,997
G
Gja1
gap junction protein, alpha 1
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of GJA1 mRNA
CTD
PMID:20843944
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
G
Glrx
glutaredoxin
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of GLRX mRNA
CTD
PMID:20843944
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
G
Gpkow
G patch domain and KOW motifs
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GPKOW mRNA
CTD
PMID:20823114
NCBI chr X:14,791,601...14,806,384
Ensembl chr X:14,791,610...14,806,384
G
Gpnmb
glycoprotein nmb
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GPNMB mRNA
CTD
PMID:20823114
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
G
Gpr34
G protein-coupled receptor 34
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of GPR34 mRNA
CTD
PMID:20843944
NCBI chr X:9,104,829...9,113,796
Ensembl chr X:9,104,565...9,148,601
G
Gpr83
G protein-coupled receptor 83
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of GPR83 mRNA
CTD
PMID:20843944
NCBI chr 8:11,693,540...11,704,028
Ensembl chr 8:11,693,540...11,704,028
G
Gpx3
glutathione peroxidase 3
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of GPX3 mRNA
CTD
PMID:20843944
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
G
Gsn
gelsolin
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of GSN mRNA
CTD
PMID:18497975
NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402
G
Gsta2
glutathione S-transferase alpha 2
increases expression
EXP
Medroxyprogesterone Acetate results in increased expression of GSTA2 mRNA
CTD
PMID:11502894
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
G
Gstm5
glutathione S-transferase, mu 5
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of GSTM3 mRNA
CTD
PMID:18497975
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
G
Havcr2
hepatitis A virus cellular receptor 2
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of HAVCR2 mRNA
CTD
PMID:20843944
NCBI chr10:30,882,484...30,914,018
Ensembl chr10:30,882,606...30,909,137
G
Hbegf
heparin-binding EGF-like growth factor
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of HBEGF mRNA
CTD
PMID:20843944
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
G
Hoxa1
homeobox A1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA]
CTD
PMID:20823114
NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504
G
Hoxa10
homeobox A10
multiple interactions increases expression
ISO
[Medroxyprogesterone Acetate co-treated with Estrogens] results in increased expression of HOXA10 mRNA; Mifepristone inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of HOXA10 mRNA]
CTD
PMID:16632680 PMID:21670700
NCBI chr 4:81,331,591...81,340,878
Ensembl chr 4:81,331,591...81,340,919
G
Hoxa11
homeobox A11
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of HOXA11 mRNA
CTD
PMID:16632680
NCBI chr 4:81,342,527...81,346,189
Ensembl chr 4:81,342,528...81,346,232
G
Hsd11b1
hydroxysteroid 11-beta dehydrogenase 1
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of and results in increased activity of HSD11B1 protein; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA
CTD
PMID:23275455
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
G
Hsd11b2
hydroxysteroid 11-beta dehydrogenase 2
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B2 protein
CTD
PMID:23275455
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
G
Hsd17b2
hydroxysteroid (17-beta) dehydrogenase 2
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of HSD17B2 mRNA
CTD
PMID:23183084
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
G
Htr1a
5-hydroxytryptamine receptor 1A
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of HTR1A mRNA
CTD
PMID:20823114
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
G
Icam1
intercellular adhesion molecule 1
multiple interactions
ISO
Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]]; Medroxyprogesterone Acetate inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]; Mifepristone inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]]
CTD
PMID:15358673
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
G
Idh1
isocitrate dehydrogenase (NADP(+)) 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of IDH1 mRNA
CTD
PMID:20843944
NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708
G
Ido1
indoleamine 2,3-dioxygenase 1
multiple interactions
ISO
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein
CTD
PMID:32781018
NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
G
Ifng
interferon gamma
multiple interactions
ISO
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; [Estrogens, Conjugated (USP) co-treated with Medroxyprogesterone Acetate] results in decreased secretion of IFNG protein; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]
CTD
PMID:16236362 PMID:32781018
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
G
Ifrd2
interferon-related developmental regulator 2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IFRD2 mRNA
CTD
PMID:20823114
NCBI chr 8:108,260,969...108,266,191
Ensembl chr 8:108,260,969...108,266,194
G
Igfbp1
insulin-like growth factor binding protein 1
multiple interactions increases expression
ISO
2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1; [Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol deficiency co-treated with Medroxyprogesterone Acetate deficiency] results in decreased expression of IGFBP1 mRNA; [Estradiol deficiency co-treated with Medroxyprogesterone Acetate deficiency] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of IGFBP1 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; Estradiol promotes the reaction [Medroxyprogesterone Acetate results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]
CTD
PMID:11756571 PMID:12093828 PMID:16709600 PMID:20685861 PMID:20823114 PMID:21903722 PMID:30328349 PMID:31154070 PMID:31953017 PMID:32781018 More...
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
G
Igfbp3
insulin-like growth factor binding protein 3
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP3 mRNA
CTD
PMID:20823114
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
G
Igfbp4
insulin-like growth factor binding protein 4
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP4 mRNA
CTD
PMID:20823114
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
G
Igfbp5
insulin-like growth factor binding protein 5
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of IGFBP5 mRNA
CTD
PMID:20843944
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
G
Il11
interleukin 11
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of IL11 mRNA
CTD
PMID:20843944
NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129
G
Il12b
interleukin 12B
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IL12B mRNA
CTD
PMID:20823114
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
G
Il1b
interleukin 1 beta
multiple interactions decreases expression
ISO
[Indomethacin co-treated with Medroxyprogesterone Acetate] results in decreased secretion of IL1B protein Medroxyprogesterone Acetate results in decreased expression of IL1B mRNA
CTD
PMID:16537180 PMID:20843944
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Il2
interleukin 2
multiple interactions
ISO
[Estrogens, Conjugated (USP) co-treated with Medroxyprogesterone Acetate] results in decreased secretion of IL2 protein
CTD
PMID:16236362
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
G
Il23a
interleukin 23 subunit alpha
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of IL23A mRNA
CTD
PMID:20823114
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
G
Il24
interleukin 24
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of IL24 mRNA
CTD
PMID:20843944
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
G
Il6
interleukin 6
multiple interactions decreases expression decreases secretion
ISO
[Polyphenols co-treated with Antioxidants co-treated with Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with Medroxyprogesterone Acetate co-treated with Celecoxib] results in decreased expression of IL6 Medroxyprogesterone Acetate results in decreased expression of IL6 mRNA Medroxyprogesterone Acetate results in decreased secretion of IL6 protein [Indomethacin co-treated with Medroxyprogesterone Acetate] results in decreased secretion of IL6 protein
CTD
PMID:16537180 PMID:16702388 PMID:20843944
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Ints7
integrator complex subunit 7
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of INTS7 mRNA
CTD
PMID:20823114
NCBI chr13:103,155,123...103,207,953
Ensembl chr13:103,155,090...103,208,592
G
Irf9
interferon regulatory factor 9
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IRF9 mRNA
CTD
PMID:20823114
NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236
G
Irs2
insulin receptor substrate 2
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of IRS2 mRNA
CTD
PMID:20843944
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
G
Isg20l2
interferon stimulated exonuclease gene 20-like 2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ISG20L2 mRNA
CTD
PMID:20823114
NCBI chr 2:173,396,780...173,407,102
Ensembl chr 2:173,396,780...173,406,614
G
Itga1
integrin subunit alpha 1
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of ITGA1 mRNA
CTD
PMID:20843944
NCBI chr 2:46,646,125...46,812,237
Ensembl chr 2:46,653,193...46,812,238
G
Itga11
integrin subunit alpha 11
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of ITGA11 mRNA
CTD
PMID:20843944
NCBI chr 8:63,145,998...63,254,714
Ensembl chr 8:63,146,001...63,254,407
G
Itga2
integrin subunit alpha 2
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of ITGA2 mRNA
CTD
PMID:18497975
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
G
Itgb1
integrin subunit beta 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITGB1 mRNA
CTD
PMID:20823114
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
G
Itgb5
integrin subunit beta 5
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of ITGB5 mRNA
CTD
PMID:18497975
NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472
G
Itih5
inter-alpha-trypsin inhibitor heavy chain 5
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITIH5 mRNA
CTD
PMID:20823114
NCBI chr17:68,248,115...68,352,216
Ensembl chr17:68,252,128...68,352,207
G
Kcnb1
potassium voltage-gated channel subfamily B member 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of KCNB1 mRNA
CTD
PMID:20843944
NCBI chr 3:155,820,255...155,913,383
Ensembl chr 3:155,822,963...155,916,194
G
Kcnc4
potassium voltage-gated channel subfamily C member 4
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KCNC4 mRNA
CTD
PMID:20823114
NCBI chr 2:195,063,967...195,100,244
Ensembl chr 2:195,071,769...195,099,233
G
Kdr
kinase insert domain receptor
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of KDR mRNA
CTD
PMID:18497975
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
G
Klf4
KLF transcription factor 4
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of KLF4 mRNA
CTD
PMID:18497975
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
G
Krt8
keratin 8
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA]
CTD
PMID:20823114
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
G
Lama4
laminin subunit alpha 4
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of LAMA4 mRNA
CTD
PMID:20843944
NCBI chr20:42,392,268...42,533,347
Ensembl chr20:42,392,268...42,533,347
G
Lamb2
laminin subunit beta 2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LAMB2 mRNA
CTD
PMID:20823114
NCBI chr 8:109,178,367...109,190,552
Ensembl chr 8:109,178,409...109,190,549
G
Lcn2
lipocalin 2
multiple interactions
ISO
[Estradiol co-treated with Medroxyprogesterone Acetate] results in decreased expression of LCN2 mRNA
CTD
PMID:15866426
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
G
Ldha
lactate dehydrogenase A
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LDHA mRNA
CTD
PMID:20823114
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
G
Lgals3
galectin 3
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of LGALS3 mRNA
CTD
PMID:20823114
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
G
LOC120095955
mucin-12-like
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MUC12 mRNA
CTD
PMID:20823114
NCBI chr12:19,486,041...19,493,995
G
Loxl4
lysyl oxidase-like 4
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of LOXL4 mRNA
CTD
PMID:20843944
NCBI chr 1:241,396,183...241,416,385
Ensembl chr 1:241,397,983...241,416,322
G
Lpar3
lysophosphatidic acid receptor 3
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LPAR3 mRNA
CTD
PMID:20823114
NCBI chr 2:235,125,234...235,193,916
Ensembl chr 2:235,149,065...235,193,357
G
Lratd2
LRAT domain containing 2
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of LRATD2 mRNA
CTD
PMID:20843944
NCBI chr 7:92,376,713...92,387,045
Ensembl chr 7:92,362,194...92,388,189
G
Ltbp1
latent transforming growth factor beta binding protein 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LTBP1 mRNA
CTD
PMID:20823114
NCBI chr 6:20,029,629...20,425,339
Ensembl chr 6:20,029,629...20,425,349
G
Lyve1
lymphatic vessel endothelial hyaluronan receptor 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of XLKD1 mRNA
CTD
PMID:20843944
NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309
G
Map1a
microtubule-associated protein 1A
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MAP1A mRNA
CTD
PMID:20823114
NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899
G
Map4k4
mitogen-activated protein kinase kinase kinase kinase 4
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MAP4K4 mRNA
CTD
PMID:20823114
NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698
G
Map7
microtubule-associated protein 7
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of MAP7 mRNA
CTD
PMID:20843944
NCBI chr 1:14,910,433...15,037,574
Ensembl chr 1:14,910,551...15,037,574
G
Mapk1
mitogen activated protein kinase 1
multiple interactions
ISO
Medroxyprogesterone Acetate results in increased phosphorylation of and results in increased activity of MAPK1 protein
CTD
PMID:20535544
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
G
Mapk3
mitogen activated protein kinase 3
multiple interactions
ISO
Medroxyprogesterone Acetate results in increased phosphorylation of and results in increased activity of MAPK3 protein
CTD
PMID:20535544
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
G
Marco
macrophage receptor with collagenous structure
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of MARCO mRNA
CTD
PMID:20843944
NCBI chr13:31,616,278...31,648,521
Ensembl chr13:31,616,278...31,648,521
G
Mgat4b
alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MGAT4B mRNA
CTD
PMID:20823114
NCBI chr10:34,548,918...34,559,229
Ensembl chr10:34,549,433...34,559,229
G
Mgst1
microsomal glutathione S-transferase 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of MGST1 mRNA
CTD
PMID:20843944
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
G
Mir142
microRNA 142
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of MIR142 mRNA
CTD
PMID:22543862
NCBI chr10:72,557,864...72,557,950
Ensembl chr10:72,557,857...72,557,967
G
Mir146b
microRNA 146b
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of MIR146B mRNA
CTD
PMID:22543862
NCBI chr 1:245,203,438...245,203,525
Ensembl chr 1:245,203,438...245,203,525
G
Mir193b
microRNA 193b
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of MIR193B mRNA
CTD
PMID:22543862
NCBI chr10:1,317,742...1,317,824
Ensembl chr10:1,317,742...1,317,824
G
Mir21
microRNA 21
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of MIR21 mRNA
CTD
PMID:22543862
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
G
Mir27b
microRNA 27b
multiple interactions
ISO
[Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MIR27B mRNA
CTD
PMID:30328349
NCBI chr17:1,813,427...1,813,523
Ensembl chr17:1,813,426...1,813,529
G
Mmp1
matrix metallopeptidase 1
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of MMP1 mRNA
CTD
PMID:20843944
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
G
Mmp2
matrix metallopeptidase 2
multiple interactions decreases activity
ISO
[Indomethacin co-treated with Medroxyprogesterone Acetate] results in decreased activity of MMP2 protein [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MMP2 mRNA Medroxyprogesterone Acetate results in decreased activity of MMP2 protein
CTD
PMID:16537180 PMID:20823114
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
G
Mmp9
matrix metallopeptidase 9
multiple interactions decreases expression decreases activity
ISO
[Indomethacin co-treated with Medroxyprogesterone Acetate] results in decreased activity of MMP9 protein Medroxyprogesterone Acetate results in decreased expression of MMP9 mRNA Medroxyprogesterone Acetate results in decreased activity of MMP9 protein
CTD
PMID:16537180 PMID:20843944
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
G
Mmrn1
multimerin 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of MMRN1 mRNA
CTD
PMID:20843944
NCBI chr 4:89,875,408...89,950,814
Ensembl chr 4:89,903,174...89,950,474
G
Ms4a6a
membrane spanning 4-domains A6A
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of MS4A6A mRNA
CTD
PMID:20843944
NCBI chr 1:208,401,465...208,414,831
Ensembl chr 1:208,401,466...208,414,758
G
Mthfd2
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTHFD2 mRNA
CTD
PMID:20823114
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
G
Mtr
5-methyltetrahydrofolate-homocysteine methyltransferase
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTR mRNA
CTD
PMID:20823114
NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822
G
Mtss1
MTSS I-BAR domain containing 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of MTSS1 mRNA
CTD
PMID:20843944
NCBI chr 7:90,488,751...90,628,007
Ensembl chr 7:90,488,754...90,627,968
G
Muc1
mucin 1, cell surface associated
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of MUC1 mRNA
CTD
PMID:18497975
NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
G
Myb
MYB proto-oncogene, transcription factor
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of MYB mRNA
CTD
PMID:18497975
NCBI chr 1:15,939,771...15,973,367
Ensembl chr 1:15,939,761...15,973,057
G
Myh9
myosin, heavy chain 9
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYH9 mRNA
CTD
PMID:20823114
NCBI chr 7:109,343,718...109,424,457
Ensembl chr 7:109,343,706...109,424,457
G
Myl12a
myosin light chain 12A
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12A mRNA
CTD
PMID:20823114
NCBI chr 9:110,891,970...110,899,655
Ensembl chr 9:110,873,959...110,916,580
G
Myl12b
myosin light chain 12B
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12B mRNA
CTD
PMID:20823114
NCBI chr 9:110,873,855...110,888,187
G
Mylk
myosin light chain kinase
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA
CTD
PMID:20823114
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
G
Myof
myoferlin
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYOF mRNA
CTD
PMID:20823114
NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334
G
Ncf1
neutrophil cytosolic factor 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NCF1 mRNA
CTD
PMID:20823114
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
G
Ncf2
neutrophil cytosolic factor 2
multiple interactions
EXP
[Medroxyprogesterone Acetate co-treated with Estradiol] results in increased expression of NCF2 protein
CTD
PMID:21670166
NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277
G
Ncoa1
nuclear receptor coactivator 1
multiple interactions
ISO
Medroxyprogesterone Acetate promotes the reaction [PGR protein binds to NCOA1 protein]
CTD
PMID:15937332
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
G
Ndst1
N-deacetylase and N-sulfotransferase 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NDST1 mRNA
CTD
PMID:20823114
NCBI chr18:54,136,887...54,199,545
Ensembl chr18:54,140,779...54,178,191
G
Nefm
neurofilament medium chain
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of NEFM mRNA
CTD
PMID:20843944
NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755
G
Nexn
nexilin (F actin binding protein)
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NEXN mRNA
CTD
PMID:20823114
NCBI chr 2:241,186,783...241,218,315
Ensembl chr 2:241,186,790...241,218,342
G
Nfe2l2
NFE2 like bZIP transcription factor 2
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of NFE2L2 mRNA
CTD
PMID:18497975
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
G
Nom1
nucleolar protein with MIF4G domain 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NOM1 mRNA
CTD
PMID:20823114
NCBI chr 4:5,891,220...5,910,741
Ensembl chr 4:5,892,909...5,909,709
G
Nos3
nitric oxide synthase 3
multiple interactions
ISO EXP
Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased activity of NOS3 protein]; Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of NOS3 protein]
CTD
PMID:15358673
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
G
Nphp1
nephrocystin 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NPHP1 mRNA
CTD
PMID:20823114
NCBI chr 3:114,960,650...115,016,234
Ensembl chr 3:114,960,650...115,016,234
G
Nptx2
neuronal pentraxin 2
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of NPTX2 mRNA
CTD
PMID:20843944
NCBI chr12:10,037,435...10,048,345
Ensembl chr12:10,037,435...10,048,345
G
Nptxr
neuronal pentraxin receptor
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NPTXR mRNA
CTD
PMID:20823114
NCBI chr 7:111,336,660...111,354,737
Ensembl chr 7:111,336,664...111,354,802
G
Npy1r
neuropeptide Y receptor Y1
multiple interactions decreases expression
ISO
Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of NPY1R mRNA] Medroxyprogesterone Acetate results in decreased expression of NPY1R mRNA
CTD
PMID:18497975 PMID:19146866
NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759
G
Nr1i2
nuclear receptor subfamily 1, group I, member 2
increases activity
ISO
Medroxyprogesterone Acetate results in increased activity of NR1I2 protein
CTD
PMID:15650019
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
G
Nr2f1
nuclear receptor subfamily 2, group F, member 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NR2F1 mRNA
CTD
PMID:20823114
NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123
G
Nr3c1
nuclear receptor subfamily 3, group C, member 1
affects response to substance multiple interactions
ISO
NR3C1 protein affects the susceptibility to Medroxyprogesterone Acetate [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 protein
CTD
PMID:23275455 PMID:23658782
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
G
Nr3c2
nuclear receptor subfamily 3, group C, member 2
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 protein
CTD
PMID:23275455
NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885
G
Nr4a2
nuclear receptor subfamily 4, group A, member 2
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of NR4A2 mRNA
CTD
PMID:20843944
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
G
Nrip1
nuclear receptor interacting protein 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NRIP1 mRNA
CTD
PMID:20823114
NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761
G
Nt5e
5' nucleotidase, ecto
decreases expression multiple interactions
ISO
Medroxyprogesterone Acetate results in decreased expression of NT5E mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NT5E mRNA
CTD
PMID:20823114 PMID:20843944
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
G
Nts
neurotensin
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NTS mRNA
CTD
PMID:20823114
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
G
Nup155
nucleoporin 155
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NUP155 mRNA
CTD
PMID:20823114
NCBI chr 2:57,201,310...57,252,918
Ensembl chr 2:57,201,272...57,254,148
G
Ogfrl1
opioid growth factor receptor-like 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OGFRL1 mRNA
CTD
PMID:20823114
NCBI chr 9:25,828,865...25,842,424
Ensembl chr 9:25,828,869...25,842,352
G
Or8b8
olfactory receptor family 8 subfamily B member 8
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OR8B8 mRNA
CTD
PMID:20823114
NCBI chr 8:37,693,578...37,694,510
Ensembl chr 8:37,693,499...37,694,547
G
P4hb
prolyl 4-hydroxylase subunit beta
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of P4HB mRNA
CTD
PMID:20823114
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
G
Paep
progestagen associated endometrial protein
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PAEP mRNA
CTD
PMID:20823114
NCBI chr 3:8,531,136...8,534,430
Ensembl chr 3:8,531,138...8,534,430
G
Pakap
paralemmin A kinase anchor protein
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PALM2AKAP2 mRNA
CTD
PMID:20823114
NCBI chr 5:72,536,986...72,648,524 NCBI chr 5:72,313,646...72,450,645
Ensembl chr 5:72,181,718...72,648,524
G
Pcdh17
protocadherin 17
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of PCDH17 mRNA
CTD
PMID:20843944
NCBI chr15:60,222,088...60,316,172
Ensembl chr15:60,222,004...60,313,999
G
Pcdh18
protocadherin 18
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDH18 mRNA
CTD
PMID:20823114
NCBI chr 2:133,831,996...133,845,992
Ensembl chr 2:133,832,001...133,845,883
G
Pcdh20
protocadherin 20
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of PCDH20 mRNA
CTD
PMID:20843944
NCBI chr15:64,425,534...64,431,790
Ensembl chr15:64,425,534...64,431,790
G
Pcdhb5
protocadherin beta 5
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDHB4 mRNA
CTD
PMID:20823114
NCBI chr18:29,024,315...29,032,183
Ensembl chr18:29,028,382...29,053,259
G
Pdgfa
platelet derived growth factor subunit A
multiple interactions
ISO
[Estradiol co-treated with Medroxyprogesterone Acetate] results in decreased secretion of [PDGFA protein binds to PDGFB protein]
CTD
PMID:15866426
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
G
Pdgfb
platelet derived growth factor subunit B
multiple interactions
ISO
[Estradiol co-treated with Medroxyprogesterone Acetate] results in decreased secretion of [PDGFA protein binds to PDGFB protein]
CTD
PMID:15866426
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
G
Pdk1
pyruvate dehydrogenase kinase 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PDK1 mRNA
CTD
PMID:20823114
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
G
Penk
proenkephalin
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of PENK mRNA
CTD
PMID:20843944
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
G
Pgr
progesterone receptor
decreases expression multiple interactions
ISO
Medroxyprogesterone Acetate results in decreased expression of PGR protein Medroxyprogesterone Acetate results in decreased expression of PGR mRNA; Medroxyprogesterone Acetate results in decreased expression of PGR protein Medroxyprogesterone Acetate promotes the reaction [PGR protein binds to NCOA1 protein]
CTD
PMID:2151368 PMID:15937332 PMID:20843944 PMID:23183084
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
G
Pgrmc2
progesterone receptor membrane component 2
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PGRMC2 mRNA
CTD
PMID:20823114
NCBI chr 2:124,068,257...124,084,155
Ensembl chr 2:124,068,260...124,084,155
G
Pitpnc1
phosphatidylinositol transfer protein, cytoplasmic 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PITPNC1 mRNA
CTD
PMID:20823114
NCBI chr10:92,163,558...92,428,971
Ensembl chr10:92,167,196...92,429,297
G
Pkd2l1
polycystin 2 like 1, transient receptor potential cation channel
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PKD2L1 mRNA
CTD
PMID:20823114
NCBI chr 1:243,032,891...243,070,031
Ensembl chr 1:243,032,913...243,070,031
G
Plat
plasminogen activator, tissue type
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLAT mRNA
CTD
PMID:20823114
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
G
Plau
plasminogen activator, urokinase
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of PLAU mRNA
CTD
PMID:20843944
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
G
Plcxd3
phosphatidylinositol-specific phospholipase C, X domain containing 3
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of PLCXD3 mRNA
CTD
PMID:20843944
NCBI chr 2:53,567,022...53,746,384
Ensembl chr 2:53,567,022...53,746,384
G
Plekhg3
pleckstrin homology and RhoGEF domain containing G3
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLEKHG3 mRNA
CTD
PMID:20823114
NCBI chr 6:95,265,756...95,308,952
Ensembl chr 6:95,266,058...95,310,359
G
Plg
plasminogen
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of PLG
CTD
PMID:1828463
NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786
G
Plod2
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of PLOD2 mRNA
CTD
PMID:20843944
NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255
G
Pls3
plastin 3
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PLS3 mRNA
CTD
PMID:20823114
NCBI chr X:111,589,193...111,683,908
Ensembl chr X:111,589,254...111,683,891
G
Ppbp
pro-platelet basic protein
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of PPBP mRNA
CTD
PMID:20843944
NCBI chr14:17,302,326...17,303,130
Ensembl chr14:17,302,326...17,303,130
G
Ppia
peptidylprolyl isomerase A
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PPIA mRNA
CTD
PMID:20823114
NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601
G
Prdx5
peroxiredoxin 5
affects expression multiple interactions
EXP
Medroxyprogesterone Acetate affects the expression of PRDX5 [Medroxyprogesterone Acetate co-treated with Estradiol] affects the expression of PRDX5
CTD
PMID:21159850
NCBI chr 1:204,099,826...204,103,589
Ensembl chr 1:204,099,826...204,114,268
G
Prl
prolactin
multiple interactions increases expression
ISO
2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL protein; [Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein; [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; Cannabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Cannabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; Dinoprostone promotes the reaction [[Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Losartan inhibits the reaction [AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]]; Mifepristone inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of PRL mRNA]; Rimonabant inhibits the reaction [Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]
CTD
PMID:7506205 PMID:15774544 PMID:16709600 PMID:20823114 PMID:21903722 PMID:30328349 PMID:31154070 PMID:31953017 PMID:32781018 PMID:36682589 More...
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
G
Prrx1
paired related homeobox 1
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of PRRX1 mRNA
CTD
PMID:20843944
NCBI chr13:75,600,777...75,671,896
Ensembl chr13:75,601,706...75,670,866
G
Prss12
serine protease 12
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PRSS12 mRNA
CTD
PMID:20823114
NCBI chr 2:211,624,134...211,684,126
Ensembl chr 2:211,624,134...211,684,126
G
Ptgs2
prostaglandin-endoperoxide synthase 2
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of PTGS2 mRNA
CTD
PMID:20843944
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
G
Ptk7
protein tyrosine kinase 7
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTK7 mRNA
CTD
PMID:20823114
NCBI chr 9:14,352,155...14,418,473
Ensembl chr 9:14,351,202...14,418,494
G
Ptp4a1
protein tyrosine phosphatase 4A1
multiple interactions
ISO
Cycloheximide inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of PTP4A1 mRNA]]; Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of PTP4A1 mRNA]
CTD
PMID:19146866
NCBI chr 9:33,214,201...33,245,046
Ensembl chr 9:33,214,208...33,221,964
G
Ptpa
protein phosphatase 2 phosphatase activator
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTPA mRNA
CTD
PMID:20823114
NCBI chr 3:13,689,742...13,720,287
Ensembl chr 3:13,689,741...13,722,549
G
Rab1b
RAB1B, member RAS oncogene family
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB1B mRNA
CTD
PMID:20823114
NCBI chr 1:202,405,759...202,413,850
Ensembl chr 1:202,405,759...202,413,868 Ensembl chr X:202,405,759...202,413,868
G
Rab31
RAB31, member RAS oncogene family
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB31 mRNA
CTD
PMID:20823114
NCBI chr 9:105,246,712...105,382,973
Ensembl chr 9:105,246,709...105,381,253
G
Ran
RAN, member RAS oncogene family
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RAN mRNA
CTD
PMID:20823114
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
G
Rela
RELA proto-oncogene, NF-kB subunit
multiple interactions
ISO
Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]]; Medroxyprogesterone Acetate inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Mifepristone inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]]
CTD
PMID:15358673
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
G
Ret
ret proto-oncogene
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RET mRNA
CTD
PMID:20823114
NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176
G
Rgs10
regulator of G-protein signaling 10
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RGS10 mRNA
CTD
PMID:20823114
NCBI chr 1:182,946,334...182,987,729
Ensembl chr 1:182,946,336...182,987,697
G
Rhobtb3
Rho-related BTB domain containing 3
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RHOBTB3 mRNA
CTD
PMID:20823114
NCBI chr 2:5,363,388...5,419,164
Ensembl chr 2:5,363,388...5,419,041
G
Rin1
Ras and Rab interactor 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RIN1 mRNA
CTD
PMID:20823114
NCBI chr 1:202,355,729...202,362,731
Ensembl chr 1:202,355,890...202,362,729
G
Rnase1
ribonuclease A family member 1, pancreatic
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of RNASE1 mRNA
CTD
PMID:20843944
NCBI chr15:24,361,924...24,363,633
Ensembl chr15:24,361,927...24,363,624
G
Rpgr
retinitis pigmentosa GTPase regulator
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of RPGR mRNA
CTD
PMID:20843944
NCBI chr X:12,566,447...12,628,171
Ensembl chr X:12,566,645...12,747,882
G
Rpn1
ribophorin I
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPN1 mRNA
CTD
PMID:20823114
NCBI chr 4:120,543,667...120,565,069
Ensembl chr 4:120,543,667...120,565,069
G
Rps6kb1
ribosomal protein S6 kinase B1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPS6KB1 mRNA
CTD
PMID:20823114
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
G
Rpsa
ribosomal protein SA
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RPSA mRNA
CTD
PMID:20823114
NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247
G
Runx1
RUNX family transcription factor 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of RUNX1 mRNA
CTD
PMID:18497975
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
G
S100a14
S100 calcium binding protein A14
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of S100A14 mRNA
CTD
PMID:20823114
NCBI chr 2:176,008,395...176,010,423
Ensembl chr 2:176,008,395...176,010,423
G
Saraf
store-operated calcium entry-associated regulatory factor
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SARAF mRNA
CTD
PMID:20823114
NCBI chr16:58,017,231...58,035,481
Ensembl chr16:58,017,231...58,035,545
G
Scamp4
secretory carrier membrane protein 4
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SCAMP4 mRNA
CTD
PMID:20823114
NCBI chr 7:9,101,504...9,113,929
Ensembl chr 7:9,101,489...9,113,967
G
Sdcbp
syndecan binding protein
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SDCBP mRNA
CTD
PMID:20823114
NCBI chr 5:19,473,499...19,517,188
Ensembl chr 5:19,489,961...19,527,572
G
Selenop
selenoprotein P
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of SELENOP mRNA
CTD
PMID:18497975
NCBI chr 2:52,498,123...52,508,409
Ensembl chr 2:52,498,339...52,508,852
G
Sema3a
semaphorin 3A
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SEMA3A mRNA
CTD
PMID:20823114
NCBI chr 4:21,282,398...21,754,834
Ensembl chr 4:21,287,982...21,494,432
G
Septin11
septin 11
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SEPTIN11 mRNA
CTD
PMID:20823114
NCBI chr14:14,844,759...14,990,856
Ensembl chr14:14,844,580...14,990,853
G
Serpinc1
serpin family C member 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of SERPINC1
CTD
PMID:1828463
NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293
G
Serpine1
serpin family E member 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of SERPINE1 mRNA; Medroxyprogesterone Acetate results in increased expression of SERPINE1 protein
CTD
PMID:16011840 PMID:20843944
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
G
Sfn
stratifin
multiple interactions
ISO
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of SFN mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of SFN protein
CTD
PMID:22534328
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
G
Sgk1
serum/glucocorticoid regulated kinase 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of SGK1 mRNA
CTD
PMID:18497975
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
G
Sirt1
sirtuin 1
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SIRT1 protein
CTD
PMID:16709600
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
G
Slc1a3
solute carrier family 1 member 3
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of SLC1A3 mRNA
CTD
PMID:20843944
NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
G
Slc46a2
solute carrier family 46, member 2
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of SLC46A2 mRNA
CTD
PMID:20843944
NCBI chr 5:74,800,226...74,808,128
Ensembl chr 5:74,800,226...74,808,128
G
Slc47a1
solute carrier family 47 member 1
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of SLC47A1 mRNA
CTD
PMID:20843944
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
G
Slc5a3
solute carrier family 5 member 3
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of SLC5A3 mRNA
CTD
PMID:20843944
NCBI chr11:31,313,847...31,316,293
Ensembl chr11:31,295,476...31,318,883
G
Slc7a2
solute carrier family 7 member 2
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of SLC7A2 mRNA
CTD
PMID:20843944
NCBI chr16:51,417,478...51,470,784
Ensembl chr16:51,417,493...51,470,784
G
Slc7a8
solute carrier family 7 member 8
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of SLC7A8 mRNA
CTD
PMID:20843944
NCBI chr15:28,183,013...28,242,717
Ensembl chr15:28,183,015...28,242,717
G
Slc9a9
solute carrier family 9 member A9
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of SLC9A9 mRNA
CTD
PMID:20843944
NCBI chr 8:95,232,889...95,797,262
Ensembl chr 8:95,232,905...95,796,318
G
Sln
sarcolipin
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of SLN mRNA
CTD
PMID:20843944
NCBI chr 8:54,221,389...54,248,110
Ensembl chr 8:54,243,542...54,247,791
G
Smox
spermine oxidase
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of SMOX mRNA
CTD
PMID:20843944
NCBI chr 3:118,731,814...118,767,242
Ensembl chr 3:118,731,900...118,765,710
G
Sod1
superoxide dismutase 1
multiple interactions increases expression increases activity
ISO
[Estradiol co-treated with Medroxyprogesterone Acetate] results in increased activity of SOD1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of SOD1 mRNA; [Estradiol deficiency co-treated with Medroxyprogesterone Acetate deficiency] results in decreased activity of SOD1 protein; [Estradiol deficiency co-treated with Medroxyprogesterone Acetate deficiency] results in decreased expression of SOD1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD1 mRNA; Estradiol promotes the reaction [Medroxyprogesterone Acetate results in increased activity of SOD1 protein] Medroxyprogesterone Acetate results in increased expression of SOD1 mRNA
CTD
PMID:11756571 PMID:12093828 PMID:16709600
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
G
Sod2
superoxide dismutase 2
multiple interactions affects expression increases expression increases activity
ISO EXP
[Estradiol co-treated with Medroxyprogesterone Acetate] results in increased activity of SOD2 protein; [Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of SOD2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 protein; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA]; Medroxyprogesterone Acetate promotes the reaction [CREBBP protein binds to SOD2 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of SOD2 mRNA]; protein kinase inhibitor peptide inhibits the reaction [[Estradiol co-treated with Medroxyprogesterone Acetate] results in increased activity of SOD2 protein]; WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA] [Medroxyprogesterone Acetate co-treated with Estradiol] affects the expression of SOD2 Medroxyprogesterone Acetate affects the expression of SOD2 Medroxyprogesterone Acetate results in increased activity of SOD2 protein
CTD
PMID:11756571 PMID:12093828 PMID:16709600 PMID:20685861 PMID:21159850
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
G
Spp1
secreted phosphoprotein 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of SPP1 mRNA
CTD
PMID:20843944
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
G
Spry1
sprouty RTK signaling antagonist 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of SPRY1 mRNA
CTD
PMID:20843944
NCBI chr 2:120,557,256...120,561,917
Ensembl chr 2:120,556,706...120,566,189
G
Srpx
sushi-repeat-containing protein, X-linked
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of SRPX mRNA
CTD
PMID:20843944
NCBI chr X:12,676,984...12,751,296
Ensembl chr X:12,566,645...12,747,882
G
Srsf7
serine and arginine rich splicing factor 7
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SRSF7 mRNA
CTD
PMID:20823114
NCBI chr 6:14,811,775...14,818,968
Ensembl chr 6:14,811,808...14,818,965
G
Stk38
serine/threonine kinase 38
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of STK38 mRNA
CTD
PMID:20823114
NCBI chr20:7,034,245...7,067,803
Ensembl chr20:7,034,242...7,068,198
G
Stom
stomatin
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of STOM mRNA
CTD
PMID:18497975
NCBI chr 3:18,645,058...18,667,343
Ensembl chr 3:18,644,378...18,667,354
G
Sulf1
sulfatase 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SULF1 mRNA
CTD
PMID:20823114
NCBI chr 5:6,362,894...6,526,174
Ensembl chr 5:6,362,911...6,525,584
G
Tagln
transgelin
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TAGLN mRNA
CTD
PMID:20823114
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
G
Tbxas1
thromboxane A synthase 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of TBXAS1 mRNA
CTD
PMID:20843944
NCBI chr 4:67,664,963...67,837,096
Ensembl chr 4:67,665,007...67,837,096
G
Tcea1
transcription elongation factor A1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TCEA1 mRNA
CTD
PMID:20823114
NCBI chr 5:14,631,454...14,668,769
Ensembl chr 5:14,631,454...14,668,745 Ensembl chr15:14,631,454...14,668,745
G
Tdo2
tryptophan 2,3-dioxygenase
multiple interactions
ISO
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA
CTD
PMID:32781018
NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511
G
Tert
telomerase reverse transcriptase
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TERT mRNA
CTD
PMID:20823114
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
G
Tfpi
tissue factor pathway inhibitor
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of TFPI mRNA
CTD
PMID:20843944
NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880
G
Tfpi2
tissue factor pathway inhibitor 2
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of TFPI2 mRNA
CTD
PMID:20843944
NCBI chr 4:31,981,786...31,986,707
Ensembl chr 4:31,982,178...31,986,600
G
Tgfb3
transforming growth factor, beta 3
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of TGFB3 mRNA
CTD
PMID:20843944
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
G
Tgfbr2
transforming growth factor, beta receptor 2
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of TGFBR2 mRNA
CTD
PMID:20843944
NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228
G
Thbs1
thrombospondin 1
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of THBS1 mRNA
CTD
PMID:18497975
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
G
Timp3
TIMP metallopeptidase inhibitor 3
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of TIMP3 mRNA
CTD
PMID:20843944
NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
G
Tmem158
transmembrane protein 158
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of TMEM158 mRNA
CTD
PMID:20843944
NCBI chr 8:122,913,675...122,914,673
Ensembl chr 8:122,913,675...122,914,673
G
Tnc
tenascin C
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TNC mRNA
CTD
PMID:20823114
NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
G
Tnf
tumor necrosis factor
multiple interactions
ISO
[Estradiol co-treated with Medroxyprogesterone Acetate] results in decreased secretion of TNF protein; [Polyphenols co-treated with Antioxidants co-treated with Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with Medroxyprogesterone Acetate co-treated with Celecoxib] results in decreased expression of TNF
CTD
PMID:15866426 PMID:16702388
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Tox2
TOX high mobility group box family member 2
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of TOX2 mRNA
CTD
PMID:20843944
NCBI chr 3:151,853,294...151,980,086
Ensembl chr 3:151,853,294...151,980,749
G
Tp53
tumor protein p53
multiple interactions
ISO
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of TP53 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of TP53 protein
CTD
PMID:22534328
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Tpd52
tumor protein D52
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of TPD52 mRNA
CTD
PMID:18497975
NCBI chr 2:92,735,365...92,816,079
Ensembl chr 2:92,735,620...92,816,622
G
Tpi1
triosephosphate isomerase 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TPI1 mRNA
CTD
PMID:20823114
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
G
Tpsg1
tryptase gamma 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TPSG1 mRNA
CTD
PMID:20823114
NCBI chr10:14,386,352...14,390,258
Ensembl chr10:14,386,352...14,390,258
G
Tsc22d3
TSC22 domain family, member 3
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of TSC22D3 mRNA
CTD
PMID:20843944
NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861
G
Tsku
tsukushi, small leucine rich proteoglycan
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of TSKU mRNA
CTD
PMID:20843944
NCBI chr 1:152,660,259...152,671,682
Ensembl chr 1:152,656,693...152,672,588
G
Txn1
thioredoxin 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TXN mRNA
CTD
PMID:20823114
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
G
Ube2d2b
ubiquitin-conjugating enzyme E2D 2B
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of UBE2D4 mRNA
CTD
PMID:20823114
NCBI chr14:1,915,999...1,917,473
Ensembl chr14:1,916,845...1,917,416
G
Ugcg
UDP-glucose ceramide glucosyltransferase
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of UGCG mRNA
CTD
PMID:20823114
NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393
G
Usp12
ubiquitin specific peptidase 12
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of USP12 mRNA
CTD
PMID:20823114
NCBI chr12:8,309,845...8,363,686
Ensembl chr12:8,309,750...8,363,656
G
Vcam1
vascular cell adhesion molecule 1
multiple interactions
ISO
Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]]; Medroxyprogesterone Acetate inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]; Mifepristone inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]]
CTD
PMID:15358673
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
G
Vdr
vitamin D receptor
multiple interactions
ISO
VDR gene polymorphism affects the susceptibility to [Alendronate co-treated with Estrogens, Conjugated (USP) co-treated with Medroxyprogesterone Acetate]; VDR gene polymorphism affects the susceptibility to [Estrogens, Conjugated (USP) co-treated with Medroxyprogesterone Acetate]
CTD
PMID:15739035
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
G
Vegfa
vascular endothelial growth factor A
increases expression multiple interactions
ISO
Medroxyprogesterone Acetate results in increased expression of VEGFA mRNA; Medroxyprogesterone Acetate results in increased expression of VEGFA mRNA alternative form Mifepristone inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of VEGFA mRNA]
CTD
PMID:15860260 PMID:17010073
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
G
Vim
vimentin
multiple interactions
ISO
[Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein
CTD
PMID:20823114
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
G
Vmo1
vitelline membrane outer layer 1 homolog
decreases expression
ISO
Medroxyprogesterone Acetate results in decreased expression of VMO1 mRNA
CTD
PMID:20843944
NCBI chr10:55,227,944...55,234,794
Ensembl chr10:55,227,944...55,229,289
G
Vps39
VPS39 subunit of HOPS complex
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VPS39 mRNA
CTD
PMID:20823114
NCBI chr 3:107,266,846...107,304,884
Ensembl chr 3:107,267,310...107,304,975
G
Vsig4
V-set and immunoglobulin domain containing 4
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of VSIG4 mRNA
CTD
PMID:20843944
NCBI chr X:61,144,926...61,170,212
Ensembl chr X:61,144,928...61,170,212
G
Wnt5a
Wnt family member 5A
multiple interactions increases expression
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WNT5A mRNA; WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]; WNT5A protein affects the reaction [Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] Medroxyprogesterone Acetate results in increased expression of WNT5A mRNA
CTD
PMID:20685861 PMID:20823114
NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234
G
Wwtr1
WW domain containing transcription regulator 1
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WWTR1 mRNA
CTD
PMID:20823114
NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:141,648,108...141,766,968
G
Zbtb16
zinc finger and BTB domain containing 16
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of ZBTB16 mRNA
CTD
PMID:20843944
NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011
G
Zbtb45
zinc finger and BTB domain containing 45
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZBTB45 mRNA
CTD
PMID:20823114
NCBI chr 1:73,634,895...73,639,802
Ensembl chr 1:73,635,448...73,639,556
G
Zfp36
zinc finger protein 36
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of ZFP36 mRNA
CTD
PMID:15866426
NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564
G
Zfp36l1
zinc finger protein 36, C3H type-like 1
multiple interactions
ISO
[Medroxyprogesterone Acetate co-treated with Estradiol] results in increased expression of ZFP36L1 mRNA
CTD
PMID:19146866
NCBI chr 6:98,930,705...98,935,748
Ensembl chr 6:98,930,718...98,935,748
G
Zpld1
zona pellucida-like domain containing 1
increases expression
ISO
Medroxyprogesterone Acetate results in increased expression of ZPLD1 mRNA
CTD
PMID:20843944
NCBI chr11:45,482,883...45,524,555
Ensembl chr11:45,482,891...45,522,385
G
Zscan10
zinc finger and SCAN domain containing 10
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN10 mRNA
CTD
PMID:20823114
NCBI chr10:12,636,302...12,646,275
Ensembl chr10:12,636,302...12,646,275
G
Zscan20
zinc finger and SCAN domain containing 20
multiple interactions
ISO
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN20 mRNA
CTD
PMID:20823114
NCBI chr 5:140,926,596...140,956,285
Ensembl chr 5:140,930,689...140,956,336
G
Abcb11
ATP binding cassette subfamily B member 11
decreases activity
ISO
Megestrol Acetate results in decreased activity of ABCB11 protein
CTD
PMID:23956101
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
G
Ahsa1
activator of Hsp90 ATPase activity 1
increases expression
ISO
Megestrol Acetate results in increased expression of AHSA1 protein
CTD
PMID:16939895
NCBI chr 6:106,913,296...106,921,347
Ensembl chr 6:106,913,530...106,921,345
G
Ar
androgen receptor
multiple interactions
ISO
Megestrol Acetate binds to and results in decreased activity of AR protein
CTD
PMID:25752796
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Bcl11b
BCL11 transcription factor B
multiple interactions
EXP
[Ethinyl Estradiol co-treated with Megestrol Acetate] results in decreased expression of BCL11B mRNA
CTD
PMID:22085904
NCBI chr 6:126,834,531...126,927,720
Ensembl chr 6:126,834,531...126,928,224
G
Cct6a
chaperonin containing TCP1 subunit 6A
increases expression
ISO
Megestrol Acetate results in increased expression of CCT6A protein
CTD
PMID:16939895
NCBI chr12:26,872,736...26,883,125
Ensembl chr12:26,872,574...26,883,337
G
Cldn1
claudin 1
multiple interactions decreases expression
ISO
Megestrol Acetate results in decreased expression of and affects the localization of CLDN1 protein Megestrol Acetate results in decreased expression of CLDN1 mRNA
CTD
PMID:22883527
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
G
Cldn4
claudin 4
multiple interactions decreases expression
ISO
Megestrol Acetate results in decreased expression of and results in increased localization of CLDN4 protein Megestrol Acetate results in decreased expression of CLDN4 mRNA
CTD
PMID:23095775
NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436
G
Comt
catechol-O-methyltransferase
increases expression
ISO
Megestrol Acetate results in increased expression of COMT protein
CTD
PMID:16939895
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
G
Esr1
estrogen receptor 1
multiple interactions
ISO
ESR1 protein affects the reaction [Megestrol Acetate results in increased expression of GREB1 mRNA]
CTD
PMID:33405908
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Greb1
growth regulating estrogen receptor binding 1
increases expression multiple interactions
ISO
Megestrol Acetate results in increased expression of GREB1 mRNA ESR1 protein affects the reaction [Megestrol Acetate results in increased expression of GREB1 mRNA]; Fulvestrant inhibits the reaction [Megestrol Acetate results in increased expression of GREB1 mRNA]
CTD
PMID:33405908
NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633
G
Krt8
keratin 8
increases expression
ISO
Megestrol Acetate results in increased expression of KRT8 protein
CTD
PMID:16939895
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
G
Mmp12
matrix metallopeptidase 12
multiple interactions
EXP
[Ethinyl Estradiol co-treated with Megestrol Acetate] results in increased expression of MMP12 protein
CTD
PMID:22085904
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
G
Mmp3
matrix metallopeptidase 3
multiple interactions
EXP
[Ethinyl Estradiol co-treated with Megestrol Acetate] results in increased expression of MMP3 protein
CTD
PMID:22085904
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
G
Mmp8
matrix metallopeptidase 8
multiple interactions
EXP
[Ethinyl Estradiol co-treated with Megestrol Acetate] results in increased expression of MMP8 protein
CTD
PMID:22085904
NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520
G
Pgr
progesterone receptor
multiple interactions
ISO
Megestrol Acetate binds to and results in increased activity of PGR protein
CTD
PMID:25752796
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
G
Ppia
peptidylprolyl isomerase A
decreases expression
ISO
Megestrol Acetate results in decreased expression of PPIA protein
CTD
PMID:16939895
NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601
G
Rab6a
RAB6A, member RAS oncogene family
increases expression
ISO
Megestrol Acetate results in increased expression of RAB6A protein
CTD
PMID:16939895
NCBI chr 1:154,957,870...155,008,922
Ensembl chr 1:154,958,189...154,996,715
G
Sf3a3
splicing factor 3a, subunit 3
increases expression
ISO
Megestrol Acetate results in increased expression of SF3A3 protein
CTD
PMID:16939895
NCBI chr 5:136,967,713...136,987,345
Ensembl chr 5:136,967,691...136,987,361
G
Sgk1
serum/glucocorticoid regulated kinase 1
increases expression multiple interactions
ISO
Megestrol Acetate results in increased expression of SGK1 mRNA Fulvestrant inhibits the reaction [Megestrol Acetate results in increased expression of SGK1 mRNA]
CTD
PMID:33405908
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
G
Slc22a2
solute carrier family 22 member 2
multiple interactions
ISO
Megestrol Acetate inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
CTD
PMID:21599003
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
G
Tnc
tenascin C
multiple interactions
EXP
[Ethinyl Estradiol co-treated with Megestrol Acetate] results in decreased expression of TNC mRNA
CTD
PMID:22085904
NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
G
Abcb1a
ATP binding cassette subfamily B member 1A
multiple interactions
ISO
Mometasone Furoate inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]; Mometasone Furoate inhibits the reaction [ABCB1 protein results in increased export of fluorexon]
CTD
PMID:16442095
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
G
Abcg2
ATP binding cassette subfamily G member 2
multiple interactions increases activity
ISO
Mometasone Furoate inhibits the reaction [ABCG2 protein results in increased export of Mitoxantrone] Mometasone Furoate results in increased activity of ABCG2 protein
CTD
PMID:16442095
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
G
Csf2
colony stimulating factor 2
multiple interactions
ISO
Mometasone Furoate inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]
CTD
PMID:10460758
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
G
Cyp2c79
cytochrome P450, family 2, subfamily c, polypeptide 79
decreases activity
ISO
Mometasone Furoate results in decreased activity of CYP2C8 protein
CTD
PMID:15601807
G
F3
coagulation factor III, tissue factor
increases expression
ISO
Mometasone Furoate results in increased expression of F3 protein
CTD
PMID:25569083
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
G
Hsf1
heat shock transcription factor 1
increases activity
ISO
Mometasone Furoate results in increased activity of HSF1 protein
CTD
PMID:34170685
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
G
Il10
interleukin 10
decreases secretion
ISO
Mometasone Furoate results in decreased secretion of IL10 protein
CTD
PMID:9819297
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
G
Il12b
interleukin 12B
multiple interactions
ISO
Mometasone Furoate inhibits the reaction [endotoxin, Escherichia coli results in increased secretion of IL12B protein]
CTD
PMID:19422381
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
G
Il1b
interleukin 1 beta
multiple interactions
ISO
Mometasone Furoate inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]
CTD
PMID:10460758
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Nr3c1
nuclear receptor subfamily 3, group C, member 1
affects binding
EXP ISO
Mometasone Furoate binds to NR3C1 protein
CTD
PMID:16507850 PMID:19422381
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
G
Nr3c2
nuclear receptor subfamily 3, group C, member 2
affects binding
ISO
Mometasone Furoate binds to NR3C2 protein
CTD
PMID:19422381
NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885
G
Pgr
progesterone receptor
multiple interactions affects binding
ISO
Mometasone Furoate binds to and results in increased activity of PGR protein Mometasone Furoate binds to PGR protein
CTD
PMID:15189034 PMID:19422381
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
G
Spp1
secreted phosphoprotein 1
increases expression
ISO
Mometasone Furoate results in increased expression of SPP1 protein
CTD
PMID:21885873
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
G
Tat
tyrosine aminotransferase
increases activity
ISO
Mometasone Furoate results in increased activity of TAT protein
CTD
PMID:19422381
NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
G
Tgm2
transglutaminase 2
increases expression
ISO
Mometasone Furoate results in increased expression of TGM2 protein
CTD
PMID:21885873
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
G
Tnf
tumor necrosis factor
multiple interactions decreases secretion
ISO
Mometasone Furoate inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] Mometasone Furoate results in decreased secretion of TNF protein
CTD
PMID:9819297 PMID:10100995
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Vcam1
vascular cell adhesion molecule 1
multiple interactions
ISO
Mometasone Furoate inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
CTD
PMID:10100995
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
G
Ace
angiotensin I converting enzyme
increases expression
EXP
nandrolone decanoate results in increased expression of ACE mRNA
CTD
PMID:17906098
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
G
Agtr1a
angiotensin II receptor, type 1a
increases expression
EXP
nandrolone decanoate results in increased expression of AGTR1A mRNA
CTD
PMID:17906098
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
G
Agtr2
angiotensin II receptor, type 2
increases expression
EXP
nandrolone decanoate results in increased expression of AGTR2 mRNA
CTD
PMID:17906098
NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057
G
Apoa1
apolipoprotein A1
decreases expression
ISO
nandrolone decanoate results in decreased expression of APOA1 protein
CTD
PMID:16153628
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
G
Apob
apolipoprotein B
increases expression
ISO
nandrolone decanoate results in increased expression of APOB protein
CTD
PMID:16153628
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
G
Ar
androgen receptor
increases expression
EXP
Nandrolone Decanoate results in increased expression of AR protein
CTD
PMID:33984419
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Casp3
caspase 3
multiple interactions increases expression
EXP
Taurine inhibits the reaction [nandrolone decanoate results in increased expression of CASP3 protein]
CTD
PMID:25542992
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
G
Col3a1
collagen type III alpha 1 chain
increases expression
EXP
nandrolone decanoate results in increased expression of COL3A1 mRNA
CTD
PMID:17906098
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
G
Cst3
cystatin C
increases expression
EXP
nandrolone decanoate results in increased expression of CST3 protein
CTD
PMID:29097219
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
G
Esr1
estrogen receptor 1
decreases expression
EXP
Nandrolone Decanoate results in decreased expression of ESR1 protein
CTD
PMID:33984419
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Esr2
estrogen receptor 2
decreases expression
EXP
Nandrolone Decanoate results in decreased expression of ESR2 protein
CTD
PMID:33984419
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
G
Icam1
intercellular adhesion molecule 1
increases expression multiple interactions
EXP
nandrolone decanoate results in increased expression of ICAM1 protein Taurine inhibits the reaction [nandrolone decanoate results in increased expression of ICAM1 protein]
CTD
PMID:25542992
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
G
Ldhc
lactate dehydrogenase C
multiple interactions decreases activity
EXP
Taurine inhibits the reaction [nandrolone decanoate results in decreased activity of LDHC protein]
CTD
PMID:25542992
NCBI chr 1:97,385,984...97,403,382
Ensembl chr 1:97,382,379...97,403,378
G
Lhb
luteinizing hormone subunit beta
increases secretion
EXP
Nandrolone Decanoate results in increased secretion of LHB protein
CTD
PMID:33984419
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
G
Mmp9
matrix metallopeptidase 9
multiple interactions increases expression
EXP
Taurine inhibits the reaction [nandrolone decanoate results in increased expression of MMP9 mRNA]
CTD
PMID:25542992
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
G
Nphs1
NPHS1 adhesion molecule, nephrin
increases expression
EXP
Nandrolone Decanoate results in increased expression of NPHS1 mRNA
CTD
PMID:29097219
NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078
G
Nphs2
NPHS2 stomatin family member, podocin
increases expression
EXP
nandrolone decanoate results in increased expression of NPHS2 mRNA
CTD
PMID:29097219
NCBI chr13:68,448,720...68,461,312
Ensembl chr13:68,448,926...68,461,313
G
Pdyn
prodynorphin
increases expression
EXP
nandrolone decanoate results in increased expression of PDYN mRNA
CTD
PMID:19782718
NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334
G
Pon1
paraoxonase 1
decreases activity
ISO
nandrolone decanoate results in decreased activity of PON1 protein
CTD
PMID:16153628
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
G
Tert
telomerase reverse transcriptase
increases activity
ISO
nandrolone decanoate results in increased activity of TERT protein
CTD
PMID:19561322
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
G
Tnf
tumor necrosis factor
increases expression multiple interactions
EXP
nandrolone decanoate results in increased expression of TNF protein Taurine inhibits the reaction [nandrolone decanoate results in increased expression of TNF protein]
CTD
PMID:25542992
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Ar
androgen receptor
multiple interactions affects localization
ISO
norethindrone enanthate binds to and results in increased activity of AR protein norethindrone enanthate affects the localization of AR protein
CTD
PMID:28478275
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Bcl2
BCL2, apoptosis regulator
multiple interactions
EXP
[norethindrone enanthate co-treated with Estradiol] results in decreased expression of BCL2 mRNA
CTD
PMID:18829022
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
G
Cycs
cytochrome c, somatic
multiple interactions
EXP
[norethindrone enanthate co-treated with Estradiol] results in increased expression of CYCS mRNA
CTD
PMID:18829022
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
G
Abcc2
ATP binding cassette subfamily C member 2
decreases activity
ISO
norgestimate results in decreased activity of ABCC2 protein
CTD
PMID:16049127
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
G
Ar
androgen receptor
multiple interactions affects localization decreases expression
ISO
norgestimate binds to and results in decreased activity of AR protein; norgestimate binds to and results in increased activity of AR protein norgestimate affects the localization of AR protein norgestimate results in decreased expression of AR mRNA
CTD
PMID:17505938 PMID:28478275
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Crp
C-reactive protein
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in increased expression of CRP protein
CTD
PMID:16982228
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
G
Cyp1a2
cytochrome P450, family 1, subfamily a, polypeptide 2
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in decreased activity of CYP1A2 protein
CTD
PMID:16291717
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
G
Cyp2c6
cytochrome P450, family 2, subfamily C, polypeptide 6
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in decreased activity of CYP2C19 protein
CTD
PMID:16291717
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
G
F7
coagulation factor VII
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in increased expression of F7 protein
CTD
PMID:12618251
NCBI chr16:76,489,775...76,500,636
Ensembl chr16:76,489,717...76,500,610
G
F8
coagulation factor VIII
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in increased expression of F8 protein
CTD
PMID:12618251
NCBI chr18:140,848...172,330
Ensembl chr18:140,955...171,857
G
Fga
fibrinogen alpha chain
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in increased expression of [FGA protein binds to FGB protein binds to FGG protein]
CTD
PMID:12618251
NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528
G
Fgb
fibrinogen beta chain
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in increased expression of [FGA protein binds to FGB protein binds to FGG protein]
CTD
PMID:12618251
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
G
Fgg
fibrinogen gamma chain
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in increased expression of [FGA protein binds to FGB protein binds to FGG protein]
CTD
PMID:12618251
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
G
Pgr
progesterone receptor
multiple interactions
ISO
norgestimate binds to and affects the activity of PGR protein
CTD
PMID:1324557 PMID:15697108
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
G
Plat
plasminogen activator, tissue type
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in decreased expression of PLAT protein; [Ethinyl Estradiol co-treated with norgestimate] results in increased activity of PLAT protein
CTD
PMID:12618251
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
G
Plg
plasminogen
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in increased expression of PLG protein
CTD
PMID:12618251
NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786
G
Proc
protein C, inactivator of coagulation factors Va and VIIIa
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in increased expression of PROC protein
CTD
PMID:12618251
NCBI chr18:23,764,367...23,774,816
Ensembl chr18:23,764,368...23,775,133
G
Pros1
protein S
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in decreased expression of PROS1 protein
CTD
PMID:12618251
NCBI chr11:230,597...311,288
Ensembl chr11:230,696...311,286
G
Serpina6
serpin family A member 6
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in increased expression of SERPINA6 protein
CTD
PMID:16982228
NCBI chr 6:122,780,040...122,790,274
Ensembl chr 6:122,780,043...122,790,349
G
Serpina7
serpin family A member 7
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in increased expression of SERPINA7 protein
CTD
PMID:16982228
NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040
G
Serpinc1
serpin family C member 1
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in decreased expression of SERPINC1 protein
CTD
PMID:12618251
NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293
G
Shbg
sex hormone binding globulin
multiple interactions
ISO
[Ethinyl Estradiol co-treated with norgestimate] results in increased expression of SHBG protein
CTD
PMID:12586319 PMID:16982228
NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
G
Casp3
caspase 3
increases activity
ISO
oleandrin results in increased activity of CASP3 protein
CTD
PMID:24172227
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
G
Casp8
caspase 8
increases activity
ISO
oleandrin results in increased activity of CASP8 protein
CTD
PMID:24172227
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
G
Cxcr1
C-X-C motif chemokine receptor 1
increases expression
ISO
oleandrin results in increased expression of CXCR1 mRNA; oleandrin results in increased expression of CXCR1 protein
CTD
PMID:24172227
NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084
G
Cxcr2
C-X-C motif chemokine receptor 2
increases expression
ISO
oleandrin results in increased expression of CXCR2 mRNA; oleandrin results in increased expression of CXCR2 protein
CTD
PMID:24172227
NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425
G
Cxcr4
C-X-C motif chemokine receptor 4
increases expression
ISO
oleandrin results in increased expression of CXCR4 mRNA
CTD
PMID:24172227
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
G
Ache
acetylcholinesterase
decreases activity
ISO
Pancuronium results in decreased activity of ACHE protein
CTD
PMID:24157926 PMID:25522658
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
G
Chrm1
cholinergic receptor, muscarinic 1
multiple interactions
ISO
Pancuronium inhibits the reaction [N-Methylscopolamine binds to CHRM1 protein]
CTD
PMID:9846649
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
G
Chrm2
cholinergic receptor, muscarinic 2
multiple interactions
ISO
Pancuronium inhibits the reaction [N-Methylscopolamine binds to CHRM2 protein]
CTD
PMID:9846649
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
G
Chrm3
cholinergic receptor, muscarinic 3
multiple interactions
ISO
Pancuronium inhibits the reaction [N-Methylscopolamine binds to CHRM3 protein]
CTD
PMID:9846649
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
G
Chrm4
cholinergic receptor, muscarinic 4
multiple interactions
ISO
Pancuronium inhibits the reaction [N-Methylscopolamine binds to CHRM4 protein]
CTD
PMID:9846649
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
G
Chrm5
cholinergic receptor, muscarinic 5
multiple interactions
ISO
Pancuronium inhibits the reaction [N-Methylscopolamine binds to CHRM5 protein]
CTD
PMID:9846649
NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252
G
Chrna3
cholinergic receptor nicotinic alpha 3 subunit
multiple interactions
ISO
Pancuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Pancuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
CTD
PMID:16931985
NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165
G
Chrna4
cholinergic receptor nicotinic alpha 4 subunit
multiple interactions
ISO
Pancuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Pancuronium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Pancuronium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
CTD
PMID:14645658 PMID:16931985
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
G
Chrna7
cholinergic receptor nicotinic alpha 7 subunit
multiple interactions
ISO
Pancuronium inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein]
CTD
PMID:16931985
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
G
Chrnb2
cholinergic receptor nicotinic beta 2 subunit
multiple interactions
ISO
Pancuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Pancuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Pancuronium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Pancuronium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
CTD
PMID:14645658 PMID:16931985
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
G
Chrnb4
cholinergic receptor nicotinic beta 4 subunit
multiple interactions
ISO
Pancuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
CTD
PMID:16931985
NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027
G
Chrm1
cholinergic receptor, muscarinic 1
multiple interactions
ISO
Pipecuronium inhibits the reaction [N-Methylscopolamine binds to CHRM1 protein]
CTD
PMID:9846649
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
G
Chrm2
cholinergic receptor, muscarinic 2
multiple interactions
ISO
Pipecuronium inhibits the reaction [N-Methylscopolamine binds to CHRM2 protein]
CTD
PMID:9846649
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
G
Chrm3
cholinergic receptor, muscarinic 3
multiple interactions
ISO
Pipecuronium inhibits the reaction [N-Methylscopolamine binds to CHRM3 protein]
CTD
PMID:9846649
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
G
Chrm4
cholinergic receptor, muscarinic 4
multiple interactions
ISO
Pipecuronium inhibits the reaction [N-Methylscopolamine binds to CHRM4 protein]
CTD
PMID:9846649
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
G
Chrm5
cholinergic receptor, muscarinic 5
multiple interactions
ISO
Pipecuronium inhibits the reaction [N-Methylscopolamine binds to CHRM5 protein]
CTD
PMID:9846649
NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252
G
Gabra1
gamma-aminobutyric acid type A receptor subunit alpha 1
multiple interactions
EXP
pregnenolone sulfate inhibits the reaction [gamma-Aminobutyric Acid binds to and affects the activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; pregnenolone sulfate results in decreased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]
CTD
PMID:17054655
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
G
Gabrb2
gamma-aminobutyric acid type A receptor subunit beta 2
multiple interactions
EXP
pregnenolone sulfate inhibits the reaction [gamma-Aminobutyric Acid binds to and affects the activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; pregnenolone sulfate results in decreased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]
CTD
PMID:17054655
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
G
Gabrg2
gamma-aminobutyric acid type A receptor subunit gamma 2
multiple interactions
EXP
pregnenolone sulfate inhibits the reaction [gamma-Aminobutyric Acid binds to and affects the activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; pregnenolone sulfate results in decreased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]
CTD
PMID:17054655
NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346
G
Glra1
glycine receptor, alpha 1
decreases activity
ISO
pregnenolone sulfate results in decreased activity of GLRA1 protein
CTD
PMID:15081878
NCBI chr10:39,625,853...39,727,897
Ensembl chr10:39,629,459...39,727,162
G
Slc10a6
solute carrier family 10 member 6
increases transport
ISO
SLC10A6 protein results in increased transport of pregnenolone sulfate
CTD
PMID:23562556
NCBI chr14:6,080,716...6,102,902
Ensembl chr14:6,080,717...6,103,037
G
Trpm3
transient receptor potential cation channel, subfamily M, member 3
multiple interactions
ISO
pregnenolone sulfate binds to and results in increased activity of TRPM3 protein
CTD
PMID:30883612
NCBI chr 1:219,673,200...220,557,610
Ensembl chr 1:219,672,892...220,560,717
G
Ache
acetylcholinesterase
decreases activity
ISO
rapacuronium results in decreased activity of ACHE protein
CTD
PMID:33844597
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
G
Ar
androgen receptor
affects binding affects expression
EXP
stanolone benzoate binds to AR protein stanolone benzoate affects the expression of AR protein
CTD
PMID:14565775 PMID:25247470
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Foxp1
forkhead box P1
affects expression
EXP
stanolone benzoate affects the expression of FOXP1 mRNA; stanolone benzoate affects the expression of FOXP1 protein
CTD
PMID:25247470
NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258
G
Foxp2
forkhead box P2
affects expression
EXP
stanolone benzoate affects the expression of FOXP2 mRNA; stanolone benzoate affects the expression of FOXP2 protein
CTD
PMID:25247470
NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683
G
Slc10a1
solute carrier family 10 member 1
increases uptake
ISO
SLC10A1 protein results in increased uptake of sulfolithocholylglycine
CTD
PMID:29024779
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
G
Agt
angiotensinogen
multiple interactions decreases response to substance
EXP
AGT protein inhibits the reaction [taurolithocholic acid 3-sulfate results in increased activity of CASP3 protein] AGT protein results in decreased susceptibility to taurolithocholic acid 3-sulfate
CTD
PMID:23300732
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
G
Casp3
caspase 3
multiple interactions increases activity
EXP
AGT protein inhibits the reaction [taurolithocholic acid 3-sulfate results in increased activity of CASP3 protein]
CTD
PMID:23300732
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
G
Cftr
CF transmembrane conductance regulator
decreases activity
ISO
taurolithocholic acid 3-sulfate results in decreased activity of CFTR protein
CTD
PMID:15634668
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
G
Chrm1
cholinergic receptor, muscarinic 1
affects binding
ISO
taurolithocholic acid 3-sulfate binds to CHRM1 protein
CTD
PMID:12464352
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
G
Ifng
interferon gamma
multiple interactions increases expression
ISO
Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IFNG mRNA]
CTD
PMID:22517774
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
G
Il6
interleukin 6
multiple interactions increases expression
ISO
Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IL6 mRNA]
CTD
PMID:22517774
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Acox1
acyl-CoA oxidase 1
multiple interactions increases expression
ISO
[testosterone 17 beta-cypionate co-treated with Dietary Fats] results in increased expression of ACOX1 mRNA testosterone 17 beta-cypionate results in increased expression of ACOX1 mRNA
CTD
PMID:29704577
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
G
Cat
catalase
multiple interactions
ISO
testosterone 17 beta-cypionate promotes the reaction [Dietary Fats results in decreased activity of CAT protein]
CTD
PMID:29704577
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
G
Gpt
glutamic--pyruvic transaminase
decreases expression multiple interactions
ISO
testosterone 17 beta-cypionate results in decreased expression of GPT protein [Dietary Fats co-treated with testosterone 17 beta-cypionate] results in increased expression of GPT protein
CTD
PMID:29704577
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
G
Ppara
peroxisome proliferator activated receptor alpha
increases expression multiple interactions
ISO
testosterone 17 beta-cypionate results in increased expression of PPARA mRNA Dietary Fats promotes the reaction [testosterone 17 beta-cypionate results in increased expression of PPARA mRNA]; testosterone 17 beta-cypionate promotes the reaction [Dietary Fats results in increased expression of PPARA mRNA]
CTD
PMID:29704577
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
G
Scd2
stearoyl-Coenzyme A desaturase 2
multiple interactions increases expression
ISO
Dietary Fats promotes the reaction [testosterone 17 beta-cypionate results in increased expression of SCD mRNA]; testosterone 17 beta-cypionate promotes the reaction [Dietary Fats results in increased expression of SCD mRNA]
CTD
PMID:29704577
NCBI chr 1:243,169,171...243,182,231
Ensembl chr 1:243,169,236...243,182,232
G
Srebf1
sterol regulatory element binding transcription factor 1
increases expression multiple interactions
ISO
testosterone 17 beta-cypionate results in increased expression of SREBF1 mRNA [testosterone 17 beta-cypionate co-treated with Dietary Fats] results in increased expression of SREBF1 mRNA
CTD
PMID:29704577
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
G
Abca7
ATP binding cassette subfamily A member 7
affects expression
ISO
testosterone enanthate affects the expression of ABCA7 mRNA
CTD
PMID:17440010
NCBI chr 7:9,691,452...9,711,466
Ensembl chr 7:9,691,449...9,711,425
G
Abhd2
abhydrolase domain containing 2, acylglycerol lipase
affects expression
ISO
testosterone enanthate affects the expression of ABHD2 mRNA
CTD
PMID:17440010
NCBI chr 1:133,217,403...133,298,564
Ensembl chr 1:133,217,375...133,299,061
G
Ablim3
actin binding LIM protein family, member 3
affects expression
ISO
testosterone enanthate affects the expression of ABLIM3 mRNA
CTD
PMID:17440010
NCBI chr18:55,256,135...55,376,629
Ensembl chr18:55,257,583...55,376,380
G
Acbd3
acyl-CoA binding domain containing 3
affects expression
ISO
testosterone enanthate affects the expression of ACBD3 mRNA
CTD
PMID:17440010
NCBI chr13:92,455,813...92,484,556
Ensembl chr13:92,455,655...92,483,380
G
Acvr2b
activin A receptor type 2B
affects expression
ISO
testosterone enanthate affects the expression of ACVR2B mRNA
CTD
PMID:17440010
NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458
G
Adam21
ADAM metallopeptidase domain 21
affects expression
ISO
testosterone enanthate affects the expression of ADAM21 mRNA
CTD
PMID:17440010
NCBI chr16:36,625,324...36,627,657
Ensembl chr16:36,618,860...36,628,008
G
Adamtsl3
ADAMTS-like 3
affects expression
ISO
testosterone enanthate affects the expression of ADAMTSL3 mRNA
CTD
PMID:17440010
NCBI chr 1:136,288,793...136,596,986
Ensembl chr 1:136,288,793...136,596,986
G
Adcy10
adenylate cyclase 10
increases expression
EXP
testosterone enanthate results in increased expression of ADCY10 mRNA
CTD
PMID:25603467
NCBI chr13:77,747,752...77,833,952
Ensembl chr13:77,768,468...77,833,951
G
Adcy3
adenylate cyclase 3
affects expression
EXP
testosterone enanthate affects the expression of ADCY3 mRNA
CTD
PMID:25603467
NCBI chr 6:27,100,089...27,203,686
Ensembl chr 6:27,124,828...27,203,686
G
Adcy6
adenylate cyclase 6
decreases expression
EXP
testosterone enanthate results in decreased expression of ADCY6 mRNA
CTD
PMID:25603467
NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754
G
Adcy9
adenylate cyclase 9
affects expression
EXP
testosterone enanthate affects the expression of ADCY9 mRNA
CTD
PMID:25603467
NCBI chr10:11,138,966...11,262,067
Ensembl chr10:11,139,446...11,262,066
G
Adnp2
ADNP homeobox 2
affects expression
ISO
testosterone enanthate affects the expression of ADNP2 mRNA
CTD
PMID:17440010
NCBI chr18:73,571,870...73,597,088
Ensembl chr18:73,571,936...73,628,484
G
Aggf1
angiogenic factor with G patch and FHA domains 1
affects expression
ISO
testosterone enanthate affects the expression of AGGF1 mRNA
CTD
PMID:17440010
NCBI chr 2:26,619,336...26,646,050
Ensembl chr 2:26,619,339...26,645,952
G
Ago3
argonaute RISC catalytic component 3
affects expression
ISO
testosterone enanthate affects the expression of AGO3 mRNA
CTD
PMID:17440010
NCBI chr 5:138,632,367...138,714,230
Ensembl chr 5:138,639,569...138,714,230
G
Akap13
A-kinase anchoring protein 13
affects expression
ISO
testosterone enanthate affects the expression of AKAP13 mRNA
CTD
PMID:17440010
NCBI chr 1:129,313,183...129,619,647
Ensembl chr 1:129,314,402...129,619,646
G
Akr1c1
aldo-keto reductase family 1, member C1
affects expression
ISO
testosterone enanthate affects the expression of AKR1C1 mRNA
CTD
PMID:17440010
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
G
Akr1c2
aldo-keto reductase family 1, member C2
affects expression
ISO
testosterone enanthate affects the expression of AKR1C2 mRNA
CTD
PMID:17440010
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
G
Akr1c3
aldo-keto reductase family 1, member C3
affects expression
ISO
testosterone enanthate affects the expression of AKR1C3 mRNA
CTD
PMID:17440010
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
G
Akt1
AKT serine/threonine kinase 1
increases phosphorylation multiple interactions
ISO EXP
testosterone enanthate results in increased phosphorylation of AKT1 protein cordycepin inhibits the reaction [testosterone enanthate results in increased phosphorylation of AKT1 protein]; Finasteride inhibits the reaction [testosterone enanthate results in increased phosphorylation of AKT1 protein]
CTD
PMID:17440010 PMID:36015278
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
G
Aldh1a3
aldehyde dehydrogenase 1 family, member A3
affects expression
ISO
testosterone enanthate affects the expression of ALDH1A3 mRNA
CTD
PMID:17440010
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
G
Aldh1b1
aldehyde dehydrogenase 1 family, member B1
affects expression
ISO
testosterone enanthate affects the expression of ALDH1B1 mRNA
CTD
PMID:17440010
NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378
G
Alkbh4
alkB homolog 4, lysine demethylase
affects expression
ISO
testosterone enanthate affects the expression of ALKBH4 mRNA
CTD
PMID:17440010
NCBI chr12:20,524,030...20,529,947
Ensembl chr12:20,524,030...20,529,947
G
Amot
angiomotin
affects expression
ISO
testosterone enanthate affects the expression of AMOT mRNA
CTD
PMID:17440010
NCBI chr X:108,982,399...109,041,265
Ensembl chr X:108,984,022...109,041,272
G
Anapc5
anaphase-promoting complex subunit 5
affects expression
ISO
testosterone enanthate affects the expression of ANAPC5 mRNA
CTD
PMID:17440010
NCBI chr12:33,748,709...33,781,709
Ensembl chr12:33,748,735...33,781,781
G
Angpt1
angiopoietin 1
affects expression
ISO
testosterone enanthate affects the expression of ANGPT1 mRNA
CTD
PMID:17440010
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
G
Ank1
ankyrin 1
affects expression
ISO
testosterone enanthate affects the expression of ANK1 mRNA
CTD
PMID:17440010
NCBI chr16:68,876,294...69,054,963
Ensembl chr16:68,877,504...69,054,759
G
Ank3
ankyrin 3
affects expression
ISO
testosterone enanthate affects the expression of ANK3 mRNA
CTD
PMID:17440010
NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300
G
Ankrd2
ankyrin repeat domain 2
affects expression
ISO
testosterone enanthate affects the expression of ANKRD2 mRNA
CTD
PMID:17440010
NCBI chr 1:240,847,111...240,856,563
Ensembl chr 1:240,847,072...240,856,566
G
Ap2b1
adaptor related protein complex 2 subunit beta 1
affects expression
ISO
testosterone enanthate affects the expression of AP2B1 mRNA
CTD
PMID:17440010
NCBI chr10:68,099,397...68,205,023
Ensembl chr10:68,099,547...68,205,013
G
Ap4s1
adaptor related protein complex 4 subunit sigma 1
affects expression
ISO
testosterone enanthate affects the expression of AP4S1 mRNA
CTD
PMID:17440010
NCBI chr 6:69,133,403...69,174,488
Ensembl chr 6:69,133,373...69,175,496
G
Api5
apoptosis inhibitor 5
affects expression
ISO
testosterone enanthate affects the expression of API5 mRNA
CTD
PMID:17440010
NCBI chr 3:80,378,096...80,403,259
Ensembl chr 3:80,378,096...80,403,264
G
Apoe
apolipoprotein E
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of APOE mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of APOE mRNA
CTD
PMID:18160741
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
G
App
amyloid beta precursor protein
affects expression
ISO
testosterone enanthate affects the expression of APP mRNA
CTD
PMID:17440010
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
G
Ar
androgen receptor
increases activity increases expression decreases expression
ISO EXP
testosterone enanthate results in increased activity of AR protein testosterone enanthate results in increased expression of AR mRNA; testosterone enanthate results in increased expression of AR protein testosterone enanthate results in decreased expression of AR mRNA; testosterone enanthate results in decreased expression of AR protein
CTD
PMID:17440010 PMID:21427060 PMID:21729141 PMID:23085480 PMID:23294483 PMID:25603467 More...
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Areg
amphiregulin
affects expression
ISO
testosterone enanthate affects the expression of AREG mRNA
CTD
PMID:17440010
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
G
Armcx3
armadillo repeat containing, X-linked 3
affects expression
ISO
testosterone enanthate affects the expression of ARMCX3 mRNA
CTD
PMID:17440010
NCBI chr X:97,937,115...97,942,098
Ensembl chr X:97,936,999...97,942,098
G
Arpc1b
actin related protein 2/3 complex, subunit 1B
affects expression
ISO
testosterone enanthate affects the expression of ARPC1B mRNA
CTD
PMID:17440010
NCBI chr12:9,482,176...9,495,772
Ensembl chr12:9,480,831...9,495,747
G
Asap3
ArfGAP with SH3 domain, ankyrin repeat and PH domain 3
affects expression
ISO
testosterone enanthate affects the expression of DDEFL1 mRNA
CTD
PMID:17440010
NCBI chr 5:148,433,382...148,476,027
Ensembl chr 5:148,433,494...148,474,073
G
Asb13
ankyrin repeat and SOCS box-containing 13
affects expression
ISO
testosterone enanthate affects the expression of ASB13 mRNA
CTD
PMID:17440010
NCBI chr17:66,564,653...66,583,365
Ensembl chr17:66,562,434...66,583,337
G
Aspn
asporin
affects expression
ISO
testosterone enanthate affects the expression of ASPN mRNA
CTD
PMID:17440010
NCBI chr17:15,079,910...15,104,369
Ensembl chr17:15,080,639...15,104,041
G
Ass1
argininosuccinate synthase 1
affects expression
ISO
testosterone enanthate affects the expression of ASS1 mRNA
CTD
PMID:17440010
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
G
Astn2
astrotactin 2
affects expression
ISO
testosterone enanthate affects the expression of ASTN2 mRNA
CTD
PMID:17440010
NCBI chr 5:78,758,142...79,744,021
Ensembl chr 5:78,758,142...79,748,273
G
Atp2b1
ATPase plasma membrane Ca2+ transporting 1
affects expression
ISO
testosterone enanthate affects the expression of ATP2B1 mRNA
CTD
PMID:17440010
NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295
G
Atp6v1a
ATPase H+ transporting V1 subunit A
affects expression
ISO
testosterone enanthate affects the expression of ATP6V1A mRNA
CTD
PMID:17440010
NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694
G
Atp8b1
ATPase phospholipid transporting 8B1
affects expression
ISO
testosterone enanthate affects the expression of ATP8B1 mRNA
CTD
PMID:17440010
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
G
Atrx
ATRX, chromatin remodeler
increases expression
ISO
testosterone enanthate results in increased expression of ATRX mRNA
CTD
PMID:17440010
NCBI chr X:70,850,981...70,997,330
Ensembl chr X:70,850,981...70,997,330
G
B4galt4
beta-1,4-galactosyltransferase 4
affects expression
ISO
testosterone enanthate affects the expression of B4GALT4 mRNA
CTD
PMID:17440010
NCBI chr11:61,995,807...62,021,751
Ensembl chr11:61,995,814...62,021,671
G
Bag5
BAG cochaperone 5
affects expression
ISO
testosterone enanthate affects the expression of BAG5 mRNA
CTD
PMID:17440010
NCBI chr 6:130,768,467...130,772,122
Ensembl chr 6:130,768,141...130,772,970
G
Bax
BCL2 associated X, apoptosis regulator
multiple interactions decreases expression
EXP
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in decreased expression of BAX mRNA]; cordycepin inhibits the reaction [testosterone enanthate results in decreased expression of BAX mRNA]; cordycepin inhibits the reaction [testosterone enanthate results in decreased expression of BAX protein]; Finasteride inhibits the reaction [testosterone enanthate results in decreased expression of BAX mRNA]; Finasteride inhibits the reaction [testosterone enanthate results in decreased expression of BAX protein] testosterone enanthate results in decreased expression of BAX mRNA; testosterone enanthate results in decreased expression of BAX protein
CTD
PMID:30154949 PMID:36015278
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
G
Baz1a
bromodomain adjacent to zinc finger domain, 1A
affects expression
ISO
testosterone enanthate affects the expression of BAZ1A mRNA
CTD
PMID:17440010
NCBI chr 6:72,389,701...72,512,516
Ensembl chr 6:72,389,703...72,512,459
G
Bbx
BBX high mobility group box domain containing
affects expression
ISO
testosterone enanthate affects the expression of BBX mRNA
CTD
PMID:17440010
NCBI chr11:50,381,249...50,628,934
Ensembl chr11:50,381,247...50,623,251
G
Bcl2
BCL2, apoptosis regulator
increases expression multiple interactions
EXP
testosterone enanthate results in increased expression of BCL2 mRNA; testosterone enanthate results in increased expression of BCL2 protein 2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of BCL2 mRNA]; cordycepin inhibits the reaction [testosterone enanthate results in increased expression of BCL2 mRNA]; cordycepin inhibits the reaction [testosterone enanthate results in increased expression of BCL2 protein]; Finasteride inhibits the reaction [testosterone enanthate results in increased expression of BCL2 mRNA]; Finasteride inhibits the reaction [testosterone enanthate results in increased expression of BCL2 protein]
CTD
PMID:30154949 PMID:36015278
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
G
Bclaf1
BCL2-associated transcription factor 1
affects expression
ISO
testosterone enanthate affects the expression of BCLAF1 mRNA
CTD
PMID:17440010
NCBI chr 1:15,088,436...15,117,666
Ensembl chr 1:15,070,894...15,148,832
G
Bcorl1
BCL6 co-repressor-like 1
affects expression
ISO
testosterone enanthate affects the expression of BCORL1 mRNA
CTD
PMID:17440010
NCBI chr X:127,516,504...127,584,529
Ensembl chr X:127,537,538...127,584,087
G
Bhmt2
betaine-homocysteine S-methyltransferase 2
affects expression
ISO
testosterone enanthate affects the expression of BHMT2 mRNA
CTD
PMID:17440010
NCBI chr 2:24,895,525...24,912,475
Ensembl chr 2:24,895,533...24,912,475
G
Bltp2
bridge-like lipid transfer protein family member 2
affects expression
ISO
testosterone enanthate affects the expression of BLTP2 mRNA
CTD
PMID:17440010
NCBI chr10:63,155,999...63,185,213
Ensembl chr10:63,156,044...63,191,141
G
Bmp2k
BMP-2 inducible kinase
affects expression
ISO
testosterone enanthate affects the expression of BMP2K mRNA
CTD
PMID:17440010
NCBI chr14:12,481,194...12,579,411
Ensembl chr14:12,484,729...12,579,134
G
Bnip3l
BCL2 interacting protein 3 like
affects expression
ISO
testosterone enanthate affects the expression of BNIP3L mRNA
CTD
PMID:17440010
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
G
Bptf
bromodomain PHD finger transcription factor
affects expression
ISO
testosterone enanthate affects the expression of BPTF mRNA
CTD
PMID:17440010
NCBI chr10:91,980,279...92,082,731
Ensembl chr10:91,982,758...92,082,769
G
Brd2
bromodomain containing 2
affects expression
ISO
testosterone enanthate affects the expression of BRD2 mRNA
CTD
PMID:17440010
NCBI chr20:4,727,078...4,735,389
Ensembl chr20:4,728,151...4,735,388
G
Btd
biotinidase
affects expression
ISO
testosterone enanthate affects the expression of BTD mRNA
CTD
PMID:17440010
NCBI chr16:6,863,068...6,894,345
Ensembl chr16:6,862,407...6,940,945
G
C1qa
complement C1q A chain
affects expression
ISO
testosterone enanthate affects the expression of C1QA mRNA
CTD
PMID:17440010
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
G
C2h1orf54
similar to human chromosome 1 open reading frame 54
affects expression
ISO
testosterone enanthate affects the expression of C1ORF54 mRNA
CTD
PMID:17440010
NCBI chr 2:183,424,989...183,434,713
Ensembl chr 2:183,424,984...183,435,089
G
Camkmt
calmodulin-lysine N-methyltransferase
affects expression
ISO
testosterone enanthate affects the expression of CAMKMT mRNA
CTD
PMID:17440010
NCBI chr 6:9,198,945...9,580,200
Ensembl chr 6:9,198,947...9,580,242
G
Camsap2
calmodulin regulated spectrin-associated protein family, member 2
affects expression
ISO
testosterone enanthate affects the expression of CAMSAP2 mRNA
CTD
PMID:17440010
NCBI chr13:47,723,251...47,802,606
Ensembl chr13:47,723,121...47,802,597
G
Capn2
calpain 2
affects expression
ISO
testosterone enanthate affects the expression of CAPN2 mRNA
CTD
PMID:17440010
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
G
Capn6
calpain 6
affects expression
ISO
testosterone enanthate affects the expression of CAPN6 mRNA
CTD
PMID:17440010
NCBI chr X:107,380,774...107,405,489
Ensembl chr X:107,380,774...107,405,489
G
Casp6
caspase 6
affects expression
ISO
testosterone enanthate affects the expression of CASP6 mRNA
CTD
PMID:17440010
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
G
Cavin1
caveolae associated protein 1
affects expression
ISO
testosterone enanthate affects the expression of CAVIN1 mRNA
CTD
PMID:17440010
NCBI chr10:85,884,100...85,896,136
Ensembl chr10:85,889,036...85,896,120
G
Cbr1
carbonyl reductase 1
affects expression
ISO
testosterone enanthate affects the expression of CBR1 mRNA
CTD
PMID:17440010
NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
G
Cbx5
chromobox 5
affects expression
ISO
testosterone enanthate affects the expression of CBX5 mRNA
CTD
PMID:17440010
NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022
G
Ccdc85b
coiled-coil domain containing 85B
affects expression
ISO
testosterone enanthate affects the expression of CCDC85B mRNA
CTD
PMID:17440010
NCBI chr 1:202,763,645...202,764,660
Ensembl chr 1:202,763,631...202,764,703
G
Cchcr1
coiled-coil alpha-helical rod protein 1
affects expression
ISO
testosterone enanthate affects the expression of CCHCR1 mRNA
CTD
PMID:17440010
NCBI chr20:3,205,675...3,218,437
Ensembl chr20:3,205,676...3,218,308
G
Ccn5
cellular communication network factor 5
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of CCN5 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of CCN5 mRNA
CTD
PMID:18160741
NCBI chr 3:152,491,247...152,502,639
Ensembl chr 3:152,491,220...152,502,636
G
Ccnd1
cyclin D1
multiple interactions increases expression
EXP
cordycepin inhibits the reaction [testosterone enanthate results in increased expression of CCND1 protein]; Finasteride inhibits the reaction [testosterone enanthate results in increased expression of CCND1 protein]
CTD
PMID:36015278
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
G
Ccne2
cyclin E2
affects expression
ISO
testosterone enanthate affects the expression of CCNE2 mRNA
CTD
PMID:17440010
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
G
Ccpg1
cell cycle progression 1
affects expression
ISO
testosterone enanthate affects the expression of CPR8 mRNA
CTD
PMID:17440010
NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430
G
Ccr1
C-C motif chemokine receptor 1
affects expression
ISO
testosterone enanthate affects the expression of CCR1 mRNA
CTD
PMID:17440010
NCBI chr 8:123,556,286...123,561,841
G
Ccs
copper chaperone for superoxide dismutase
affects expression
ISO
testosterone enanthate affects the expression of CCS mRNA
CTD
PMID:17440010
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
G
Cd151
CD151 molecule (Raph blood group)
affects expression
ISO
testosterone enanthate affects the expression of CD151 mRNA
CTD
PMID:17440010
NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753
G
Cd53
Cd53 molecule
affects expression
ISO
testosterone enanthate affects the expression of CD53 mRNA
CTD
PMID:17440010
NCBI chr 2:194,352,139...194,399,668
Ensembl chr 2:194,352,139...194,399,657
G
Cdk1
cyclin-dependent kinase 1
affects expression
ISO
testosterone enanthate affects the expression of CDK1 mRNA
CTD
PMID:17440010
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
G
Cdkal1
CDK5 regulatory subunit associated protein 1-like 1
affects expression
ISO
testosterone enanthate affects the expression of CDKAL1 mRNA
CTD
PMID:17440010
NCBI chr17:34,718,701...35,271,276
Ensembl chr17:34,718,687...35,407,524
G
Cep104
centrosomal protein 104
affects expression
ISO
testosterone enanthate affects the expression of CEP104 mRNA
CTD
PMID:17440010
NCBI chr 5:164,534,773...164,567,260
Ensembl chr 5:164,534,782...164,567,248
G
Cep57
centrosomal protein 57
affects expression
ISO
testosterone enanthate affects the expression of CEP57 mRNA
CTD
PMID:17440010
NCBI chr 8:10,669,588...10,689,257
Ensembl chr 8:10,669,590...10,689,249
G
Ces2h
carboxylesterase 2H
affects expression
ISO
testosterone enanthate affects the expression of CES2 mRNA
CTD
PMID:17440010
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
G
Cfh
complement factor H
affects expression
ISO
testosterone enanthate affects the expression of CFH mRNA
CTD
PMID:17440010
NCBI chr13:51,512,376...51,613,829
Ensembl chr13:51,511,828...51,613,838
G
Cga
glycoprotein hormones, alpha polypeptide
decreases expression
EXP
testosterone enanthate results in decreased expression of CGA mRNA
CTD
PMID:25603467
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
G
Chd4
chromodomain helicase DNA binding protein 4
affects expression
ISO
testosterone enanthate affects the expression of CHD4 mRNA
CTD
PMID:17440010
NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541
G
Chd8
chromodomain helicase DNA binding protein 8
affects expression
ISO
testosterone enanthate affects the expression of CHD8 mRNA
CTD
PMID:17440010
NCBI chr15:24,905,789...24,965,461
Ensembl chr15:24,905,789...24,951,285
G
Chga
chromogranin A
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate] results in decreased expression of CHGA mRNA
CTD
PMID:18160741
NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
G
Ckap2
cytoskeleton associated protein 2
affects expression
ISO
testosterone enanthate affects the expression of CKAP2 mRNA
CTD
PMID:17440010
NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913
G
Cks2
CDC28 protein kinase regulatory subunit 2
affects expression
ISO
testosterone enanthate affects the expression of CKS2 mRNA
CTD
PMID:17440010
NCBI chr17:13,570,611...13,575,770
G
Clcn3
chloride voltage-gated channel 3
affects expression
ISO
testosterone enanthate affects the expression of CLCN3 mRNA
CTD
PMID:17440010
NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119
G
Clic4
chloride intracellular channel 4
affects expression
ISO
testosterone enanthate affects the expression of CLIC4 mRNA
CTD
PMID:17440010
NCBI chr 5:147,453,702...147,513,455
Ensembl chr 5:147,453,712...147,513,452
G
Cluap1
clusterin associated protein 1
affects expression
ISO
testosterone enanthate affects the expression of CLUAP1 mRNA
CTD
PMID:17440010
NCBI chr10:11,587,963...11,619,711
Ensembl chr10:11,588,017...11,619,711
G
Cnot3
CCR4-NOT transcription complex, subunit 3
affects expression
ISO
testosterone enanthate affects the expression of CNOT3 mRNA
CTD
PMID:17440010
NCBI chr 1:65,555,924...65,572,167
Ensembl chr 1:65,555,924...65,572,167
G
Cnot4
CCR4-NOT transcription complex, subunit 4
affects expression
ISO
testosterone enanthate affects the expression of CNOT4 mRNA
CTD
PMID:17440010
NCBI chr 4:63,712,770...63,814,355
Ensembl chr 4:63,712,770...63,814,360
G
Col14a1
collagen type XIV alpha 1 chain
affects expression
ISO
testosterone enanthate affects the expression of COL14A1 mRNA
CTD
PMID:17440010
NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214
G
Col1a1
collagen type I alpha 1 chain
affects expression
ISO
testosterone enanthate affects the expression of COL1A1 mRNA
CTD
PMID:17440010
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
G
Col1a2
collagen type I alpha 2 chain
affects expression
ISO
testosterone enanthate affects the expression of COL1A2 mRNA
CTD
PMID:17440010
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
G
Col3a1
collagen type III alpha 1 chain
affects expression
ISO
testosterone enanthate affects the expression of COL3A1 mRNA
CTD
PMID:17440010
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
G
Col4a2
collagen type IV alpha 2 chain
affects expression
ISO
testosterone enanthate affects the expression of COL4A2 mRNA
CTD
PMID:17440010
NCBI chr16:78,047,591...78,183,360
Ensembl chr16:78,047,602...78,183,839
G
Col5a1
collagen type V alpha 1 chain
affects expression
ISO
testosterone enanthate affects the expression of COL5A1 mRNA
CTD
PMID:17440010
NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
G
Col5a2
collagen type V alpha 2 chain
affects expression
ISO
testosterone enanthate affects the expression of COL5A2 mRNA
CTD
PMID:17440010
NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154
G
Col6a1
collagen type VI alpha 1 chain
affects expression
ISO
testosterone enanthate affects the expression of COL6A1 mRNA
CTD
PMID:17440010
NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597
G
Col6a2
collagen type VI alpha 2 chain
affects expression
ISO
testosterone enanthate affects the expression of COL6A2 mRNA
CTD
PMID:17440010
NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564
G
Cpne3
copine 3
affects expression
ISO
testosterone enanthate affects the expression of CPNE3 mRNA
CTD
PMID:17440010
NCBI chr 5:33,014,658...33,063,934
Ensembl chr 5:33,016,307...33,063,934
G
Creb1
cAMP responsive element binding protein 1
decreases expression
EXP
testosterone enanthate results in decreased expression of CREB1 mRNA
CTD
PMID:25603467
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
G
Crim1
cysteine rich transmembrane BMP regulator 1
affects expression
ISO
testosterone enanthate affects the expression of CRIM1 mRNA
CTD
PMID:17440010
NCBI chr 6:16,695,864...16,870,264
Ensembl chr 6:16,697,829...16,870,259
G
Cst9l
cystatin 9-like
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in increased expression of CST9L mRNA; [cetrorelix co-treated with testosterone enanthate] results in increased expression of CST9L mRNA
CTD
PMID:18160741
NCBI chr 3:136,288,093...136,290,906
Ensembl chr 3:136,288,093...136,290,906
G
Ctdp1
CTD phosphatase subunit 1
affects expression
ISO
testosterone enanthate affects the expression of CTDP1 mRNA
CTD
PMID:17440010
NCBI chr18:73,854,277...73,916,232
Ensembl chr18:73,854,282...73,916,457
G
Ctss
cathepsin S
affects expression
ISO
testosterone enanthate affects the expression of CTSS mRNA
CTD
PMID:17440010
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
G
Cul5
cullin 5
affects expression
ISO
testosterone enanthate affects the expression of CUL5 mRNA
CTD
PMID:17440010
NCBI chr 8:54,012,963...54,066,751
Ensembl chr 8:54,016,006...54,066,666
G
Cyb5a
cytochrome b5 type A
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate] results in decreased expression of CYB5A mRNA
CTD
PMID:18160741
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
G
Cyba
cytochrome b-245 alpha chain
affects expression
ISO
testosterone enanthate affects the expression of CYBA mRNA
CTD
PMID:17440010
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
G
Cyp11a1
cytochrome P450, family 11, subfamily a, polypeptide 1
decreases expression multiple interactions
EXP ISO
testosterone enanthate results in decreased expression of CYP11A1 mRNA [cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of CYP11A1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of CYP11A1 mRNA
CTD
PMID:18160741 PMID:21427060 PMID:25603467
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
G
Cyp17a1
cytochrome P450, family 17, subfamily a, polypeptide 1
multiple interactions decreases expression
ISO EXP
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of CYP17A1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of CYP17A1 mRNA testosterone enanthate results in decreased expression of CYP17A1 mRNA
CTD
PMID:18160741 PMID:21427060 PMID:25603467
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
G
Cyp19a1
cytochrome P450, family 19, subfamily a, polypeptide 1
increases expression decreases expression
EXP
testosterone enanthate results in increased expression of CYP19A1 mRNA testosterone enanthate results in decreased expression of CYP19A1 mRNA
CTD
PMID:21427060
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
G
Cyp2a1
cytochrome P450, family 2, subfamily a, polypeptide 1
decreases expression
EXP
testosterone enanthate results in decreased expression of CYP2A1 protein
CTD
PMID:8573203
NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887
G
Cyp2c11
cytochrome P450, subfamily 2, polypeptide 11
multiple interactions increases expression
EXP
Tamoxifen promotes the reaction [testosterone enanthate results in increased expression of CYP2C11 protein] testosterone enanthate results in increased expression of CYP2C11 mRNA; testosterone enanthate results in increased expression of CYP2C11 protein
CTD
PMID:8573203 PMID:8819526
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
G
Cyp3a2
cytochrome P450, family 3, subfamily a, polypeptide 2
multiple interactions increases expression
EXP
Tamoxifen promotes the reaction [testosterone enanthate results in increased expression of CYP3A2 protein]
CTD
PMID:8573203
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
G
Cytip
cytohesin 1 interacting protein
affects expression
ISO
testosterone enanthate affects the expression of CYTIP mRNA
CTD
PMID:17440010
NCBI chr 3:42,698,058...42,774,955
Ensembl chr 3:42,698,768...42,725,993
G
Dab2
DAB adaptor protein 2
affects expression
ISO
testosterone enanthate affects the expression of DAB2 mRNA
CTD
PMID:17440010
NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
G
Ddr1
discoidin domain receptor tyrosine kinase 1
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in increased expression of DDR1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in increased expression of DDR1 mRNA
CTD
PMID:18160741
NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
G
Ddx17
DEAD-box helicase 17
affects expression
ISO
testosterone enanthate affects the expression of DDX17 mRNA
CTD
PMID:17440010
NCBI chr 7:111,091,127...111,109,353
Ensembl chr 7:111,089,445...111,109,193
G
Ddx24
DEAD-box helicase 24
affects expression
ISO
testosterone enanthate affects the expression of DDX24 mRNA
CTD
PMID:17440010
NCBI chr 6:122,564,767...122,582,032
Ensembl chr 6:122,564,767...122,581,927
G
Ddx3y
DEAD box helicase 3, Y-linked
affects expression
ISO
testosterone enanthate affects the expression of DDX3Y mRNA
CTD
PMID:17440010
NCBI chr Y:1,115,095...1,135,754
Ensembl chr Y:1,116,309...1,135,706
G
Desi2
desumoylating isopeptidase 2
affects expression
ISO
testosterone enanthate affects the expression of DESI2 mRNA
CTD
PMID:17440010
NCBI chr13:89,961,767...90,011,255
Ensembl chr13:89,961,934...90,016,416
G
Dhcr24
24-dehydrocholesterol reductase
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of DHCR24 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of DHCR24 mRNA
CTD
PMID:18160741
NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
G
Dhrs4
dehydrogenase/reductase 4
affects expression
ISO
testosterone enanthate affects the expression of DHRS4 mRNA
CTD
PMID:17440010
NCBI chr15:28,966,544...28,978,135
Ensembl chr15:28,966,553...28,978,127
G
Dhx29
DExH-box helicase 29
affects expression
ISO
testosterone enanthate affects the expression of DHX29 mRNA
CTD
PMID:17440010
NCBI chr 2:44,560,653...44,611,450
Ensembl chr 2:44,560,714...44,611,445
G
Dhx38
DEAH-box helicase 38
affects expression
ISO
testosterone enanthate affects the expression of DHX38 mRNA
CTD
PMID:17440010
NCBI chr19:37,512,893...37,530,135
Ensembl chr19:37,512,891...37,530,140
G
Diaph2
diaphanous-related formin 2
affects expression
ISO
testosterone enanthate affects the expression of DIAPH2 mRNA
CTD
PMID:17440010
NCBI chr X:92,395,189...93,234,521
Ensembl chr X:92,395,251...93,229,869
G
Dip2a
disco-interacting protein 2 homolog A
affects expression
ISO
testosterone enanthate affects the expression of DIP2A mRNA
CTD
PMID:17440010
NCBI chr20:12,284,566...12,371,068
Ensembl chr20:12,284,654...12,370,217
G
Dkk2
dickkopf WNT signaling pathway inhibitor 2
affects expression
ISO
testosterone enanthate affects the expression of DKK2 mRNA
CTD
PMID:17440010
NCBI chr 2:220,568,338...220,660,225
Ensembl chr 2:220,568,338...220,660,225
G
Dnajb14
DnaJ heat shock protein family (Hsp40) member B14
affects expression
ISO
testosterone enanthate affects the expression of DNAJB14 mRNA
CTD
PMID:17440010
NCBI chr 2:226,358,988...226,409,461
Ensembl chr 2:226,358,996...226,402,490
G
Dnajc4
DnaJ heat shock protein family (Hsp40) member C4
affects expression
ISO
testosterone enanthate affects the expression of DNAJC4 mRNA
CTD
PMID:17440010
NCBI chr 1:204,178,189...204,182,412
Ensembl chr 1:204,178,191...204,182,387
G
Dnajc7
DnaJ heat shock protein family (Hsp40) member C7
affects expression
ISO
testosterone enanthate affects the expression of DNAJC7 mRNA
CTD
PMID:17440010
NCBI chr10:85,518,637...85,555,079
Ensembl chr10:85,518,621...85,555,575
G
Dnph1
2'-deoxynucleoside 5'-phosphate N-hydrolase 1
affects expression
ISO
testosterone enanthate affects the expression of DNPH1 mRNA
CTD
PMID:17440010
NCBI chr 9:14,481,296...14,484,034
Ensembl chr 9:14,481,066...14,484,022
G
Dpep3
dipeptidase 3
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of DPEP3 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of DPEP3 mRNA
CTD
PMID:18160741
NCBI chr19:33,868,229...33,876,609
Ensembl chr19:33,868,242...33,873,896
G
Dpt
dermatopontin
affects expression
ISO
testosterone enanthate affects the expression of DPT mRNA
CTD
PMID:17440010
NCBI chr13:77,123,224...77,151,646
Ensembl chr13:77,123,115...77,151,639
G
Dsn1
DSN1 component of MIS12 kinetochore complex
affects expression
ISO
testosterone enanthate affects the expression of DSN1 mRNA
CTD
PMID:17440010
NCBI chr 3:145,652,741...145,668,025
Ensembl chr 3:145,652,737...145,665,856
G
Dusp1
dual specificity phosphatase 1
decreases expression
EXP
testosterone enanthate results in decreased expression of DUSP1 mRNA
CTD
PMID:23085480
NCBI chr10:16,680,478...16,683,275
G
E2f3
E2F transcription factor 3
affects expression
ISO
testosterone enanthate affects the expression of E2F3 mRNA
CTD
PMID:17440010
NCBI chr17:34,601,756...34,679,139
Ensembl chr17:34,601,830...34,676,253
G
Ect2
epithelial cell transforming 2
affects expression
ISO
testosterone enanthate affects the expression of ECT2 mRNA
CTD
PMID:17440010
NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911
G
Ednra
endothelin receptor type A
affects expression
ISO
testosterone enanthate affects the expression of EDNRA mRNA
CTD
PMID:17440010
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
G
Ednrb
endothelin receptor type B
affects expression
ISO
testosterone enanthate affects the expression of EDNRB mRNA
CTD
PMID:17440010
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
G
Efemp2
EGF containing fibulin extracellular matrix protein 2
affects expression
ISO
testosterone enanthate affects the expression of EFEMP2 mRNA
CTD
PMID:17440010
NCBI chr 1:202,781,692...202,789,784
Ensembl chr 1:202,781,665...202,789,414
G
Efnb2
ephrin B2
affects expression
ISO
testosterone enanthate affects the expression of EFNB2 mRNA
CTD
PMID:17440010
NCBI chr16:80,783,389...80,827,420
Ensembl chr16:80,783,417...80,824,391
G
Ehbp1l1
EH domain binding protein 1-like 1
affects expression
ISO
testosterone enanthate affects the expression of EHBP1L1 mRNA
CTD
PMID:17440010
NCBI chr 1:202,994,115...203,014,320
Ensembl chr 1:202,994,118...203,014,270
G
Eif2ak2
eukaryotic translation initiation factor 2-alpha kinase 2
affects expression
ISO
testosterone enanthate affects the expression of EIF2AK2 mRNA
CTD
PMID:17440010
NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
G
Eif2s1
eukaryotic translation initiation factor 2 subunit alpha
affects expression
ISO
testosterone enanthate affects the expression of EIF2S1 mRNA
CTD
PMID:17440010
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
G
Eif4g1
eukaryotic translation initiation factor 4 gamma 1
affects expression
ISO
testosterone enanthate affects the expression of EIF4G1 mRNA
CTD
PMID:17440010
NCBI chr11:80,221,919...80,241,958
Ensembl chr11:80,221,919...80,241,941
G
Eif4g3
eukaryotic translation initiation factor 4 gamma, 3
affects expression
ISO
testosterone enanthate affects the expression of EIF4G3 mRNA
CTD
PMID:17440010
NCBI chr 5:150,197,410...150,418,862
Ensembl chr 5:150,195,226...150,418,363
G
Eif5b
eukaryotic translation initiation factor 5B
affects expression
ISO
testosterone enanthate affects the expression of IF2 mRNA
CTD
PMID:17440010
NCBI chr 9:40,222,769...40,277,482
Ensembl chr 9:40,222,898...40,277,482
G
Elf1
E74 like ETS transcription factor 1
affects expression
ISO
testosterone enanthate affects the expression of ELF1 mRNA
CTD
PMID:17440010
NCBI chr15:54,890,644...54,986,721
Ensembl chr15:54,865,616...54,986,699
G
Elk1
ETS transcription factor ELK1
affects expression
ISO
testosterone enanthate affects the expression of ELK1 mRNA
CTD
PMID:17440010
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
G
Eloa
elongin A
affects expression
ISO
testosterone enanthate affects the expression of ELOA mRNA
CTD
PMID:17440010
NCBI chr 5:148,231,600...148,246,760
Ensembl chr 5:148,231,596...148,246,765
G
Elp5
elongator acetyltransferase complex subunit 5
affects expression
ISO
testosterone enanthate affects the expression of ELP5 mRNA
CTD
PMID:17440010
NCBI chr10:54,692,526...54,704,255
Ensembl chr10:54,692,530...54,704,923
G
Emc1
ER membrane protein complex subunit 1
affects expression
ISO
testosterone enanthate affects the expression of EMC1 mRNA
CTD
PMID:17440010
NCBI chr 5:151,608,557...151,633,888
Ensembl chr 5:151,608,568...151,633,888
G
Emd
emerin
affects expression
ISO
testosterone enanthate affects the expression of EMD mRNA
CTD
PMID:17440010
NCBI chr X:152,038,990...152,042,190
Ensembl chr X:152,038,998...152,045,807
G
Eng
endoglin
affects expression
ISO
testosterone enanthate affects the expression of ENG mRNA
CTD
PMID:17440010
NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230
G
Enpp1
ectonucleotide pyrophosphatase/phosphodiesterase 1
affects expression
ISO
testosterone enanthate affects the expression of ENPP1 mRNA
CTD
PMID:17440010
NCBI chr 1:20,698,746...20,763,741
Ensembl chr 1:20,698,764...20,763,715
G
Entpd1
ectonucleoside triphosphate diphosphohydrolase 1
affects expression
ISO
testosterone enanthate affects the expression of ENTPD1 mRNA
CTD
PMID:17440010
NCBI chr 1:239,425,515...239,552,323
Ensembl chr 1:239,425,430...239,552,317
G
Ephb4
EPH receptor B4
affects expression
ISO
testosterone enanthate affects the expression of EPHB4 mRNA
CTD
PMID:17440010
NCBI chr12:19,326,411...19,351,667
Ensembl chr12:19,326,427...19,351,314
G
Eprs1
glutamyl-prolyl-tRNA synthetase 1
affects expression
ISO
testosterone enanthate affects the expression of EPRS1 mRNA
CTD
PMID:17440010
NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966
G
Erc1
ELKS/RAB6-interacting/CAST family member 1
affects expression
ISO
testosterone enanthate affects the expression of ERC1 mRNA
CTD
PMID:17440010
NCBI chr 4:152,763,664...153,055,724
Ensembl chr 4:152,767,419...153,055,639
G
Esf1
ESF1 nucleolar pre-rRNA processing protein homolog
affects expression
ISO
testosterone enanthate affects the expression of ESF1 mRNA
CTD
PMID:17440010
NCBI chr 3:127,454,744...127,507,941
Ensembl chr 3:127,454,811...127,507,817
G
Esr1
estrogen receptor 1
increases expression decreases expression increases activity
EXP
testosterone enanthate results in increased expression of ESR1 mRNA; testosterone enanthate results in increased expression of ESR1 protein testosterone enanthate results in decreased expression of ESR1 mRNA testosterone enanthate results in increased activity of ESR1 protein
CTD
PMID:12504345 PMID:21427060 PMID:21729141
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Esrrg
estrogen-related receptor gamma
affects expression
ISO
testosterone enanthate affects the expression of ESRRG mRNA
CTD
PMID:17440010
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
G
Extl1
exostosin-like glycosyltransferase 1
affects expression
ISO
testosterone enanthate affects the expression of EXTL1 mRNA
CTD
PMID:17440010
NCBI chr 5:146,573,911...146,589,115
Ensembl chr 5:146,573,912...146,589,115
G
Ezr
ezrin
affects expression
ISO
testosterone enanthate affects the expression of EZR mRNA
CTD
PMID:17440010
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
G
F2
coagulation factor II, thrombin
increases expression
ISO
testosterone enanthate results in increased expression of F2 protein
CTD
PMID:8585008
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
G
Faf2
Fas associated factor family member 2
affects expression
ISO
testosterone enanthate affects the expression of FAF2 mRNA
CTD
PMID:17440010
NCBI chr17:9,947,211...9,989,474
Ensembl chr17:9,947,220...9,989,485
G
Fam149a
family with sequence similarity 149, member A
affects expression
ISO
testosterone enanthate affects the expression of FAM149A mRNA
CTD
PMID:17440010
NCBI chr16:46,855,377...46,914,553
Ensembl chr16:46,854,635...46,912,066
G
Fam162a
family with sequence similarity 162, member A
affects expression
ISO
testosterone enanthate affects the expression of FAM162A mRNA
CTD
PMID:17440010
NCBI chr11:64,680,978...64,709,865
Ensembl chr11:64,680,323...64,711,239
G
Fancc
FA complementation group C
affects expression
ISO
testosterone enanthate affects the expression of FANCC mRNA
CTD
PMID:17440010
NCBI chr17:1,680,660...1,822,610
Ensembl chr17:1,681,324...1,829,376
G
Fastk
Fas-activated serine/threonine kinase
affects expression
ISO
testosterone enanthate affects the expression of FASTK mRNA
CTD
PMID:17440010
NCBI chr 4:10,732,273...10,736,332
Ensembl chr 4:10,732,256...10,737,430
G
Fbxo40
F-box protein 40
affects expression
ISO
testosterone enanthate affects the expression of FBXO40 mRNA
CTD
PMID:17440010
NCBI chr11:63,794,452...63,812,697
Ensembl chr11:63,794,624...63,812,697
G
Fcer1g
Fc epsilon receptor Ig
affects expression
ISO
testosterone enanthate affects the expression of FCER1G mRNA
CTD
PMID:17440010
NCBI chr13:83,649,447...83,654,248
Ensembl chr13:83,649,449...83,671,443
G
Fcgr2a
Fc gamma receptor 2A
affects expression
ISO
testosterone enanthate affects the expression of FCGR2A mRNA
CTD
PMID:17440010
NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
G
Fermt2
FERM domain containing kindlin 2
affects expression
ISO
testosterone enanthate affects the expression of FERMT2 mRNA
CTD
PMID:17440010
NCBI chr15:18,682,927...18,751,959
Ensembl chr15:18,682,927...18,751,811
G
Fez1
fasciculation and elongation protein zeta 1
affects expression
ISO
testosterone enanthate affects the expression of FEZ1 mRNA
CTD
PMID:17440010
NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683
G
Fhit
fragile histidine triad diadenosine triphosphatase
affects expression
ISO
testosterone enanthate affects the expression of FHIT mRNA
CTD
PMID:17440010
NCBI chr15:13,935,029...15,442,620
Ensembl chr15:13,934,995...15,442,340
G
Fkbp4
FKBP prolyl isomerase 4
affects expression
ISO
testosterone enanthate affects the expression of FKBP4 mRNA
CTD
PMID:17440010
NCBI chr 4:161,703,379...161,711,833
Ensembl chr 4:161,703,379...161,711,833
G
Fkbp5
FKBP prolyl isomerase 5
affects expression
ISO
testosterone enanthate affects the expression of FKBP5 mRNA
CTD
PMID:17440010
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
G
Fkbp8
FKBP prolyl isomerase 8
affects expression
ISO
testosterone enanthate affects the expression of FKBP8 mRNA
CTD
PMID:17440010
NCBI chr16:18,895,608...18,902,648
Ensembl chr16:18,893,576...18,902,612
G
Flrt2
fibronectin leucine rich transmembrane protein 2
affects expression
ISO
testosterone enanthate affects the expression of FLRT2 mRNA
CTD
PMID:17440010
NCBI chr 6:114,777,547...114,872,688
Ensembl chr 6:114,777,599...114,872,785
G
Fmo2
flavin containing dimethylaniline monoxygenase 2
affects expression
ISO
testosterone enanthate affects the expression of FMO2 mRNA
CTD
PMID:17440010
NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308
G
Frzb
frizzled-related protein
affects expression
ISO
testosterone enanthate affects the expression of FRZB mRNA
CTD
PMID:17440010
NCBI chr 3:65,332,274...65,365,208
Ensembl chr 3:65,332,277...65,365,208
G
Fshb
follicle stimulating hormone subunit beta
multiple interactions decreases expression
ISO EXP
[FSHB protein co-treated with testosterone enanthate] results in increased abundance of Dihydrotestosterone; [FSHB protein co-treated with testosterone enanthate] results in increased abundance of Estradiol; [FSHB protein co-treated with testosterone enanthate] results in increased abundance of Testosterone testosterone enanthate results in decreased expression of FSHB protein
CTD
PMID:8263139 PMID:21729141
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
G
Fxr1
FMR1 autosomal homolog 1
affects expression
ISO
testosterone enanthate affects the expression of FXR1 mRNA
CTD
PMID:17440010
NCBI chr 2:116,884,167...116,937,590
Ensembl chr 2:116,884,248...116,937,590
G
Fxr2
FMR1 autosomal homolog 2
affects expression
ISO
testosterone enanthate affects the expression of FXR2 mRNA
CTD
PMID:17440010
NCBI chr10:54,350,577...54,370,964
Ensembl chr10:54,350,131...54,370,964
G
Galk2
galactokinase 2
affects expression
ISO
testosterone enanthate affects the expression of GALK2 mRNA
CTD
PMID:17440010
NCBI chr 3:113,110,057...113,243,014
Ensembl chr 3:113,110,030...113,233,306
G
Gata4
GATA binding protein 4
affects expression
EXP
testosterone enanthate affects the expression of GATA4 mRNA
CTD
PMID:25603467
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
G
Gbp1
guanylate binding protein 1
affects expression
ISO
testosterone enanthate affects the expression of GBP1 mRNA
CTD
PMID:17440010
NCBI chr 2:231,398,136...231,432,773
Ensembl chr 2:231,398,163...231,432,131 Ensembl chr 2:231,398,163...231,432,131
G
Gbp2
guanylate binding protein 2
affects expression
ISO
testosterone enanthate affects the expression of GBP2 mRNA
CTD
PMID:17440010
NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
G
Gcat
glycine C-acetyltransferase
affects expression
ISO
testosterone enanthate affects the expression of GCAT mRNA
CTD
PMID:17440010
NCBI chr 7:110,595,126...110,601,474
Ensembl chr 7:110,595,091...110,601,473
G
Gid4
GID complex subunit 4
affects expression
ISO
testosterone enanthate affects the expression of GID4 mRNA
CTD
PMID:17440010
NCBI chr10:45,221,556...45,247,627
Ensembl chr10:45,245,754...45,247,621 Ensembl chr10:45,245,754...45,247,621
G
Glg1
golgi glycoprotein 1
affects expression
ISO
testosterone enanthate affects the expression of GLG1 mRNA
CTD
PMID:17440010
NCBI chr19:39,124,892...39,224,178
Ensembl chr19:39,124,641...39,224,178
G
Gnb1
G protein subunit beta 1
affects expression
ISO
testosterone enanthate affects the expression of GNB1 mRNA
CTD
PMID:17440010
NCBI chr 5:166,075,508...166,142,223
Ensembl chr 5:166,075,629...166,142,124
G
Gnl3l
G protein nucleolar 3 like
affects expression
ISO
testosterone enanthate affects the expression of GNL3L mRNA
CTD
PMID:17440010
NCBI chr X:19,961,277...19,994,454
Ensembl chr X:19,958,603...19,994,508
G
Gnrhr
gonadotropin releasing hormone receptor
affects expression
EXP
testosterone enanthate affects the expression of GNRHR mRNA
CTD
PMID:25603467
NCBI chr14:21,856,871...21,874,861
Ensembl chr14:21,856,871...21,874,861
G
Golga1
golgin A1
affects expression
ISO
testosterone enanthate affects the expression of GOLGA1 mRNA
CTD
PMID:17440010
NCBI chr 3:22,765,690...22,812,637
Ensembl chr 3:22,767,761...22,812,585
G
Golga2
golgin A2
affects expression
ISO
testosterone enanthate affects the expression of GOLGA2 mRNA
CTD
PMID:17440010
NCBI chr 3:15,583,862...15,604,279
Ensembl chr 3:15,584,039...15,604,279
G
Golga4
golgin A4
affects expression
ISO
testosterone enanthate affects the expression of GOLGA4 mRNA
CTD
PMID:17440010
NCBI chr 8:118,208,200...118,285,003
G
Golim4
golgi integral membrane protein 4
affects expression
ISO
testosterone enanthate affects the expression of GOLIM4 mRNA
CTD
PMID:17440010
NCBI chr 2:160,640,837...160,733,475
Ensembl chr 2:160,640,938...160,733,253
G
Gpatch8
G patch domain containing 8
affects expression
ISO
testosterone enanthate affects the expression of GPATCH8 mRNA
CTD
PMID:17440010
NCBI chr10:87,432,020...87,512,594
Ensembl chr10:87,433,266...87,512,419
G
Gpc1
glypican 1
affects expression
ISO
testosterone enanthate affects the expression of GPC1 mRNA
CTD
PMID:17440010
NCBI chr 9:93,396,234...93,424,047
Ensembl chr 9:93,396,234...93,424,047
G
Gpm6b
glycoprotein m6b
affects expression
ISO
testosterone enanthate affects the expression of GPM6B mRNA
CTD
PMID:17440010
NCBI chr X:28,057,788...28,204,409
Ensembl chr X:28,059,450...28,204,211
G
Gpsm2
G-protein signaling modulator 2
affects expression
ISO
testosterone enanthate affects the expression of GPSM2 mRNA
CTD
PMID:17440010
NCBI chr 2:196,327,149...196,375,322
Ensembl chr 2:196,327,149...196,375,154
G
Grem1
gremlin 1, DAN family BMP antagonist
affects expression
ISO
testosterone enanthate affects the expression of GREM1 mRNA
CTD
PMID:17440010
NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082
G
Gsk3b
glycogen synthase kinase 3 beta
affects expression
ISO
testosterone enanthate affects the expression of GSK3B mRNA
CTD
PMID:17440010
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
G
Gsta2
glutathione S-transferase alpha 2
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate] results in decreased expression of GSTA2 mRNA
CTD
PMID:18160741
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
G
Gstm1
glutathione S-transferase mu 1
affects expression
ISO
testosterone enanthate affects the expression of GSTM1 mRNA
CTD
PMID:17440010
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
G
Gtpbp8
GTP-binding protein 8 (putative)
affects expression
ISO
testosterone enanthate affects the expression of GTPBP8 mRNA
CTD
PMID:17440010
NCBI chr11:55,945,778...55,955,743
Ensembl chr11:55,945,795...55,955,635
G
Hadha
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha
affects expression
ISO
testosterone enanthate affects the expression of HADHA mRNA
CTD
PMID:17440010
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
G
Hbg1
hemoglobin subunit gamma 1
affects expression
ISO
testosterone enanthate affects the expression of HBG1 mRNA
CTD
PMID:17440010
NCBI chr 1:158,271,871...158,273,426
Ensembl chr 1:158,271,873...158,273,425
G
Hck
HCK proto-oncogene, Src family tyrosine kinase
affects expression
ISO
testosterone enanthate affects the expression of HCK mRNA
CTD
PMID:17440010
NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693
G
Hcls1
hematopoietic cell specific Lyn substrate 1
affects expression
ISO
testosterone enanthate affects the expression of HCLS1 mRNA
CTD
PMID:17440010
NCBI chr11:63,817,482...63,840,943
Ensembl chr11:63,817,476...63,841,014
G
Heph
hephaestin
affects expression
ISO
testosterone enanthate affects the expression of HEPH mRNA
CTD
PMID:17440010
NCBI chr X:61,151,131...61,402,980
Ensembl chr X:61,296,345...61,402,980
G
Hibch
3-hydroxyisobutyryl-CoA hydrolase
affects expression
ISO
testosterone enanthate affects the expression of HIBCH mRNA
CTD
PMID:17440010
NCBI chr 9:48,590,097...48,669,896
Ensembl chr 9:48,590,099...48,669,824
G
Hif1a
hypoxia inducible factor 1 subunit alpha
decreases expression multiple interactions increases expression
EXP
testosterone enanthate results in decreased expression of HIF1A mRNA 2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of HIF1A protein]
CTD
PMID:23085480 PMID:30154949
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
G
Hipk1
homeodomain interacting protein kinase 1
affects expression
ISO
testosterone enanthate affects the expression of HIPK1 mRNA
CTD
PMID:17440010
NCBI chr 2:191,248,817...191,299,787
Ensembl chr 2:191,248,817...191,298,902
G
Hivep2
HIVEP zinc finger 2
affects expression
ISO
testosterone enanthate affects the expression of HIVEP2 mRNA
CTD
PMID:17440010
NCBI chr 1:8,358,205...8,555,993
Ensembl chr 1:8,359,289...8,555,993
G
Hmgcs2
3-hydroxy-3-methylglutaryl-CoA synthase 2
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of HMGCS2 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of HMGCS2 mRNA
CTD
PMID:18160741
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
G
Hnrnpc
heterogeneous nuclear ribonucleoprotein C
affects expression
ISO
testosterone enanthate affects the expression of HNRNPC mRNA
CTD
PMID:17440010
NCBI chr15:24,779,593...24,809,213
Ensembl chr15:24,779,450...24,809,183
G
Hnrnpr
heterogeneous nuclear ribonucleoprotein R
affects expression
ISO
testosterone enanthate affects the expression of HNRNPR mRNA
CTD
PMID:17440010
NCBI chr 5:148,542,999...148,574,888
Ensembl chr 5:148,543,044...148,574,867
G
Hoxa7
homeobox A7
affects expression
ISO
testosterone enanthate affects the expression of HOXA7 mRNA
CTD
PMID:17440010
NCBI chr 4:81,315,730...81,317,629
Ensembl chr 4:81,314,625...81,317,659
G
Hoxb6
homeo box B6
affects expression
ISO
testosterone enanthate affects the expression of HOXB6 mRNA
CTD
PMID:17440010
NCBI chr10:81,258,726...81,267,458
Ensembl chr10:81,265,056...81,267,449
G
Hoxb7
homeo box B7
affects expression
ISO
testosterone enanthate affects the expression of HOXB7 mRNA
CTD
PMID:17440010
NCBI chr10:81,252,616...81,256,034
Ensembl chr10:81,252,553...81,256,034
G
Hps1
HPS1, biogenesis of lysosomal organelles complex 3 subunit 1
affects expression
ISO
testosterone enanthate affects the expression of HPS1 mRNA
CTD
PMID:17440010
NCBI chr 1:241,551,180...241,577,292
Ensembl chr 1:241,551,175...241,577,268
G
Hsd17b4
hydroxysteroid (17-beta) dehydrogenase 4
affects expression
EXP
testosterone enanthate affects the expression of HSD17B4 mRNA
CTD
PMID:25603467
NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952
G
Hsd17b6
hydroxysteroid (17-beta) dehydrogenase 6
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate] results in decreased expression of HSD17B6 mRNA
CTD
PMID:18160741
NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425
G
Hsp90b1
heat shock protein 90 beta family member 1
affects expression
ISO
testosterone enanthate affects the expression of HSP90B1 mRNA
CTD
PMID:17440010
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
G
Hspa1b
heat shock protein family A (Hsp70) member 1B
affects expression
ISO
testosterone enanthate affects the expression of HSPA1B mRNA
CTD
PMID:17440010
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
G
Hspa4
heat shock protein family A (Hsp70) member 4
affects expression
ISO
testosterone enanthate affects the expression of HSPA4 mRNA
CTD
PMID:17440010
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
G
Htatip2
HIV-1 Tat interactive protein 2
affects expression
ISO
testosterone enanthate affects the expression of HTATIP2 mRNA
CTD
PMID:17440010
NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629
G
Htatsf1
HIV-1 Tat specific factor 1
affects expression
ISO
testosterone enanthate affects the expression of HTATSF1 mRNA
CTD
PMID:17440010
NCBI chr X:134,935,426...134,949,607
Ensembl chr X:134,935,426...134,949,607
G
Hyal4
hyaluronidase 4
affects expression
ISO
testosterone enanthate affects the expression of HYAL4 mRNA
CTD
PMID:17440010
NCBI chr 4:53,256,179...53,274,819
Ensembl chr 4:53,256,179...53,274,819
G
Ido1
indoleamine 2,3-dioxygenase 1
affects expression
ISO
testosterone enanthate affects the expression of IDO1 mRNA
CTD
PMID:17440010
NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
G
Ids
iduronate 2-sulfatase
affects expression
ISO
testosterone enanthate affects the expression of IDS mRNA
CTD
PMID:17440010
NCBI chr X:149,025,976...149,046,641
Ensembl chr X:149,025,976...149,046,663
G
Ifi27
interferon, alpha-inducible protein 27
affects expression
ISO
testosterone enanthate affects the expression of IFI27 mRNA
CTD
PMID:17440010
NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294
G
Ifi44l
interferon-induced protein 44-like
affects expression
ISO
testosterone enanthate affects the expression of IFI44L mRNA
CTD
PMID:17440010
NCBI chr 2:240,668,742...240,706,425
Ensembl chr 2:240,668,713...240,706,359
G
Ifit3
interferon-induced protein with tetratricopeptide repeats 3
affects expression
ISO
testosterone enanthate affects the expression of IFIT3 mRNA
CTD
PMID:17440010
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
G
Igf1
insulin-like growth factor 1
decreases expression
EXP
testosterone enanthate results in decreased expression of IGF1 mRNA
CTD
PMID:23085480
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
G
Igf1r
insulin-like growth factor 1 receptor
increases expression
EXP
testosterone enanthate results in increased expression of IGF1R mRNA
CTD
PMID:23085480
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
G
Igf2r
insulin-like growth factor 2 receptor
increases expression
EXP
testosterone enanthate results in increased expression of IGF2R mRNA
CTD
PMID:23085480
NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501
G
Il10rb
interleukin 10 receptor subunit beta
affects expression
ISO
testosterone enanthate affects the expression of IL10RB mRNA
CTD
PMID:17440010
NCBI chr11:30,646,494...30,668,081
Ensembl chr11:30,652,096...30,668,074
G
Il1a
interleukin 1 alpha
multiple interactions increases expression
EXP
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of IL1A protein]
CTD
PMID:30154949
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
G
Il1b
interleukin 1 beta
multiple interactions increases expression
EXP
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of IL1B protein]
CTD
PMID:30154949
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Il6
interleukin 6
multiple interactions increases expression
EXP
cordycepin inhibits the reaction [testosterone enanthate results in increased expression of IL6 protein]; Finasteride inhibits the reaction [testosterone enanthate results in increased expression of IL6 protein]
CTD
PMID:36015278
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Il6r
interleukin 6 receptor
affects expression
ISO
testosterone enanthate affects the expression of IL6R mRNA
CTD
PMID:17440010
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
G
Il6st
interleukin 6 cytokine family signal transducer
affects expression
ISO
testosterone enanthate affects the expression of IL6ST mRNA
CTD
PMID:17440010
NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936
G
Inppl1
inositol polyphosphate phosphatase-like 1
affects expression
ISO
testosterone enanthate affects the expression of INPPL1 mRNA
CTD
PMID:17440010
NCBI chr 1:156,183,043...156,197,500
Ensembl chr 1:156,183,059...156,197,500
G
Insl3
insulin-like 3
multiple interactions decreases expression
ISO EXP
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of INSL3 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of INSL3 mRNA testosterone enanthate results in decreased expression of INSL3 mRNA
CTD
PMID:18160741 PMID:25603467
NCBI chr16:18,398,682...18,400,566
Ensembl chr16:18,384,829...18,400,560
G
Ints6
integrator complex subunit 6
affects expression
ISO
testosterone enanthate affects the expression of INTS6 mRNA
CTD
PMID:17440010
NCBI chr15:36,908,966...37,048,043
Ensembl chr15:36,933,724...37,021,527
G
Irf9
interferon regulatory factor 9
affects expression
ISO
testosterone enanthate affects the expression of IRF9 mRNA
CTD
PMID:17440010
NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236
G
Isg15
ISG15 ubiquitin-like modifier
affects expression
ISO
testosterone enanthate affects the expression of ISG15 mRNA
CTD
PMID:17440010
NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
G
Itgav
integrin subunit alpha V
affects expression
ISO
testosterone enanthate affects the expression of ITGAV mRNA
CTD
PMID:17440010
NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639
G
Jak1
Janus kinase 1
increases expression
EXP
testosterone enanthate results in increased expression of JAK1 mRNA
CTD
PMID:25603467
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
G
Jak2
Janus kinase 2
increases expression
EXP
testosterone enanthate results in increased expression of JAK2 mRNA
CTD
PMID:25603467
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
G
Jak3
Janus kinase 3
increases expression
EXP
testosterone enanthate results in increased expression of JAK3 mRNA
CTD
PMID:25603467
NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536
G
Kcnj12
potassium inwardly-rectifying channel, subfamily J, member 12
affects expression
ISO
testosterone enanthate affects the expression of KCNJ12 mRNA
CTD
PMID:17440010
NCBI chr10:45,696,621...45,745,528
Ensembl chr10:45,696,849...45,745,492
G
Kdm5a
lysine demethylase 5A
affects expression
ISO
testosterone enanthate affects the expression of KDM5A mRNA
CTD
PMID:17440010
NCBI chr 4:153,565,909...153,643,912
Ensembl chr 4:153,565,846...153,642,422
G
Kdm6a
lysine demethylase 6A
affects expression
ISO
testosterone enanthate affects the expression of KDM6A mRNA
CTD
PMID:17440010
NCBI chr X:4,337,466...4,477,100
Ensembl chr X:4,337,750...4,477,062
G
Klhl24
kelch-like family member 24
affects expression
ISO
testosterone enanthate affects the expression of KLHL24 mRNA
CTD
PMID:17440010
NCBI chr11:80,843,621...80,877,649
Ensembl chr11:80,846,755...80,877,636
G
Kmt2a
lysine methyltransferase 2A
affects expression
ISO
testosterone enanthate affects the expression of KMT2A mRNA
CTD
PMID:17440010
NCBI chr 8:45,116,763...45,193,320
Ensembl chr 8:45,118,814...45,193,181
G
Kpnb1
karyopherin subunit beta 1
affects expression
ISO
testosterone enanthate affects the expression of KPNB1 mRNA
CTD
PMID:17440010
NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605
G
Kras
KRAS proto-oncogene, GTPase
affects expression
ISO
testosterone enanthate affects the expression of KRAS mRNA
CTD
PMID:17440010
NCBI chr 4:178,185,418...178,218,484
G
Lama4
laminin subunit alpha 4
affects expression
ISO
testosterone enanthate affects the expression of LAMA4 mRNA
CTD
PMID:17440010
NCBI chr20:42,392,268...42,533,347
Ensembl chr20:42,392,268...42,533,347
G
Laptm5
lysosomal protein transmembrane 5
affects expression
ISO
testosterone enanthate affects the expression of LAPTM5 mRNA
CTD
PMID:17440010
NCBI chr 5:143,087,759...143,109,807
Ensembl chr 5:143,087,759...143,109,807
G
Ldaf1
lipid droplet assembly factor 1
affects expression
ISO
testosterone enanthate affects the expression of LDAF1 mRNA
CTD
PMID:17440010
NCBI chr 1:174,484,438...174,503,037
Ensembl chr 1:174,484,447...174,503,036
G
Lhb
luteinizing hormone subunit beta
multiple interactions decreases expression
EXP
Cyproterone Acetate inhibits the reaction [testosterone enanthate results in decreased expression of LHB protein] testosterone enanthate results in decreased expression of LHB mRNA; testosterone enanthate results in decreased expression of LHB protein
CTD
PMID:20463352 PMID:21427060 PMID:23085480 PMID:25603467
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
G
Lhcgr
luteinizing hormone/choriogonadotropin receptor
decreases expression
EXP
testosterone enanthate results in decreased expression of LHCGR mRNA
CTD
PMID:21427060 PMID:25603467
NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
G
Limk2
LIM domain kinase 2
affects expression
ISO
testosterone enanthate affects the expression of LIMK2 mRNA
CTD
PMID:17440010
NCBI chr14:78,208,182...78,286,106
Ensembl chr14:78,218,063...78,286,007
G
Lims1
LIM zinc finger domain containing 1
affects expression
ISO
testosterone enanthate affects the expression of LIMS1 mRNA
CTD
PMID:17440010
NCBI chr20:26,309,833...26,418,511
Ensembl chr20:26,309,895...26,418,500
G
Loxl2
lysyl oxidase-like 2
affects expression
ISO
testosterone enanthate affects the expression of LOXL2 mRNA
CTD
PMID:17440010
NCBI chr15:44,683,449...44,773,067
Ensembl chr15:44,683,880...44,773,067
G
Lpar6
lysophosphatidic acid receptor 6
affects expression
ISO
testosterone enanthate affects the expression of LPAR6 mRNA
CTD
PMID:17440010
NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331
G
Lrrc8b
leucine rich repeat containing 8 VRAC subunit B
affects expression
ISO
testosterone enanthate affects the expression of LRRC8B mRNA
CTD
PMID:17440010
NCBI chr14:4,350,462...4,416,336
Ensembl chr14:4,354,508...4,416,311
G
Ltbp1
latent transforming growth factor beta binding protein 1
affects expression
ISO
testosterone enanthate affects the expression of LTBP1 mRNA
CTD
PMID:17440010
NCBI chr 6:20,029,629...20,425,339
Ensembl chr 6:20,029,629...20,425,349
G
Ltbp3
latent transforming growth factor beta binding protein 3
affects expression
ISO
testosterone enanthate affects the expression of LTBP3 mRNA
CTD
PMID:17440010
NCBI chr 1:203,029,412...203,045,975
Ensembl chr 1:203,029,877...203,045,975
G
Luc7l3
LUC7-like 3 pre-mRNA splicing factor
affects expression
ISO
testosterone enanthate affects the expression of LUC7L3 mRNA
CTD
PMID:17440010
NCBI chr10:79,240,050...79,276,555
Ensembl chr10:79,240,563...79,276,538
G
Lum
lumican
affects expression
ISO
testosterone enanthate affects the expression of LUM mRNA
CTD
PMID:17440010
NCBI chr 7:32,358,990...32,365,794
Ensembl chr 7:32,358,614...32,365,793
G
Macf1
microtubule-actin crosslinking factor 1
affects expression
ISO
testosterone enanthate affects the expression of MACF1 mRNA
CTD
PMID:17440010
NCBI chr 5:135,623,734...135,949,097
Ensembl chr 5:135,623,742...135,945,905
G
Man2b2
mannosidase, alpha, class 2B, member 2
affects expression
ISO
testosterone enanthate affects the expression of MAN2B2 mRNA
CTD
PMID:17440010
NCBI chr14:73,969,079...73,994,089
Ensembl chr14:73,969,003...74,004,281
G
Mapk3
mitogen activated protein kinase 3
decreases expression
EXP
testosterone enanthate results in decreased expression of MAPK3 mRNA
CTD
PMID:23085480
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
G
Mapt
microtubule-associated protein tau
affects expression
ISO
testosterone enanthate affects the expression of MAPT mRNA
CTD
PMID:17440010
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
G
Marcks
myristoylated alanine rich protein kinase C substrate
affects expression
ISO
testosterone enanthate affects the expression of MARCKS mRNA
CTD
PMID:17440010
NCBI chr20:40,685,315...40,691,012
Ensembl chr20:40,685,315...40,691,012
G
Mbd4
methyl-CpG binding domain 4 DNA glycosylase
affects expression
ISO
testosterone enanthate affects the expression of MBD4 mRNA
CTD
PMID:17440010
NCBI chr 4:148,893,049...148,904,833
Ensembl chr 4:148,894,280...148,904,982
G
Mbnl2
muscleblind-like splicing regulator 2
affects expression
ISO
testosterone enanthate affects the expression of MBNL2 mRNA
CTD
PMID:17440010
NCBI chr15:97,385,278...97,542,924
Ensembl chr15:97,385,244...97,542,937
G
Med8
mediator complex subunit 8
affects expression
ISO
testosterone enanthate affects the expression of MED8 mRNA
CTD
PMID:17440010
NCBI chr 5:131,948,632...131,949,516
Ensembl chr 5:131,943,982...131,950,305
G
Mettl4
methyltransferase 4, N6-adenosine
affects expression
ISO
testosterone enanthate affects the expression of METTL4 mRNA
CTD
PMID:17440010
NCBI chr 9:111,440,976...111,523,871
Ensembl chr 9:111,441,027...111,464,749
G
Mlec
malectin
affects expression
ISO
testosterone enanthate affects the expression of MLEC mRNA
CTD
PMID:17440010
NCBI chr12:41,458,234...41,468,710
Ensembl chr12:41,458,231...41,468,708
G
Mpdz
multiple PDZ domain crumbs cell polarity complex component
affects expression
ISO
testosterone enanthate affects the expression of MPDZ mRNA
CTD
PMID:17440010
NCBI chr 5:95,766,112...95,920,531
Ensembl chr 5:95,766,118...95,920,499
G
Mphosph9
M-phase phosphoprotein 9
affects expression
ISO
testosterone enanthate affects the expression of MPHOSPH9 mRNA
CTD
PMID:17440010
NCBI chr12:32,275,449...32,346,097
Ensembl chr12:32,275,558...32,342,392
G
Mrps31
mitochondrial ribosomal protein S31
affects expression
ISO
testosterone enanthate affects the expression of MRPS31 mRNA
CTD
PMID:17440010
NCBI chr16:69,601,349...69,621,609
Ensembl chr16:69,601,349...69,630,654
G
Mrps6
mitochondrial ribosomal protein S6
affects expression
ISO
testosterone enanthate affects the expression of MRPS6 mRNA
CTD
PMID:17440010
NCBI chr11:31,295,358...31,348,483
Ensembl chr11:31,295,614...31,348,484
G
Msl2
MSL complex subunit 2
affects expression
ISO
testosterone enanthate affects the expression of MSL2 mRNA
CTD
PMID:17440010
NCBI chr 8:101,676,605...101,702,818
Ensembl chr 8:101,676,765...101,763,833
G
Msmo1
methylsterol monooxygenase 1
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate] results in decreased expression of MSMO1 mRNA
CTD
PMID:18160741
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
G
Msn
moesin
affects expression
ISO
testosterone enanthate affects the expression of MSN mRNA
CTD
PMID:17440010
NCBI chr X:60,996,043...61,064,011
Ensembl chr X:60,995,951...61,065,628
G
Mtus1
microtubule associated scaffold protein 1
affects expression
ISO
testosterone enanthate affects the expression of MTUS1 mRNA
CTD
PMID:17440010
NCBI chr16:51,202,497...51,347,794
Ensembl chr16:51,253,562...51,347,793
G
Mx1
MX dynamin like GTPase 1
affects expression
ISO
testosterone enanthate affects the expression of MX1 mRNA
CTD
PMID:17440010
NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507
G
Mx2
MX dynamin like GTPase 2
affects expression
ISO
testosterone enanthate affects the expression of MX2 mRNA
CTD
PMID:17440010
NCBI chr11:36,905,698...36,936,308
Ensembl chr11:36,906,111...36,930,342
G
Mxd4
Max dimerization protein 4
affects expression
ISO
testosterone enanthate affects the expression of MXD4 mRNA
CTD
PMID:17440010
NCBI chr14:76,562,105...76,576,224
Ensembl chr14:76,561,774...76,576,221
G
Myh11
myosin heavy chain 11
affects expression
ISO
testosterone enanthate affects the expression of MYH11 mRNA
CTD
PMID:17440010
NCBI chr10:743,364...838,459
Ensembl chr10:743,685...838,459
G
Myh3
myosin heavy chain 3
affects expression
ISO
testosterone enanthate affects the expression of MYH3 mRNA
CTD
PMID:17440010
NCBI chr10:51,770,177...51,793,994
Ensembl chr10:51,770,177...51,793,992
G
Myo9a
myosin IXA
affects expression
ISO
testosterone enanthate affects the expression of MYO9A mRNA
CTD
PMID:17440010
NCBI chr 8:60,149,234...60,352,330
Ensembl chr 8:60,149,234...60,350,514
G
N4bp2l2
NEDD4 binding protein 2-like 2
affects expression
ISO
testosterone enanthate affects the expression of N4BP2L2 mRNA
CTD
PMID:17440010
NCBI chr12:137,342...200,292
Ensembl chr12:103,590...197,784
G
Naa15
N(alpha)-acetyltransferase 15, NatA auxiliary subunit
affects expression
ISO
testosterone enanthate affects the expression of NAA15 mRNA
CTD
PMID:17440010
NCBI chr 2:135,458,018...135,520,756
Ensembl chr 2:135,457,948...135,520,756
G
Ncoa3
nuclear receptor coactivator 3
increases expression
ISO
testosterone enanthate results in increased expression of NCOA3 mRNA
CTD
PMID:17440010
NCBI chr 3:154,738,566...154,821,395
Ensembl chr 3:154,738,581...154,818,594
G
Ndnf
neuron-derived neurotrophic factor
affects expression
ISO
testosterone enanthate affects the expression of NDNF mRNA
CTD
PMID:17440010
NCBI chr 4:94,944,392...94,981,871
Ensembl chr 4:94,944,360...94,981,873
G
Ndrg2
NDRG family member 2
affects expression
ISO
testosterone enanthate affects the expression of NDRG2 mRNA
CTD
PMID:17440010
NCBI chr15:24,600,981...24,609,621
Ensembl chr15:24,600,982...24,609,626
G
Nek1
NIMA-related kinase 1
affects expression
ISO
testosterone enanthate affects the expression of NEK1 mRNA
CTD
PMID:17440010
NCBI chr16:28,998,229...29,125,426
Ensembl chr16:28,998,231...29,117,723
G
Nes
nestin
affects expression
ISO
testosterone enanthate affects the expression of NES mRNA
CTD
PMID:17440010
NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
G
Neurl1
neuralized E3 ubiquitin protein ligase 1
affects expression
ISO
testosterone enanthate affects the expression of NEURL1 mRNA
CTD
PMID:17440010
NCBI chr 1:246,066,830...246,152,890
Ensembl chr 1:246,067,100...246,152,903
G
Nfat5
nuclear factor of activated T-cells 5
increases expression
ISO
testosterone enanthate results in increased expression of NFAT5 mRNA
CTD
PMID:17440010
NCBI chr19:35,199,737...35,286,675
Ensembl chr19:35,199,016...35,286,675
G
Nfatc2ip
nuclear factor of activated T-cells 2 interacting protein
affects expression
ISO
testosterone enanthate affects the expression of NFATC2IP mRNA
CTD
PMID:17440010
NCBI chr 1:180,954,834...180,971,847
Ensembl chr 1:180,955,043...180,971,747
G
Nktr
natural killer cell triggering receptor
affects expression
ISO
testosterone enanthate affects the expression of NKTR mRNA
CTD
PMID:17440010
NCBI chr 8:121,380,010...121,420,495
Ensembl chr 8:121,382,436...121,418,314
G
Nlk
nemo like kinase
affects expression
ISO
testosterone enanthate affects the expression of NLK mRNA
CTD
PMID:17440010
NCBI chr10:63,467,388...63,590,960
Ensembl chr10:63,438,222...63,589,730
G
Nnmt
nicotinamide N-methyltransferase
affects expression
ISO
testosterone enanthate affects the expression of NNMT mRNA
CTD
PMID:17440010
NCBI chr 8:48,928,663...48,947,734
Ensembl chr 8:48,933,598...48,946,655
G
Nos2
nitric oxide synthase 2
multiple interactions increases expression
EXP
[pimagedine inhibits the reaction [testosterone enanthate results in increased expression of NOS2 mRNA]] which results in decreased secretion of Nitrites; [pimagedine inhibits the reaction [testosterone enanthate results in increased expression of NOS2 mRNA]] which results in increased secretion of Dihydrotestosterone; [pimagedine inhibits the reaction [testosterone enanthate results in increased expression of NOS2 mRNA]] which results in increased secretion of Testosterone; [testosterone enanthate results in increased expression of NOS2 mRNA] which results in increased abundance of Cyclic GMP; [testosterone enanthate results in increased expression of NOS2 mRNA] which results in increased abundance of Nitrites; Cyproterone Acetate inhibits the reaction [testosterone enanthate results in increased expression of NOS2 mRNA]; Cyproterone Acetate inhibits the reaction [testosterone enanthate results in increased expression of NOS2 protein]; pimagedine inhibits the reaction [testosterone enanthate results in increased expression of NOS2 mRNA]; testosterone enanthate inhibits the reaction [Triptorelin Pamoate inhibits the reaction [testosterone enanthate results in increased expression of NOS2 mRNA]]; testosterone enanthate inhibits the reaction [Triptorelin Pamoate inhibits the reaction [testosterone enanthate results in increased expression of NOS2 protein]]; Triptorelin Pamoate inhibits the reaction [testosterone enanthate results in increased expression of NOS2 mRNA]; Triptorelin Pamoate inhibits the reaction [testosterone enanthate results in increased expression of NOS2 protein] testosterone enanthate results in increased expression of NOS2 mRNA; testosterone enanthate results in increased expression of NOS2 protein
CTD
PMID:20463352 PMID:23085480
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
G
Npepps
aminopeptidase puromycin sensitive
affects expression
ISO
testosterone enanthate affects the expression of NPEPPS mRNA
CTD
PMID:17440010
NCBI chr10:82,191,454...82,273,967
Ensembl chr10:82,191,456...82,273,967
G
Nr0b1
nuclear receptor subfamily 0, group B, member 1
decreases expression
EXP
testosterone enanthate results in decreased expression of NR0B1 mRNA
CTD
PMID:25603467
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
G
Nr5a1
nuclear receptor subfamily 5, group A, member 1
decreases expression
EXP
testosterone enanthate results in decreased expression of NR5A1 mRNA
CTD
PMID:21427060
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
G
Oas2
2'-5' oligoadenylate synthetase 2
affects expression
ISO
testosterone enanthate affects the expression of OAS2 mRNA
CTD
PMID:17440010
NCBI chr12:35,802,824...35,830,778
Ensembl chr12:35,806,759...35,829,371
G
Oaz2
ornithine decarboxylase antizyme 2
affects expression
ISO
testosterone enanthate affects the expression of OAZ2 mRNA
CTD
PMID:17440010
NCBI chr 8:66,199,694...66,213,513
Ensembl chr 8:66,199,706...66,231,453
G
Ogdh
oxoglutarate dehydrogenase
affects expression
ISO
testosterone enanthate affects the expression of OGDH mRNA
CTD
PMID:17440010
NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
G
Ogfod2
2-oxoglutarate and iron-dependent oxygenase domain containing 2
affects expression
ISO
testosterone enanthate affects the expression of OGFOD2 mRNA
CTD
PMID:17440010
NCBI chr12:32,482,386...32,485,688
Ensembl chr12:32,482,377...32,485,673
G
Ogfr
opioid growth factor receptor
affects expression
ISO
testosterone enanthate affects the expression of OGFR mRNA
CTD
PMID:17440010
NCBI chr 3:167,703,173...167,709,459
Ensembl chr 3:167,702,695...167,709,473
G
Orc4
origin recognition complex, subunit 4
affects expression
ISO
testosterone enanthate affects the expression of ORC4 mRNA
CTD
PMID:17440010
NCBI chr 3:33,290,844...33,334,022
Ensembl chr 3:33,294,355...33,333,824
G
Osbpl8
oxysterol binding protein-like 8
affects expression
ISO
testosterone enanthate affects the expression of OSBPL8 mRNA
CTD
PMID:17440010
NCBI chr 7:46,596,944...46,749,888
Ensembl chr 7:46,596,983...46,749,888
G
P3h4
prolyl 3-hydroxylase family member 4
affects expression
ISO
testosterone enanthate affects the expression of P3H4 mRNA
CTD
PMID:17440010
NCBI chr10:85,338,158...85,345,108
Ensembl chr10:85,338,161...85,345,093
G
Pakap
paralemmin A kinase anchor protein
affects expression
ISO
testosterone enanthate affects the expression of PALM2AKAP2 mRNA
CTD
PMID:17440010
NCBI chr 5:72,536,986...72,648,524 NCBI chr 5:72,313,646...72,450,645
Ensembl chr 5:72,181,718...72,648,524
G
Palld
palladin, cytoskeletal associated protein
affects expression
ISO
testosterone enanthate affects the expression of PALLD mRNA
CTD
PMID:17440010
NCBI chr16:28,228,006...28,621,349
Ensembl chr16:27,981,354...28,621,337
G
Papss2
3'-phosphoadenosine 5'-phosphosulfate synthase 2
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of PAPSS2 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of PAPSS2 mRNA
CTD
PMID:18160741
NCBI chr 1:230,454,314...230,539,332
Ensembl chr 1:230,454,426...230,539,331
G
Pard3
par-3 family cell polarity regulator
affects expression
ISO
testosterone enanthate affects the expression of PARD3 mRNA
CTD
PMID:17440010
NCBI chr19:55,080,282...55,630,111
Ensembl chr19:55,080,282...55,629,778
G
Pcdh17
protocadherin 17
affects expression
ISO
testosterone enanthate affects the expression of PCDH17 mRNA
CTD
PMID:17440010
NCBI chr15:60,222,088...60,316,172
Ensembl chr15:60,222,004...60,313,999
G
Pcna
proliferating cell nuclear antigen
increases expression multiple interactions
EXP
testosterone enanthate results in increased expression of PCNA protein Finasteride inhibits the reaction [testosterone enanthate results in increased expression of PCNA protein]
CTD
PMID:36015278
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
G
Pcyox1
prenylcysteine oxidase 1
affects expression
ISO
testosterone enanthate affects the expression of PCYOX1 mRNA
CTD
PMID:17440010
NCBI chr 4:118,832,114...118,842,951
Ensembl chr 4:118,830,638...118,842,951
G
Pdcd4
programmed cell death 4
affects expression
ISO
testosterone enanthate affects the expression of PDCD4 mRNA
CTD
PMID:17440010
NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275
G
Pde10a
phosphodiesterase 10A
increases expression
EXP
testosterone enanthate results in increased expression of PDE10A mRNA
CTD
PMID:20463352 PMID:21427060
NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
G
Pde1c
phosphodiesterase 1C
increases expression
EXP
testosterone enanthate results in increased expression of PDE1C mRNA
CTD
PMID:20463352 PMID:21427060
NCBI chr 4:85,300,858...85,777,948
Ensembl chr 4:85,300,858...85,863,219
G
Pde3a
phosphodiesterase 3A
increases expression
EXP
testosterone enanthate results in increased expression of PDE3A mRNA
CTD
PMID:20463352 PMID:21427060
NCBI chr 4:174,172,804...174,443,944
Ensembl chr 4:174,172,868...174,438,274
G
Pde4a
phosphodiesterase 4A
increases expression
EXP
testosterone enanthate results in increased expression of PDE4A mRNA
CTD
PMID:21427060 PMID:25603467
NCBI chr 8:19,690,816...19,753,538
Ensembl chr 8:19,703,290...19,751,961
G
Pde4b
phosphodiesterase 4B
increases expression
EXP
testosterone enanthate results in increased expression of PDE4B mRNA
CTD
PMID:21427060 PMID:25603467
NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696
G
Pde4d
phosphodiesterase 4D
increases expression
EXP
testosterone enanthate results in increased expression of PDE4D mRNA
CTD
PMID:25603467
NCBI chr 2:40,014,933...41,529,190
Ensembl chr 2:40,019,933...41,525,884
G
Pde4dip
phosphodiesterase 4D interacting protein
affects expression
ISO
testosterone enanthate affects the expression of PDE4DIP mRNA
CTD
PMID:17440010
NCBI chr 2:185,293,236...185,490,100
Ensembl chr 2:185,293,214...185,468,379
G
Pde5a
phosphodiesterase 5A
multiple interactions increases expression
EXP
[testosterone enanthate co-treated with Triptorelin Pamoate] results in increased expression of PDE5A mRNA; [testosterone enanthate co-treated with Triptorelin Pamoate] results in increased expression of PDE5A protein; Cyproterone Acetate inhibits the reaction [testosterone enanthate results in increased expression of PDE5A mRNA] testosterone enanthate results in increased expression of PDE5A mRNA; testosterone enanthate results in increased expression of PDE5A protein
CTD
PMID:20463352
NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701
G
Pde6d
phosphodiesterase 6D
increases expression
EXP
testosterone enanthate results in increased expression of PDE6D mRNA
CTD
PMID:20463352
NCBI chr 9:87,192,989...87,237,979
Ensembl chr 9:87,192,983...87,237,969
G
Pde7a
phosphodiesterase 7A
increases expression
EXP
testosterone enanthate results in increased expression of PDE7A mRNA
CTD
PMID:21427060
NCBI chr 2:101,714,767...101,806,853
Ensembl chr 2:101,718,444...101,806,681
G
Pde7b
phosphodiesterase 7B
increases metabolic processing increases hydrolysis
ISO
PDE7B protein results in increased metabolism of testosterone enanthate PDE7B protein results in increased hydrolysis of testosterone enanthate
CTD
PMID:21383644
NCBI chr 1:15,174,001...15,493,267
Ensembl chr 1:15,182,704...15,492,900
G
Pde8b
phosphodiesterase 8B
increases expression
EXP
testosterone enanthate results in increased expression of PDE8B mRNA
CTD
PMID:21427060
NCBI chr 2:26,275,117...26,479,725
Ensembl chr 2:26,276,635...26,509,209
G
Pde9a
phosphodiesterase 9A
increases expression
EXP
testosterone enanthate results in increased expression of PDE9A mRNA
CTD
PMID:20463352
NCBI chr20:9,469,809...9,562,949
Ensembl chr20:9,469,848...9,562,948
G
Pdk4
pyruvate dehydrogenase kinase 4
affects expression
ISO
testosterone enanthate affects the expression of PDK4 mRNA
CTD
PMID:17440010
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
G
Pdp1
pyruvate dehydrogenase phosphatase catalytic subunit 1
affects expression
ISO
testosterone enanthate affects the expression of PDP1 mRNA
CTD
PMID:17440010
NCBI chr 5:25,446,843...25,455,107
Ensembl chr 5:25,446,272...25,455,217
G
Pfkl
phosphofructokinase, liver type
affects expression
ISO
testosterone enanthate affects the expression of PFKL mRNA
CTD
PMID:17440010
NCBI chr20:10,664,285...10,686,324
Ensembl chr20:10,664,272...10,686,315
G
Pgghg
protein-glucosylgalactosylhydroxylysine glucosidase
affects expression
ISO
testosterone enanthate affects the expression of PGGHG mRNA
CTD
PMID:17440010
NCBI chr 1:196,038,276...196,044,561
Ensembl chr 1:196,039,103...196,044,372
G
Pgrmc1
progesterone receptor membrane component 1
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of PGRMC1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of PGRMC1 mRNA
CTD
PMID:18160741
NCBI chr X:115,832,865...115,841,060
Ensembl chr X:115,832,884...115,888,682
G
Phf14
PHD finger protein 14
affects expression
ISO
testosterone enanthate affects the expression of PHF14 mRNA
CTD
PMID:17440010
NCBI chr 4:40,009,691...40,195,877
Ensembl chr 4:40,009,264...40,195,885
G
Phf3
PHD finger protein 3
affects expression
ISO
testosterone enanthate affects the expression of PHF3 mRNA
CTD
PMID:17440010
NCBI chr 9:33,063,855...33,136,013
Ensembl chr 9:33,063,857...33,135,994
G
Phlda1
pleckstrin homology-like domain, family A, member 1
affects expression
ISO
testosterone enanthate affects the expression of PHLDA1 mRNA
CTD
PMID:17440010
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
G
Picalm
phosphatidylinositol binding clathrin assembly protein
affects expression
ISO
testosterone enanthate affects the expression of PICALM mRNA
CTD
PMID:17440010
NCBI chr 1:144,056,415...144,138,045
Ensembl chr 1:144,056,721...144,137,557
G
Pitpna
phosphatidylinositol transfer protein, alpha
affects expression
ISO
testosterone enanthate affects the expression of PITPNA mRNA
CTD
PMID:17440010
NCBI chr10:60,430,712...60,473,564
Ensembl chr10:60,430,748...60,471,342
G
Plekha1
pleckstrin homology domain containing A1
affects expression
ISO
testosterone enanthate affects the expression of PLEKHA1 mRNA
CTD
PMID:17440010
NCBI chr 1:185,427,982...185,479,157
Ensembl chr 1:185,428,048...185,479,156
G
Plod2
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2
affects expression
ISO
testosterone enanthate affects the expression of PLOD2 mRNA
CTD
PMID:17440010
NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255
G
Plpp3
phospholipid phosphatase 3
affects expression
ISO
testosterone enanthate affects the expression of PLPP3 mRNA
CTD
PMID:17440010
NCBI chr 5:119,927,085...120,002,206
Ensembl chr 5:119,927,085...120,002,205
G
Pmvk
phosphomevalonate kinase
affects expression
ISO
testosterone enanthate affects the expression of PMVK mRNA
CTD
PMID:17440010
NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364
G
Ppargc1a
PPARG coactivator 1 alpha
increases expression
EXP
testosterone enanthate results in increased expression of PPARGC1A mRNA
CTD
PMID:25603467
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
G
Ppargc1b
PPARG coactivator 1 beta
increases expression
EXP
testosterone enanthate results in increased expression of PPARGC1B mRNA
CTD
PMID:25603467
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
G
Ppib
peptidylprolyl isomerase B
affects expression
ISO
testosterone enanthate affects the expression of PPIB mRNA
CTD
PMID:17440010
NCBI chr 8:66,603,877...66,609,734
Ensembl chr 8:66,603,861...66,630,428
G
Ppig
peptidylprolyl isomerase G
affects expression
ISO
testosterone enanthate affects the expression of PPIG mRNA
CTD
PMID:17440010
NCBI chr 3:54,484,023...54,512,929
Ensembl chr 3:54,484,023...54,512,926
G
Ppm1a
protein phosphatase, Mg2+/Mn2+ dependent, 1A
affects expression
ISO
testosterone enanthate affects the expression of PPM1A mRNA
CTD
PMID:17440010
NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697
G
Ppp1r12a
protein phosphatase 1, regulatory subunit 12A
affects expression
ISO
testosterone enanthate affects the expression of PPP1R12A mRNA
CTD
PMID:17440010
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
G
Ppp1r3a
protein phosphatase 1, regulatory subunit 3A
affects expression
ISO
testosterone enanthate affects the expression of PPP1R3A mRNA
CTD
PMID:17440010
NCBI chr 4:42,937,353...42,980,195
Ensembl chr 4:42,939,599...42,980,638
G
Ppp1r7
protein phosphatase 1, regulatory subunit 7
affects expression
ISO
testosterone enanthate affects the expression of PPP1R7 mRNA
CTD
PMID:17440010
NCBI chr 9:93,886,068...93,911,198
Ensembl chr 9:93,886,143...93,914,850
G
Ppp1r9a
protein phosphatase 1, regulatory subunit 9A
affects expression
ISO
testosterone enanthate affects the expression of PPP1R9A mRNA
CTD
PMID:17440010
NCBI chr 4:32,970,501...33,292,360
Ensembl chr 4:33,024,450...33,286,907
G
Ppp4c
protein phosphatase 4, catalytic subunit
affects expression
ISO
testosterone enanthate affects the expression of PPP4C mRNA
CTD
PMID:17440010
NCBI chr 1:181,392,899...181,399,703
Ensembl chr 1:181,392,923...181,399,659
G
Prf1
perforin 1
affects expression
ISO
testosterone enanthate affects the expression of PRF1 mRNA
CTD
PMID:17440010
NCBI chr20:29,246,202...29,251,712
Ensembl chr20:29,246,202...29,251,701
G
Prkaa1
protein kinase AMP-activated catalytic subunit alpha 1
decreases phosphorylation multiple interactions
EXP
testosterone enanthate results in decreased phosphorylation of PRKAA1 protein cordycepin inhibits the reaction [testosterone enanthate results in decreased phosphorylation of PRKAA1 protein]; Finasteride inhibits the reaction [testosterone enanthate results in decreased phosphorylation of PRKAA1 protein]
CTD
PMID:36015278
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
G
Prkaa2
protein kinase AMP-activated catalytic subunit alpha 2
affects expression multiple interactions decreases phosphorylation
ISO EXP
testosterone enanthate affects the expression of PRKAA2 mRNA cordycepin inhibits the reaction [testosterone enanthate results in decreased phosphorylation of PRKAA2 protein]; Finasteride inhibits the reaction [testosterone enanthate results in decreased phosphorylation of PRKAA2 protein]
CTD
PMID:17440010 PMID:36015278
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
G
Prkab2
protein kinase AMP-activated non-catalytic subunit beta 2
affects expression
ISO
testosterone enanthate affects the expression of PRKAB2 mRNA
CTD
PMID:17440010
NCBI chr 2:185,257,218...185,272,846
Ensembl chr 2:185,257,213...185,269,872
G
Prkacb
protein kinase cAMP-activated catalytic subunit beta
affects expression
ISO EXP
testosterone enanthate affects the expression of PRKACB mRNA
CTD
PMID:17440010 PMID:25603467
NCBI chr 2:235,636,878...235,726,928
Ensembl chr 2:235,636,885...235,726,198
G
Prkar1a
protein kinase cAMP-dependent type I regulatory subunit alpha
affects expression
EXP
testosterone enanthate affects the expression of PRKAR1A mRNA
CTD
PMID:25603467
NCBI chr10:94,621,042...94,639,534
Ensembl chr10:94,620,039...94,639,041
G
Prkar2a
protein kinase cAMP-dependent type II regulatory subunit alpha
decreases expression affects expression
EXP ISO
testosterone enanthate results in decreased expression of PRKAR2A mRNA testosterone enanthate affects the expression of PRKAR2A mRNA
CTD
PMID:17440010 PMID:25603467
NCBI chr 8:109,393,189...109,458,832
Ensembl chr 8:109,395,833...109,455,628
G
Prkar2b
protein kinase cAMP-dependent type II regulatory subunit beta
affects expression
EXP
testosterone enanthate affects the expression of PRKAR2B mRNA
CTD
PMID:25603467
NCBI chr 6:48,563,659...48,653,933
Ensembl chr 6:48,563,662...48,653,933
G
Prkca
protein kinase C, alpha
decreases expression
EXP
testosterone enanthate results in decreased expression of PRKCA mRNA
CTD
PMID:25603467
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
G
Prkg1
protein kinase cGMP-dependent 1
multiple interactions affects expression decreases expression
EXP ISO
testosterone enanthate promotes the reaction [Triptorelin Pamoate results in decreased expression of PRKG1 mRNA]; testosterone enanthate promotes the reaction [Triptorelin Pamoate results in decreased expression of PRKG1 protein] testosterone enanthate affects the expression of PRKG1 mRNA testosterone enanthate results in decreased expression of PRKG1 mRNA; testosterone enanthate results in decreased expression of PRKG1 protein
CTD
PMID:17440010 PMID:20463352 PMID:23085480
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
G
Prl
prolactin
affects expression
EXP
testosterone enanthate affects the expression of PRL mRNA
CTD
PMID:25603467
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
G
Prlr
prolactin receptor
decreases expression
EXP
testosterone enanthate results in decreased expression of PRLR mRNA
CTD
PMID:25603467
NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718
G
Proc
protein C, inactivator of coagulation factors Va and VIIIa
decreases expression
ISO
testosterone enanthate results in decreased expression of PROC protein
CTD
PMID:8585008
NCBI chr18:23,764,367...23,774,816
Ensembl chr18:23,764,368...23,775,133
G
Prok1
prokineticin 1
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of PROK1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of PROK1 mRNA
CTD
PMID:18160741
NCBI chr 2:194,850,539...194,859,343
Ensembl chr 2:194,853,991...194,859,250
G
Pros1
protein S
decreases expression
ISO
testosterone enanthate results in decreased expression of PROS1 protein
CTD
PMID:8585008
NCBI chr11:230,597...311,288
Ensembl chr11:230,696...311,286
G
Prox1
prospero homeobox 1
affects expression
ISO
testosterone enanthate affects the expression of PROX1 mRNA
CTD
PMID:17440010
NCBI chr13:101,669,184...101,719,804
Ensembl chr13:101,669,184...101,711,183
G
Prps2
phosphoribosyl pyrophosphate synthetase 2
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate] results in decreased expression of PRPS2 mRNA
CTD
PMID:18160741
NCBI chr X:26,975,915...27,013,184
Ensembl chr X:26,976,061...27,013,181
G
Prrc2c
proline-rich coiled-coil 2C
affects expression
ISO
testosterone enanthate affects the expression of PRRC2C mRNA
CTD
PMID:17440010
NCBI chr13:75,003,995...75,073,701
Ensembl chr13:75,004,010...75,073,643
G
Prss22
serine protease 22
affects expression
ISO
testosterone enanthate affects the expression of PRSS22 mRNA
CTD
PMID:17440010
NCBI chr10:13,029,153...13,033,863
Ensembl chr10:13,029,153...13,033,863
G
Prune2
prune homolog 2 with BCH domain
affects expression
ISO
testosterone enanthate affects the expression of PRUNE2 mRNA
CTD
PMID:17440010
NCBI chr 1:214,352,586...214,624,848
Ensembl chr 1:214,352,955...214,622,650
G
Psme4
proteasome activator subunit 4
affects expression
ISO
testosterone enanthate affects the expression of PSME4 mRNA
CTD
PMID:17440010
NCBI chr14:104,505,716...104,609,410
Ensembl chr14:104,505,716...104,609,408
G
Psph
phosphoserine phosphatase
affects expression
ISO
testosterone enanthate affects the expression of PSPH mRNA
CTD
PMID:17440010
NCBI chr12:26,882,524...26,905,084
Ensembl chr12:26,883,133...26,905,074
G
Ptbp1
polypyrimidine tract binding protein 1
affects expression
ISO
testosterone enanthate affects the expression of PTBP1 mRNA
CTD
PMID:17440010
NCBI chr 7:9,842,574...9,852,332
Ensembl chr 7:9,842,574...9,852,397
G
Ptcd2
pentatricopeptide repeat domain 2
affects expression
ISO
testosterone enanthate affects the expression of PTCD2 mRNA
CTD
PMID:17440010
NCBI chr 2:30,712,276...30,739,968
Ensembl chr 2:30,712,280...30,739,942
G
Ptma
prothymosin alpha
affects expression
ISO
testosterone enanthate affects the expression of PTMA mRNA
CTD
PMID:17440010
NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333
G
Ptn
pleiotrophin
affects expression
ISO
testosterone enanthate affects the expression of PTN mRNA
CTD
PMID:17440010
NCBI chr 4:65,293,731...65,375,572
Ensembl chr 4:65,293,734...65,375,456
G
Ptpn4
protein tyrosine phosphatase, non-receptor type 4
affects expression
ISO
testosterone enanthate affects the expression of PTPN4 mRNA
CTD
PMID:17440010
NCBI chr13:30,772,012...30,952,340
Ensembl chr13:30,776,682...30,952,170
G
Ptprd
protein tyrosine phosphatase, receptor type, D
affects expression
ISO
testosterone enanthate affects the expression of PTPRD mRNA
CTD
PMID:17440010
NCBI chr 5:90,046,993...90,698,977 NCBI chr 5:91,122,354...91,641,754
Ensembl chr 5:90,048,966...92,369,396
G
Pvalb
parvalbumin
affects expression
ISO
testosterone enanthate affects the expression of PVALB mRNA
CTD
PMID:17440010
NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561
G
Pwwp3a
PWWP domain containing 3A, DNA repair factor
affects expression
ISO
testosterone enanthate affects the expression of PWWP3A mRNA
CTD
PMID:17440010
NCBI chr 7:9,465,180...9,482,053
Ensembl chr 7:9,465,195...9,481,966
G
Pxdn
peroxidasin
affects expression
ISO
testosterone enanthate affects the expression of PXDN mRNA
CTD
PMID:17440010
NCBI chr 6:46,580,749...46,658,345
Ensembl chr 6:46,580,761...46,658,345
G
Rab14
RAB14, member RAS oncogene family
affects expression
ISO
testosterone enanthate affects the expression of RAB14 mRNA
CTD
PMID:17440010
NCBI chr 3:18,501,953...18,523,253
Ensembl chr 3:18,501,963...18,523,172
G
Rab27a
RAB27A, member RAS oncogene family
affects expression
ISO
testosterone enanthate affects the expression of RAB27A mRNA
CTD
PMID:17440010
NCBI chr 8:73,782,730...73,836,630
Ensembl chr 8:73,782,694...73,847,829
G
Rad50
RAD50 double strand break repair protein
affects expression
ISO
testosterone enanthate affects the expression of RAD50 mRNA
CTD
PMID:17440010
NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396
G
Ranbp2
RAN binding protein 2
affects expression
ISO
testosterone enanthate affects the expression of RANBP2 mRNA
CTD
PMID:17440010
NCBI chr20:26,442,156...26,493,481
Ensembl chr20:26,442,217...26,493,481
G
Rap2a
RAP2A, member of RAS oncogene family
affects expression
ISO
testosterone enanthate affects the expression of RAP2A mRNA
CTD
PMID:17440010
NCBI chr15:97,596,848...97,597,338
Ensembl chr15:97,596,020...97,624,138
G
Rapgef2
Rap guanine nucleotide exchange factor 2
affects expression
ISO
testosterone enanthate affects the expression of RAPGEF2 mRNA
CTD
PMID:17440010
NCBI chr 2:164,207,513...164,322,157
Ensembl chr 2:164,207,513...164,244,247
G
Rbbp5
RB binding protein 5, histone lysine methyltransferase complex subunit
affects expression
ISO
testosterone enanthate affects the expression of RBBP5 mRNA
CTD
PMID:17440010
NCBI chr13:43,912,254...43,939,107
Ensembl chr13:43,912,254...43,939,107
G
Rbl2
RB transcriptional corepressor like 2
affects expression
ISO
testosterone enanthate affects the expression of RBL2 mRNA
CTD
PMID:17440010
NCBI chr19:15,876,852...15,923,632
Ensembl chr19:15,876,853...15,923,572
G
Rbm25
RNA binding motif protein 25
affects expression
ISO
testosterone enanthate affects the expression of RBM25 mRNA
CTD
PMID:17440010
NCBI chr 6:103,271,775...103,319,090
Ensembl chr 6:103,271,801...103,317,854
G
Rbm41
RNA binding motif protein 41
affects expression
ISO
testosterone enanthate affects the expression of RBM41 mRNA
CTD
PMID:17440010
NCBI chr X:103,605,732...103,660,381
Ensembl chr X:103,608,585...103,660,381
G
Rela
RELA proto-oncogene, NF-kB subunit
multiple interactions increases expression
EXP
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of RELA protein]; cordycepin inhibits the reaction [testosterone enanthate results in increased expression of RELA protein]; Finasteride inhibits the reaction [testosterone enanthate results in increased expression of RELA protein]
CTD
PMID:30154949 PMID:36015278
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
G
Retreg3
reticulophagy regulator family member 3
affects expression
ISO
testosterone enanthate affects the expression of RETREG3 mRNA
CTD
PMID:17440010
NCBI chr10:86,028,767...86,052,575
Ensembl chr10:86,028,774...86,052,692
G
Rgn
regucalcin
affects expression
ISO
testosterone enanthate affects the expression of RGN mRNA
CTD
PMID:17440010
NCBI chr X:1,619,030...1,634,456
Ensembl chr X:1,619,032...1,634,450
G
Rhob
ras homolog family member B
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of RHOB mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of RHOB mRNA
CTD
PMID:18160741
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
G
Rhobtb3
Rho-related BTB domain containing 3
affects expression
ISO
testosterone enanthate affects the expression of RHOBTB3 mRNA
CTD
PMID:17440010
NCBI chr 2:5,363,388...5,419,164
Ensembl chr 2:5,363,388...5,419,041
G
Rngtt
RNA guanylyltransferase and 5'-phosphatase
affects expression
ISO
testosterone enanthate affects the expression of RNGTT mRNA
CTD
PMID:17440010
NCBI chr 5:47,706,929...47,913,297
Ensembl chr 5:47,706,799...47,913,295
G
Rora
RAR-related orphan receptor A
increases expression
ISO
testosterone enanthate results in increased expression of RORA mRNA
CTD
PMID:17440010
NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931
G
Rpl30
ribosomal protein L30
affects expression
ISO
testosterone enanthate affects the expression of RPL30 mRNA
CTD
PMID:17440010
NCBI chr 7:65,648,266...65,651,401
Ensembl chr 7:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363
G
Rrad
RRAD, Ras related glycolysis inhibitor and calcium channel regulator
affects expression
ISO
testosterone enanthate affects the expression of RRAD mRNA
CTD
PMID:17440010
NCBI chr19:354,184...357,424
Ensembl chr19:354,198...357,417
G
Rrbp1
ribosome binding protein 1
affects expression
ISO
testosterone enanthate affects the expression of RRBP1 mRNA
CTD
PMID:17440010
NCBI chr 3:131,314,996...131,376,930
Ensembl chr 3:131,314,998...131,376,981
G
Rrp7a
ribosomal RNA processing 7 homolog A
affects expression
ISO
testosterone enanthate affects the expression of RRP7A mRNA
CTD
PMID:17440010
NCBI chr 7:114,262,929...114,272,817
Ensembl chr 7:114,256,472...114,272,817
G
Rsad2
radical S-adenosyl methionine domain containing 2
affects expression
ISO
testosterone enanthate affects the expression of RSAD2 mRNA
CTD
PMID:17440010
NCBI chr 6:43,046,514...43,059,737
Ensembl chr 6:43,047,658...43,059,699
G
Rsl1d1
ribosomal L1 domain containing 1
affects expression
ISO
testosterone enanthate affects the expression of RSL1D1 mRNA
CTD
PMID:17440010
NCBI chr10:4,424,868...4,436,753
Ensembl chr10:4,397,821...4,439,593
G
Rsrc1
arginine and serine rich coiled-coil 1
affects expression
ISO
testosterone enanthate affects the expression of RSRC1 mRNA
CTD
PMID:17440010
NCBI chr 2:151,226,821...151,632,771
Ensembl chr 2:151,231,156...151,632,765
G
RT1-Ba
RT1 class II, locus Ba
affects expression
ISO
testosterone enanthate affects the expression of HLA-DQA1 mRNA
CTD
PMID:17440010
NCBI chr20:4,575,134...4,579,727
Ensembl chr20:4,575,134...4,579,744
G
RT1-Bb
RT1 class II, locus Bb
affects expression
ISO
testosterone enanthate affects the expression of HLA-DQB1 mRNA
CTD
PMID:17440010
NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597
G
RT1-Ha
RT1 class II, locus Ha
affects expression
ISO
testosterone enanthate affects the expression of HLA-DPA1 mRNA
CTD
PMID:17440010
NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,760,118...4,770,244
G
Rufy3
RUN and FYVE domain containing 3
affects expression
ISO
testosterone enanthate affects the expression of RUFY3 mRNA
CTD
PMID:17440010
NCBI chr14:19,431,530...19,506,476
Ensembl chr14:19,432,524...19,507,004
G
Rxrb
retinoid X receptor beta
affects expression
ISO
testosterone enanthate affects the expression of RXRB mRNA
CTD
PMID:17440010
NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773
G
Sart3
spliceosome associated factor 3, U4/U6 recycling protein
affects expression
ISO
testosterone enanthate affects the expression of SART3 mRNA
CTD
PMID:17440010
NCBI chr12:42,859,026...42,887,041
Ensembl chr12:42,859,305...42,887,038
G
Scaf11
SR-related CTD-associated factor 11
affects expression
ISO
testosterone enanthate affects the expression of SCAF11 mRNA
CTD
PMID:17440010
NCBI chr 7:127,571,678...127,624,089
Ensembl chr 7:127,574,463...127,624,101
G
Scamp1
secretory carrier membrane protein 1
affects expression
ISO
testosterone enanthate affects the expression of SCAMP1 mRNA
CTD
PMID:17440010
NCBI chr 2:25,433,958...25,516,734
Ensembl chr 2:25,433,959...25,516,673
G
Scarb1
scavenger receptor class B, member 1
decreases expression
EXP
testosterone enanthate results in decreased expression of SCARB1 mRNA
CTD
PMID:21427060
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
G
Scd
stearoyl-CoA desaturase
affects expression
ISO
testosterone enanthate affects the expression of SCD mRNA
CTD
PMID:17440010
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
G
Scpep1
serine carboxypeptidase 1
affects expression
ISO
testosterone enanthate affects the expression of SCPEP1 mRNA
CTD
PMID:17440010
NCBI chr10:73,703,275...73,732,892
Ensembl chr10:73,703,278...73,732,850
G
Scrg1
stimulator of chondrogenesis 1
affects expression
ISO
testosterone enanthate affects the expression of SCRG1 mRNA
CTD
PMID:17440010
NCBI chr16:32,760,028...32,788,299
Ensembl chr16:32,760,028...32,788,299
G
Sec14l1
SEC14-like lipid binding 1
affects expression
ISO
testosterone enanthate affects the expression of SEC14L1 mRNA
CTD
PMID:17440010
NCBI chr10:102,319,920...102,367,070
Ensembl chr10:102,319,920...102,367,068
G
Sec23b
Sec23 homolog B, COPII coat complex component
affects expression
ISO
testosterone enanthate affects the expression of SEC23B mRNA
CTD
PMID:17440010
NCBI chr 3:131,939,011...131,981,489
Ensembl chr 3:131,939,337...131,981,489
G
Sec23ip
SEC23 interacting protein
affects expression
ISO
testosterone enanthate affects the expression of SEC23IP mRNA
CTD
PMID:17440010
NCBI chr 1:183,320,950...183,363,944
Ensembl chr 1:183,321,075...183,363,920
G
Sec61a1
SEC61 translocon subunit alpha 1
affects expression
ISO
testosterone enanthate affects the expression of SEC61A1 mRNA
CTD
PMID:17440010
NCBI chr 4:120,973,519...120,987,871
Ensembl chr 4:120,960,626...120,987,925
G
Sel1l3
SEL1L family member 3
affects expression
ISO
testosterone enanthate affects the expression of SEL1L3 mRNA
CTD
PMID:17440010
NCBI chr14:57,775,515...57,882,076
Ensembl chr14:57,775,501...57,882,644
G
Serbp1
Serpine1 mRNA binding protein 1
affects expression
ISO
testosterone enanthate affects the expression of SERBP1 mRNA
CTD
PMID:17440010
NCBI chr 4:96,401,587...96,421,816
Ensembl chr 4:96,401,477...96,421,813
G
Serpina3n
serine (or cysteine) peptidase inhibitor, clade A, member 3N
affects expression
ISO
testosterone enanthate affects the expression of SERPINA3 mRNA
CTD
PMID:17440010
NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433
G
Serpinc1
serpin family C member 1
increases expression
ISO
testosterone enanthate results in increased expression of SERPINC1 protein
CTD
PMID:8585008
NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293
G
Sf3b1
splicing factor 3b, subunit 1
affects expression
ISO
testosterone enanthate affects the expression of SF3B1 mRNA
CTD
PMID:17440010
NCBI chr 9:56,492,403...56,532,300
Ensembl chr 9:56,492,403...56,532,300
G
Sfxn3
sideroflexin 3
affects expression
ISO
testosterone enanthate affects the expression of SFXN3 mRNA
CTD
PMID:17440010
NCBI chr 1:243,907,958...243,917,065
Ensembl chr 1:243,907,751...243,917,073
G
Sgk3
serum/glucocorticoid regulated kinase family, member 3
affects expression
ISO
testosterone enanthate affects the expression of SGK3 mRNA
CTD
PMID:17440010
NCBI chr 5:9,345,761...9,472,243
Ensembl chr 5:9,346,040...9,415,476
G
Slc16a7
solute carrier family 16 member 7
affects expression
ISO
testosterone enanthate affects the expression of SLC16A7 mRNA
CTD
PMID:17440010
NCBI chr 7:61,043,667...61,211,547
Ensembl chr 7:61,051,167...61,154,994
G
Slc25a16
solute carrier family 25 member 16
affects expression
ISO
testosterone enanthate affects the expression of SLC25A16 mRNA
CTD
PMID:17440010
NCBI chr20:25,691,474...25,717,558
Ensembl chr20:25,662,055...25,716,319
G
Slc35d1
solute carrier family 35 member D1
affects expression
ISO
testosterone enanthate affects the expression of SLC35D1 mRNA
CTD
PMID:17440010
NCBI chr 5:117,928,628...117,981,289
Ensembl chr 5:117,934,352...117,981,311
G
Slc38a4
solute carrier family 38, member 4
affects expression
ISO
testosterone enanthate affects the expression of SLC38A4 mRNA
CTD
PMID:17440010
NCBI chr 7:128,142,866...128,203,000
Ensembl chr 7:128,144,807...128,202,995
G
Slc38a6
solute carrier family 38, member 6
affects expression
ISO
testosterone enanthate affects the expression of SLC38A6 mRNA
CTD
PMID:17440010
NCBI chr 6:91,987,652...92,076,416
Ensembl chr 6:91,987,672...92,049,935
G
Slc4a7
solute carrier family 4 member 7
affects expression
ISO
testosterone enanthate affects the expression of SLC4A7 mRNA
CTD
PMID:17440010
NCBI chr15:10,585,307...10,664,780
Ensembl chr15:10,588,979...10,664,781
G
Slc5a2
solute carrier family 5 member 2
decreases expression
EXP
testosterone enanthate results in decreased expression of SLC5A2 protein
CTD
PMID:22262063
NCBI chr 1:182,847,185...182,853,309
Ensembl chr 1:182,847,106...182,853,306
G
Slco1a4
solute carrier organic anion transporter family, member 1a4
affects expression
ISO
testosterone enanthate affects the expression of SLCO1A2 mRNA
CTD
PMID:17440010
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
G
Smad2
SMAD family member 2
multiple interactions increases phosphorylation
EXP
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased phosphorylation of SMAD2 protein]
CTD
PMID:30154949
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
G
Smad4
SMAD family member 4
affects expression
ISO
testosterone enanthate affects the expression of SMAD4 mRNA
CTD
PMID:17440010
NCBI chr18:67,243,742...67,274,438
Ensembl chr18:67,243,742...67,274,438
G
Smad5
SMAD family member 5
affects expression
ISO
testosterone enanthate affects the expression of SMAD5 mRNA
CTD
PMID:17440010
NCBI chr17:7,862,332...7,891,678
Ensembl chr17:7,864,720...7,891,634
G
Smc2
structural maintenance of chromosomes 2
affects expression
ISO
testosterone enanthate affects the expression of SMC2 mRNA
CTD
PMID:17440010
NCBI chr 5:66,806,882...66,853,478
Ensembl chr 5:66,807,011...66,853,242
G
Smc3
structural maintenance of chromosomes 3
affects expression
ISO
testosterone enanthate affects the expression of SMC3 mRNA
CTD
PMID:17440010
NCBI chr 1:252,601,422...252,644,522
Ensembl chr 1:252,601,753...252,644,522
G
Smc5
structural maintenance of chromosomes 5
affects expression
ISO
testosterone enanthate affects the expression of SMC5 mRNA
CTD
PMID:17440010
NCBI chr 1:220,769,366...220,839,138
Ensembl chr 1:220,769,366...220,839,096
G
Smg1
SMG1, nonsense mediated mRNA decay associated PI3K related kinase
affects expression
ISO
testosterone enanthate affects the expression of SMG1 mRNA
CTD
PMID:17440010
NCBI chr 1:172,441,892...172,543,667
Ensembl chr 1:172,444,936...172,543,698
G
Snap29
synaptosome associated protein 29
affects expression
ISO
testosterone enanthate affects the expression of SNAP29 mRNA
CTD
PMID:17440010
NCBI chr11:83,578,479...83,608,953
Ensembl chr11:83,578,489...83,608,958
G
Snapc1
small nuclear RNA activating complex, polypeptide 1
affects expression
ISO
testosterone enanthate affects the expression of SNAPC1 mRNA
CTD
PMID:17440010
NCBI chr 6:92,684,785...92,710,772
Ensembl chr 6:92,684,752...92,707,746
G
Snca
synuclein alpha
affects expression
ISO
testosterone enanthate affects the expression of SNCA mRNA
CTD
PMID:17440010
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
G
Snrnp35
small nuclear ribonucleoprotein U11/U12 subunit 35
affects expression
ISO
testosterone enanthate affects the expression of SNRNP35 mRNA
CTD
PMID:17440010
NCBI chr12:32,112,032...32,119,829
Ensembl chr12:32,110,993...32,122,660
G
Snrpe
small nuclear ribonucleoprotein polypeptide E
affects expression
ISO
testosterone enanthate affects the expression of SNRPE mRNA
CTD
PMID:17440010
NCBI chr13:45,050,986...45,057,231
Ensembl chr13:45,050,986...45,057,310 Ensembl chr 8:45,050,986...45,057,310
G
Snrpn
small nuclear ribonucleoprotein polypeptide N
affects expression
ISO
testosterone enanthate affects the expression of SNRPN mRNA
CTD
PMID:17440010
NCBI chr 1:111,101,327...111,123,400
Ensembl chr 1:111,101,329...111,123,634
G
Sod1
superoxide dismutase 1
decreases activity multiple interactions
EXP
testosterone enanthate results in decreased activity of SOD1 protein cordycepin inhibits the reaction [testosterone enanthate results in decreased activity of SOD1 protein]; Finasteride inhibits the reaction [testosterone enanthate results in decreased activity of SOD1 protein]
CTD
PMID:36015278
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
G
Sorbs1
sorbin and SH3 domain containing 1
affects expression
ISO
testosterone enanthate affects the expression of SORBS1 mRNA
CTD
PMID:17440010
NCBI chr 1:239,107,882...239,330,276
Ensembl chr 1:239,108,777...239,330,169
G
Sos1
SOS Ras/Rac guanine nucleotide exchange factor 1
affects expression
ISO
testosterone enanthate affects the expression of SOS1 mRNA
CTD
PMID:17440010
NCBI chr 6:14,533,870...14,613,348
Ensembl chr 6:14,533,360...14,611,107
G
Sos2
SOS Ras/Rho guanine nucleotide exchange factor 2
affects expression
ISO
testosterone enanthate affects the expression of SOS2 mRNA
CTD
PMID:17440010
NCBI chr 6:88,042,966...88,156,140
Ensembl chr 6:88,042,966...88,156,692
G
Sox4
SRY-box transcription factor 4
affects expression
ISO
testosterone enanthate affects the expression of SOX4 mRNA
CTD
PMID:17440010
NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665
G
Sp110
SP110 nuclear body protein
affects expression
ISO
testosterone enanthate affects the expression of SP110 mRNA
CTD
PMID:17440010
NCBI chr 9:86,200,503...86,225,355
Ensembl chr 9:86,200,503...86,222,670
G
Spag9
sperm associated antigen 9
affects expression
ISO
testosterone enanthate affects the expression of SPAG9 mRNA
CTD
PMID:17440010
NCBI chr10:78,943,439...79,077,797
Ensembl chr10:78,943,479...79,077,797
G
Spen
spen family transcriptional repressor
increases expression
ISO
testosterone enanthate results in increased expression of SPEN mRNA
CTD
PMID:17440010
NCBI chr 5:153,775,287...153,848,677
Ensembl chr 5:153,776,234...153,848,811
G
Sqstm1
sequestosome 1
affects expression
ISO
testosterone enanthate affects the expression of SQSTM1 mRNA
CTD
PMID:17440010
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
G
Srpk2
SRSF protein kinase 2
affects expression
ISO
testosterone enanthate affects the expression of SRPK2 mRNA
CTD
PMID:17440010
NCBI chr 4:11,464,684...11,655,993
Ensembl chr 4:11,464,674...11,655,990
G
Srpx
sushi-repeat-containing protein, X-linked
affects expression
ISO
testosterone enanthate affects the expression of SRPX mRNA
CTD
PMID:17440010
NCBI chr X:12,676,984...12,751,296
Ensembl chr X:12,566,645...12,747,882
G
Srrm2
serine/arginine repetitive matrix 2
affects expression
ISO
testosterone enanthate affects the expression of SRRM2 mRNA
CTD
PMID:17440010
NCBI chr10:12,815,471...12,848,750
Ensembl chr10:12,815,471...12,848,751
G
Srsf6
serine and arginine rich splicing factor 6
affects expression
ISO
testosterone enanthate affects the expression of SRSF6 mRNA
CTD
PMID:17440010
NCBI chr 3:151,589,546...151,594,869
Ensembl chr 3:151,589,535...151,594,860
G
Ssb
small RNA binding exonuclease protection factor La
affects expression
ISO
testosterone enanthate affects the expression of SSB mRNA
CTD
PMID:17440010
NCBI chr 3:54,616,616...54,626,203
Ensembl chr 3:54,616,619...54,626,203
G
Ssbp1
single stranded DNA binding protein 1
affects expression
ISO
testosterone enanthate affects the expression of SSBP1 mRNA
CTD
PMID:17440010
NCBI chr 4:69,266,024...69,276,135
Ensembl chr 4:69,266,102...69,276,135
G
Sspn
sarcospan
affects expression
ISO
testosterone enanthate affects the expression of SSPN mRNA
CTD
PMID:17440010
NCBI chr 4:178,890,030...178,946,267
Ensembl chr 4:178,897,147...178,931,554
G
St3gal6
ST3 beta-galactoside alpha-2,3-sialyltransferase 6
affects expression
ISO
testosterone enanthate affects the expression of ST3GAL6 mRNA
CTD
PMID:17440010
NCBI chr11:42,061,282...42,121,801
Ensembl chr11:42,077,621...42,121,776
G
ST7
suppression of tumorigenicity 7
affects expression
ISO
testosterone enanthate affects the expression of ST7 mRNA
CTD
PMID:17440010
NCBI chr 4:46,041,655...46,289,745
Ensembl chr 4:46,042,236...46,289,740
G
Star
steroidogenic acute regulatory protein
decreases expression multiple interactions
EXP ISO
testosterone enanthate results in decreased expression of STAR mRNA; testosterone enanthate results in decreased expression of STAR protein [cetrorelix co-treated with testosterone enanthate] results in decreased expression of STAR mRNA
CTD
PMID:18160741 PMID:21427060 PMID:25603467
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
G
Stat1
signal transducer and activator of transcription 1
affects expression
ISO
testosterone enanthate affects the expression of STAT1 mRNA
CTD
PMID:17440010
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
G
Stk10
serine/threonine kinase 10
affects expression
ISO
testosterone enanthate affects the expression of STK10 mRNA
CTD
PMID:17440010
NCBI chr10:17,117,860...17,212,065
Ensembl chr10:17,117,878...17,212,061
G
Stk38
serine/threonine kinase 38
affects expression
ISO
testosterone enanthate affects the expression of STK38 mRNA
CTD
PMID:17440010
NCBI chr20:7,034,245...7,067,803
Ensembl chr20:7,034,242...7,068,198
G
Strn3
striatin 3
affects expression
ISO
testosterone enanthate affects the expression of STRN3 mRNA
CTD
PMID:17440010
NCBI chr 6:69,047,776...69,134,102
Ensembl chr 6:69,047,776...69,134,102
G
Sugp2
SURP and G patch domain containing 2
affects expression
ISO
testosterone enanthate affects the expression of SUGP2 mRNA
CTD
PMID:17440010
NCBI chr16:19,159,951...19,191,412
Ensembl chr16:19,164,767...19,191,340
G
Sycp1
synaptonemal complex protein 1
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of SYCP1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of SYCP1 mRNA
CTD
PMID:18160741
NCBI chr 2:190,296,688...190,456,687
Ensembl chr 2:190,296,954...190,456,737
G
Syncrip
synaptotagmin binding, cytoplasmic RNA interacting protein
affects expression
ISO
testosterone enanthate affects the expression of SYNCRIP mRNA
CTD
PMID:17440010
NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515
G
Taf4b
TATA-box binding protein associated factor 4b
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of TAF4B mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of TAF4B mRNA
CTD
PMID:18160741
NCBI chr18:5,952,737...6,086,408
Ensembl chr18:5,952,769...6,068,307
G
Tbx1
T-box transcription factor 1
affects expression
ISO
testosterone enanthate affects the expression of TBX1 mRNA
CTD
PMID:17440010
NCBI chr11:82,409,275...82,419,058
Ensembl chr11:82,409,275...82,418,380
G
Tcaf1
TRPM8 channel-associated factor 1
affects expression
ISO
testosterone enanthate affects the expression of TCAF1 mRNA
CTD
PMID:17440010
NCBI chr 4:71,589,674...71,639,274
Ensembl chr 4:71,591,200...71,613,309
G
Tcap
titin-cap
affects expression
ISO
testosterone enanthate affects the expression of TCAP mRNA
CTD
PMID:17440010
NCBI chr10:83,381,719...83,382,887
Ensembl chr10:83,381,719...83,382,887
G
Tcf25
transcription factor 25
affects expression
ISO
testosterone enanthate affects the expression of TCF25 mRNA
CTD
PMID:17440010
NCBI chr19:51,415,341...51,449,725
Ensembl chr19:51,415,543...51,449,723
G
Tcf4
transcription factor 4
increases expression
ISO
testosterone enanthate results in increased expression of TCF4 mRNA
CTD
PMID:17440010
NCBI chr18:62,941,739...63,288,126
Ensembl chr18:62,943,782...63,284,425
G
Tcof1
treacle ribosome biogenesis factor 1
affects expression
ISO
testosterone enanthate affects the expression of TCOF1 mRNA
CTD
PMID:17440010
NCBI chr18:54,267,015...54,300,324
Ensembl chr18:54,267,026...54,300,324
G
Tex19.2
testis expressed gene 19.2
multiple interactions
ISO
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of TEX19 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of TEX19 mRNA
CTD
PMID:18160741
NCBI chr10:106,379,757...106,382,344
Ensembl chr10:106,379,757...106,382,344
G
Tgfb1
transforming growth factor, beta 1
multiple interactions increases expression
EXP
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of TGFB1 protein]
CTD
PMID:30154949
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
G
Tgoln2
trans-golgi network protein 2
affects expression
ISO
testosterone enanthate affects the expression of TGOLN2 mRNA
CTD
PMID:17440010
NCBI chr 4:104,663,356...104,671,208
Ensembl chr 4:104,663,353...104,671,164
G
Thbs4
thrombospondin 4
affects expression
ISO
testosterone enanthate affects the expression of THBS4 mRNA
CTD
PMID:17440010
NCBI chr 2:23,983,158...24,025,289
Ensembl chr 2:23,983,158...24,026,313
G
Thnsl1
threonine synthase-like 1
affects expression
ISO
testosterone enanthate affects the expression of THNSL1 mRNA
CTD
PMID:17440010
NCBI chr17:83,714,794...83,722,190
Ensembl chr17:83,714,738...83,723,805
G
Tie1
tyrosine kinase with immunoglobulin-like and EGF-like domains 1
affects expression
ISO
testosterone enanthate affects the expression of TIE mRNA
CTD
PMID:17440010
NCBI chr 5:132,000,013...132,019,658
Ensembl chr 5:132,000,015...132,019,592
G
Timp3
TIMP metallopeptidase inhibitor 3
affects expression
ISO
testosterone enanthate affects the expression of TIMP3 mRNA
CTD
PMID:17440010
NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
G
Tipin
timeless interacting protein
affects expression
ISO
testosterone enanthate affects the expression of TIPIN mRNA
CTD
PMID:17440010
NCBI chr 8:64,780,813...64,801,358
Ensembl chr 8:64,780,828...64,801,352
G
Tiprl
TOR signaling pathway regulator
affects expression
ISO
testosterone enanthate affects the expression of TIPRL mRNA
CTD
PMID:17440010
NCBI chr13:77,527,176...77,552,026
Ensembl chr13:77,527,176...77,552,074
G
Tlr3
toll-like receptor 3
affects expression
ISO
testosterone enanthate affects the expression of TLR3 mRNA
CTD
PMID:17440010
NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545
G
Tmbim1
transmembrane BAX inhibitor motif containing 1
affects expression
ISO
testosterone enanthate affects the expression of TMBIM1 mRNA
CTD
PMID:17440010
NCBI chr 9:75,871,835...75,889,366
Ensembl chr 9:75,871,835...75,889,069
G
Tmem11
transmembrane protein 11
affects expression
ISO
testosterone enanthate affects the expression of TMEM11 mRNA
CTD
PMID:17440010
NCBI chr10:45,542,753...45,557,570
Ensembl chr10:45,542,755...45,557,570
G
Tmem259
transmembrane protein 259
affects expression
ISO
testosterone enanthate affects the expression of TMEM259 mRNA
CTD
PMID:17440010
NCBI chr 7:9,724,196...9,730,932
Ensembl chr 7:9,722,485...9,730,932
G
Tmf1
TATA element modulatory factor 1
affects expression
ISO
testosterone enanthate affects the expression of TMF1 mRNA
CTD
PMID:17440010
NCBI chr 4:129,759,952...129,785,705
Ensembl chr 4:129,763,114...129,785,629
G
Tnf
tumor necrosis factor
multiple interactions increases expression
EXP
cordycepin inhibits the reaction [testosterone enanthate results in increased expression of TNF protein]; Finasteride inhibits the reaction [testosterone enanthate results in increased expression of TNF protein]
CTD
PMID:36015278
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Tnfsf10
TNF superfamily member 10
affects expression
ISO
testosterone enanthate affects the expression of TNFSF10 mRNA
CTD
PMID:17440010
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
G
Tnpo1
transportin 1
affects expression
ISO
testosterone enanthate affects the expression of TNPO1 mRNA
CTD
PMID:17440010
NCBI chr 2:30,207,529...30,300,162
Ensembl chr 2:30,211,510...30,300,375
G
Tnpo3
transportin 3
affects expression
ISO
testosterone enanthate affects the expression of TNPO3 mRNA
CTD
PMID:17440010
NCBI chr 4:58,142,954...58,220,365
Ensembl chr 4:58,143,001...58,220,433
G
Tor3a
torsin family 3, member A
affects expression
ISO
testosterone enanthate affects the expression of TOR3A mRNA
CTD
PMID:17440010
NCBI chr13:68,769,893...68,798,738
Ensembl chr13:68,769,605...68,798,475
G
Tox4
TOX high mobility group box family member 4
affects expression
ISO
testosterone enanthate affects the expression of TOX4 mRNA
CTD
PMID:17440010
NCBI chr15:24,989,246...25,002,833
Ensembl chr15:24,988,853...25,002,833
G
Tpd52l1
TPD52 like 1
affects expression
ISO
testosterone enanthate affects the expression of TPD52L1 mRNA
CTD
PMID:17440010
NCBI chr 1:26,172,038...26,290,704
Ensembl chr 1:26,172,170...26,291,109
G
Tpd52l2
TPD52 like 2
affects expression
ISO
testosterone enanthate affects the expression of TPD52L2 mRNA
CTD
PMID:17440010
NCBI chr 3:168,598,449...168,618,201
Ensembl chr 3:168,594,609...168,619,762
G
Tpr
translocated promoter region, nuclear basket protein
affects expression
ISO
testosterone enanthate affects the expression of TPR mRNA
CTD
PMID:17440010
NCBI chr13:62,424,312...62,487,502
Ensembl chr13:62,424,312...62,487,496
G
Tra2a
transformer 2 alpha
affects expression
ISO
testosterone enanthate affects the expression of TRA2A mRNA
CTD
PMID:17440010
NCBI chr 4:78,220,838...78,239,737
Ensembl chr 4:78,220,883...78,239,712
G
Trappc6a
trafficking protein particle complex subunit 6A
affects expression
ISO
testosterone enanthate affects the expression of TRAPPC6A mRNA
CTD
PMID:17440010
NCBI chr 1:79,158,587...79,165,502
Ensembl chr 1:79,158,529...79,165,493
G
Tril
TLR4 interactor with leucine-rich repeats
affects expression
ISO
testosterone enanthate affects the expression of TRIL mRNA
CTD
PMID:17440010
NCBI chr 4:82,922,327...82,927,172
Ensembl chr 4:82,922,328...82,927,172
G
Trim16
tripartite motif-containing 16
affects expression
ISO
testosterone enanthate affects the expression of TRIM16 mRNA
CTD
PMID:17440010
NCBI chr10:47,485,982...47,509,010
Ensembl chr10:47,486,297...47,551,907
G
Trim38
tripartite motif containing 38
affects expression
ISO
testosterone enanthate affects the expression of TRIM38 mRNA
CTD
PMID:17440010
NCBI chr17:41,351,857...41,365,021
G
Tshz1
teashirt zinc finger homeobox 1
affects expression
ISO
testosterone enanthate affects the expression of TSHZ1 mRNA
CTD
PMID:17440010
NCBI chr18:77,376,399...77,452,815
Ensembl chr18:77,377,394...77,453,509
G
Tspo
translocator protein
decreases expression
EXP
testosterone enanthate results in decreased expression of TSPO mRNA
CTD
PMID:21427060 PMID:25603467
NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450
G
Ttc3
tetratricopeptide repeat domain 3
affects expression
ISO
testosterone enanthate affects the expression of TTC3 mRNA
CTD
PMID:17440010
NCBI chr11:33,689,119...33,788,976
Ensembl chr11:33,688,952...33,788,975
G
Ttc9
tetratricopeptide repeat domain 9
affects expression
ISO
testosterone enanthate affects the expression of TTC9 mRNA
CTD
PMID:17440010
NCBI chr 6:101,333,274...101,368,110
Ensembl chr 6:101,333,141...101,368,110
G
Twf2
twinfilin actin-binding protein 2
affects expression
ISO
testosterone enanthate affects the expression of TWF2 mRNA
CTD
PMID:17440010
NCBI chr 8:106,845,253...106,858,298
Ensembl chr 8:106,845,253...106,858,298
G
Txnip
thioredoxin interacting protein
affects expression
ISO
testosterone enanthate affects the expression of TXNIP mRNA
CTD
PMID:17440010
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
G
Tyk2
tyrosine kinase 2
increases expression
EXP
testosterone enanthate results in increased expression of TYK2 mRNA
CTD
PMID:25603467
NCBI chr 8:19,641,881...19,667,157
Ensembl chr 8:19,641,884...19,667,044
G
Tyrp1
tyrosinase-related protein 1
affects expression
ISO
testosterone enanthate affects the expression of TYRP1 mRNA
CTD
PMID:17440010
NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
G
Ube2w
ubiquitin-conjugating enzyme E2W
affects expression
ISO
testosterone enanthate affects the expression of UBE2W mRNA
CTD
PMID:17440010
NCBI chr 5:2,690,742...2,754,491
Ensembl chr 5:2,690,763...2,814,965
G
Ubn1
ubinuclein 1
affects expression
ISO
testosterone enanthate affects the expression of UBN1 mRNA
CTD
PMID:17440010
NCBI chr10:10,496,576...10,532,010
Ensembl chr10:10,496,576...10,532,010
G
Ubxn4
UBX domain protein 4
affects expression
ISO
testosterone enanthate affects the expression of UBXD2 mRNA
CTD
PMID:17440010
NCBI chr13:39,740,064...39,772,493
Ensembl chr13:39,740,107...39,772,491
G
Ufl1
Ufm1-specific ligase 1
affects expression
ISO
testosterone enanthate affects the expression of UFL1 mRNA
CTD
PMID:17440010
NCBI chr 5:38,962,721...38,995,134
Ensembl chr 5:38,962,171...38,995,199
G
Ugcg
UDP-glucose ceramide glucosyltransferase
affects expression
ISO
testosterone enanthate affects the expression of UGCG mRNA
CTD
PMID:17440010
NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393
G
Usp1
ubiquitin specific peptidase 1
affects expression
ISO
testosterone enanthate affects the expression of USP1 mRNA
CTD
PMID:17440010
NCBI chr 5:113,587,564...113,598,934
Ensembl chr 5:113,587,564...113,598,932
G
Usp2
ubiquitin specific peptidase 2
affects expression
ISO
testosterone enanthate affects the expression of USP2 mRNA
CTD
PMID:17440010
NCBI chr 8:44,411,457...44,439,668
Ensembl chr 8:44,411,607...44,438,331
G
Usp31
ubiquitin specific peptidase 31
affects expression
ISO
testosterone enanthate affects the expression of USP31 mRNA
CTD
PMID:17440010
NCBI chr 1:176,211,334...176,278,183
Ensembl chr 1:176,215,889...176,278,355
G
Usp33
ubiquitin specific peptidase 33
affects expression
ISO
testosterone enanthate affects the expression of USP33 mRNA
CTD
PMID:17440010
NCBI chr 2:241,283,209...241,328,479
Ensembl chr 2:241,292,985...241,328,479
G
Usp34
ubiquitin specific peptidase 34
affects expression
ISO
testosterone enanthate affects the expression of USP34 mRNA
CTD
PMID:17440010
NCBI chr14:97,285,799...97,476,376
Ensembl chr14:97,286,018...97,476,376
G
Usp47
ubiquitin specific peptidase 47
affects expression
ISO
testosterone enanthate affects the expression of USP47 mRNA
CTD
PMID:17440010
NCBI chr 1:166,152,104...166,235,312
Ensembl chr 1:166,152,199...166,235,312
G
Vasp
vasodilator-stimulated phosphoprotein
affects expression
ISO
testosterone enanthate affects the expression of VASP mRNA
CTD
PMID:17440010
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
G
Vcp
valosin-containing protein
affects expression
ISO
testosterone enanthate affects the expression of VCP mRNA
CTD
PMID:17440010
NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571
G
Washc4
WASH complex subunit 4
affects expression
ISO
testosterone enanthate affects the expression of WASHC4 mRNA
CTD
PMID:17440010
NCBI chr 7:20,187,905...20,240,228
Ensembl chr 7:20,187,922...20,240,226
G
Wasl
WASP like actin nucleation promoting factor
affects expression
ISO
testosterone enanthate affects the expression of WASL mRNA
CTD
PMID:17440010
NCBI chr 4:53,083,536...53,132,061
Ensembl chr 4:53,083,536...53,132,022
G
Wdr18
WD repeat domain 18
affects expression
ISO
testosterone enanthate affects the expression of WDR18 mRNA
CTD
PMID:17440010
NCBI chr 7:9,740,245...9,748,041
Ensembl chr 7:9,739,604...9,748,070
G
Wdr46
WD repeat domain 46
affects expression
ISO
testosterone enanthate affects the expression of WDR46 mRNA
CTD
PMID:17440010
NCBI chr20:4,937,845...4,945,796
Ensembl chr20:4,937,847...4,946,535
G
Wdr48
WD repeat domain 48
affects expression
ISO
testosterone enanthate affects the expression of WDR48 mRNA
CTD
PMID:17440010
NCBI chr 8:119,622,053...119,655,264
Ensembl chr 8:119,622,048...119,655,264
G
Wipf1
WAS/WASL interacting protein family, member 1
affects expression
ISO
testosterone enanthate affects the expression of WIPF1 mRNA
CTD
PMID:17440010
NCBI chr 3:58,314,521...58,416,668
Ensembl chr 3:58,314,542...58,372,742
G
Wnk1
WNK lysine deficient protein kinase 1
affects expression
ISO
testosterone enanthate affects the expression of WNK1 mRNA
CTD
PMID:17440010
NCBI chr 4:153,128,334...153,253,905
Ensembl chr 4:153,128,334...153,253,905
G
Wwp2
WW domain containing E3 ubiquitin protein ligase 2
affects expression
ISO
testosterone enanthate affects the expression of WWP2 mRNA
CTD
PMID:17440010
NCBI chr19:35,346,826...35,471,251
Ensembl chr19:35,346,814...35,472,699
G
Yeats2
YEATS domain containing 2
affects expression
ISO
testosterone enanthate affects the expression of YEATS2 mRNA
CTD
PMID:17440010
NCBI chr11:80,743,134...80,829,253
Ensembl chr11:80,743,134...80,829,208
G
Ykt6
YKT6 v-SNARE homolog
affects expression
ISO
testosterone enanthate affects the expression of YKT6 mRNA
CTD
PMID:17440010
NCBI chr14:80,832,187...80,843,394
Ensembl chr14:80,832,187...80,843,385
G
Ywhab
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta
affects expression
ISO
testosterone enanthate affects the expression of YWHAB mRNA
CTD
PMID:17440010
NCBI chr 3:152,659,663...152,682,105
Ensembl chr 3:152,659,651...152,682,105
G
Zeb1
zinc finger E-box binding homeobox 1
affects expression
ISO
testosterone enanthate affects the expression of ZEB1 mRNA
CTD
PMID:17440010
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
G
Zfp148
zinc finger protein 148
affects expression
ISO
testosterone enanthate affects the expression of ZNF148 mRNA
CTD
PMID:17440010
NCBI chr11:67,276,455...67,385,803
Ensembl chr11:67,281,707...67,385,772
G
Zfp266
zinc finger protein 266
affects expression
ISO
testosterone enanthate affects the expression of ZNF562 mRNA
CTD
PMID:17440010
NCBI chr 8:19,030,766...19,061,381
Ensembl chr 8:19,030,768...19,060,937
G
Zfp37
zinc finger protein 37
affects expression
ISO
testosterone enanthate affects the expression of ZFP37 mRNA
CTD
PMID:17440010
NCBI chr 5:75,598,732...75,638,896
Ensembl chr 5:75,598,732...75,638,942
G
Zfp709
zinc finger protein 709
affects expression
ISO
testosterone enanthate affects the expression of ZNF443 mRNA
CTD
PMID:17440010
NCBI chr16:17,907,599...17,920,047
Ensembl chr16:17,909,641...17,919,700
G
Zftraf1
zinc finger TRAF type containing 1
affects expression
ISO
testosterone enanthate affects the expression of ZFTRAF1 mRNA
CTD
PMID:17440010
NCBI chr 7:108,363,989...108,377,428
Ensembl chr 7:108,364,381...108,380,021
G
Zgpat
zinc finger CCCH-type and G-patch domain containing
affects expression
ISO
testosterone enanthate affects the expression of ZGPAT mRNA
CTD
PMID:17440010
NCBI chr 3:168,473,836...168,490,380
Ensembl chr 3:168,473,981...168,490,380
G
Zic1
Zic family member 1
affects expression
ISO
testosterone enanthate affects the expression of ZIC1 mRNA
CTD
PMID:17440010
NCBI chr 8:91,908,548...91,918,020
Ensembl chr 8:91,908,576...91,912,731
G
Zmym1
zinc finger MYM-type containing 1
affects expression
ISO
testosterone enanthate affects the expression of ZMYM1 mRNA
CTD
PMID:17440010
NCBI chr 5:139,364,788...139,381,883
Ensembl chr 5:139,364,789...139,381,873
G
Zmym5
zinc finger MYM-type containing 5
affects expression
ISO
testosterone enanthate affects the expression of ZMYM5 mRNA
CTD
PMID:17440010
NCBI chr15:30,920,479...30,941,249
Ensembl chr15:30,923,241...30,941,240
G
Acvr2b
activin A receptor type 2B
multiple interactions increases expression
EXP
Flutamide inhibits the reaction [Testosterone Propionate results in increased expression of SCGB2A2 mRNA]; prochloraz inhibits the reaction [Testosterone Propionate results in increased expression of SCGB2A2 mRNA]; vinclozolin inhibits the reaction [Testosterone Propionate results in increased expression of SCGB2A2 mRNA]
CTD
PMID:11376863 PMID:12377983
NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458
G
Adcyap1
adenylate cyclase activating polypeptide 1
increases expression
EXP
Testosterone Propionate results in increased expression of ADCYAP1 mRNA
CTD
PMID:19427307
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
G
Adgrg2
adhesion G protein-coupled receptor G2
increases expression
ISO
Testosterone Propionate results in increased expression of ADGRG2 mRNA
CTD
PMID:15601916
NCBI chr X:34,297,402...34,422,590
Ensembl chr X:34,297,402...34,422,609
G
Adprhl1
ADP-ribosylhydrolase like 1
decreases expression
ISO
Testosterone Propionate results in decreased expression of ADPRHL1 mRNA
CTD
PMID:15601916
NCBI chr16:76,283,186...76,315,075
Ensembl chr16:76,283,103...76,354,440
G
Agt
angiotensinogen
increases expression
EXP
Testosterone Propionate results in increased expression of AGT mRNA
CTD
PMID:1568764
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
G
Amotl1
angiomotin-like 1
increases expression
ISO
Testosterone Propionate results in increased expression of AMOTL1 mRNA
CTD
PMID:15601916
NCBI chr 8:11,348,651...11,467,564
Ensembl chr 8:11,353,674...11,467,573
G
Ar
androgen receptor
affects binding increases expression multiple interactions
EXP ISO
Testosterone Propionate binds to AR protein Testosterone Propionate results in increased expression of AR protein Testosterone Propionate inhibits the reaction [Endosulfan results in decreased expression of AR mRNA] Testosterone Propionate inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]
CTD
PMID:14565775 PMID:23669243 PMID:25077688 PMID:33049310
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Atp6v0d2
ATPase H+ transporting V0 subunit D2
increases expression
ISO
Testosterone Propionate results in increased expression of ATP6V0D2 mRNA
CTD
PMID:15601916
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
G
Bdnf
brain-derived neurotrophic factor
increases expression
EXP
Testosterone Propionate results in increased expression of BDNF mRNA
CTD
PMID:19427307
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
G
Cacna1a
calcium voltage-gated channel subunit alpha1 A
increases expression
ISO
Testosterone Propionate results in increased expression of CACNA1A mRNA
CTD
PMID:15601916
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
G
Cat
catalase
decreases expression multiple interactions
EXP
Testosterone Propionate results in decreased expression of CAT protein Testosterone Propionate inhibits the reaction [Vanadium results in decreased activity of CAT protein]
CTD
PMID:9430440 PMID:20521886
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
G
Clu
clusterin
multiple interactions decreases expression
EXP
Flutamide inhibits the reaction [Testosterone Propionate results in decreased expression of CLU mRNA]; vinclozolin inhibits the reaction [Testosterone Propionate results in decreased expression of CLU mRNA]
CTD
PMID:11376863
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
G
Cr1l
complement C3b/C4b receptor 1 like
multiple interactions
ISO
Testosterone Propionate inhibits the reaction [Endosulfan results in decreased expression of CR1L mRNA]
CTD
PMID:25242399
NCBI chr13:106,606,952...106,660,442
Ensembl chr13:106,574,858...106,660,445
G
Creg2
cellular repressor of E1A-stimulated genes 2
decreases expression
ISO
Testosterone Propionate results in decreased expression of CREG2 mRNA
CTD
PMID:15601916
NCBI chr 9:41,872,000...41,945,413
Ensembl chr 9:41,902,304...41,945,095
G
Cyp17a1
cytochrome P450, family 17, subfamily a, polypeptide 1
decreases expression
ISO
Testosterone Propionate results in decreased expression of CYP17A1 mRNA
CTD
PMID:15601916
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
G
Cyp2a3
cytochrome P450, family 2, subfamily a, polypeptide 3
affects expression
ISO
Testosterone Propionate affects the expression of CYP2A4
CTD
PMID:20943812
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
G
Dhx9
DExH-box helicase 9
decreases expression
ISO
Testosterone Propionate results in decreased expression of DHX9 mRNA
CTD
PMID:15601916
NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069
G
Dnai1
dynein, axonemal, intermediate chain 1
increases expression
ISO
Testosterone Propionate results in increased expression of DNAI1 mRNA
CTD
PMID:15601916
NCBI chr 5:56,730,179...56,800,926
Ensembl chr 5:56,730,179...56,800,925
G
Epha2
Eph receptor A2
decreases expression
ISO
Testosterone Propionate results in decreased expression of EPHA2 mRNA
CTD
PMID:15601916
NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117
G
Esr1
estrogen receptor 1
decreases expression multiple interactions
EXP ISO
Testosterone Propionate results in decreased expression of ESR1 protein Testosterone Propionate binds to and results in increased activity of ESR1 protein
CTD
PMID:23669243 PMID:33049310
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Esr2
estrogen receptor 2
multiple interactions
ISO
Testosterone Propionate binds to and results in decreased activity of ESR2 protein
CTD
PMID:33049310
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
G
Fshb
follicle stimulating hormone subunit beta
multiple interactions
EXP
Testosterone Propionate inhibits the reaction [Cyclosporine results in increased expression of FSHB protein]
CTD
PMID:2128298
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
G
Gabra1
gamma-aminobutyric acid type A receptor subunit alpha 1
decreases expression
ISO
Testosterone Propionate results in decreased expression of GABRA1 mRNA
CTD
PMID:16957604
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
G
Gabra2
gamma-aminobutyric acid type A receptor subunit alpha 2
decreases expression
ISO
Testosterone Propionate results in decreased expression of GABRA2 mRNA
CTD
PMID:16957604
NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944
G
Gabra4
gamma-aminobutyric acid type A receptor subunit alpha 4
increases expression
ISO
Testosterone Propionate results in increased expression of GABRA4 mRNA
CTD
PMID:16957604
NCBI chr14:36,590,782...36,667,724
Ensembl chr14:36,590,782...36,665,844
G
Gabra5
gamma-aminobutyric acid type A receptor subunit alpha 5
increases expression
ISO
Testosterone Propionate results in increased expression of GABRA5 mRNA
CTD
PMID:16957604
NCBI chr 1:108,268,728...108,381,670
Ensembl chr 1:108,268,776...108,380,917
G
Gabrg2
gamma-aminobutyric acid type A receptor subunit gamma 2
decreases expression
ISO
Testosterone Propionate results in decreased expression of GABRG2 mRNA
CTD
PMID:16957604
NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346
G
Gap43
growth associated protein 43
increases expression
EXP
Testosterone Propionate results in increased expression of GAP43 mRNA
CTD
PMID:19427307
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
G
Ghrh
growth hormone releasing hormone
affects expression
ISO
Testosterone Propionate affects the expression of GHRH mRNA
CTD
PMID:20943812
NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
G
Gmppb
GDP-mannose pyrophosphorylase B
decreases expression
ISO
Testosterone Propionate results in decreased expression of GMPPB mRNA
CTD
PMID:15601916
NCBI chr 8:108,737,429...108,740,437
Ensembl chr 8:108,693,060...108,767,286
G
Gstp1
glutathione S-transferase pi 1
multiple interactions
ISO
Testosterone Propionate inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]
CTD
PMID:23769903
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
G
H3c1
H3 clustered histone 1
decreases expression
ISO
Testosterone Propionate results in decreased expression of H3C1 mRNA
CTD
PMID:15601916
NCBI chr17:41,368,379...41,368,902
Ensembl chr17:41,368,386...41,368,856 Ensembl chr17:41,368,386...41,368,856 Ensembl chr17:41,368,386...41,368,856 Ensembl chr17:41,368,386...41,368,856
G
Hspbap1
HSPB1 associated protein 1
decreases expression
ISO
Testosterone Propionate results in decreased expression of HSPBAP1 mRNA
CTD
PMID:15601916
NCBI chr11:64,940,089...64,994,753
Ensembl chr11:64,940,091...64,994,756
G
Il1b
interleukin 1 beta
multiple interactions
ISO
Testosterone Propionate promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL1B mRNA]
CTD
PMID:21745355
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Il6
interleukin 6
multiple interactions
ISO
Testosterone Propionate inhibits the reaction [Endosulfan results in increased expression of IL6 mRNA]; Testosterone Propionate promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 mRNA]
CTD
PMID:21745355 PMID:22591281
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Lhb
luteinizing hormone subunit beta
decreases expression multiple interactions
EXP ISO
Testosterone Propionate results in decreased expression of LHB protein Flutamide inhibits the reaction [Testosterone Propionate results in decreased expression of LHB protein] Testosterone Propionate inhibits the reaction [Endosulfan results in increased expression of LHB]
CTD
PMID:2128298 PMID:11376863 PMID:25077688
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
G
Mir204
microRNA 204
decreases expression
EXP
Testosterone Propionate results in decreased expression of MIR204 mRNA
CTD
PMID:25797256
NCBI chr 1:220,316,931...220,317,040
Ensembl chr 1:220,316,931...220,317,040
G
Mpv17
mitochondrial inner membrane protein MPV17
increases expression
ISO
Testosterone Propionate results in increased expression of MPV17 mRNA
CTD
PMID:15601916
NCBI chr 6:25,221,668...25,236,241
Ensembl chr 6:25,222,896...25,236,244
G
Mrpl54
mitochondrial ribosomal protein L54
increases expression
ISO
Testosterone Propionate results in increased expression of MRPL54 mRNA
CTD
PMID:15601916
NCBI chr 7:8,452,801...8,455,321
Ensembl chr 7:8,452,716...8,455,321
G
Mycn
MYCN proto-oncogene, bHLH transcription factor
decreases expression
ISO
Testosterone Propionate results in decreased expression of MYCN mRNA
CTD
PMID:15601916
NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590
G
Nphp1
nephrocystin 1
decreases expression
ISO
Testosterone Propionate results in decreased expression of NPHP1 mRNA
CTD
PMID:15601916
NCBI chr 3:114,960,650...115,016,234
Ensembl chr 3:114,960,650...115,016,234
G
Nqo1
NAD(P)H quinone dehydrogenase 1
increases expression
IEP
Testosterone propionate increases NQO1 protein in liver
RGD
PMID:31819135
RGD:25823186
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
G
Nr1i2
nuclear receptor subfamily 1, group I, member 2
multiple interactions
ISO
Testosterone Propionate binds to and results in increased activity of NR1I2 protein Testosterone Propionate binds to and results in decreased activity of NR1I2 protein
CTD
PMID:33049310
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
G
Nrn1
neuritin 1
increases expression
EXP
Testosterone Propionate results in increased expression of NRN1 mRNA
CTD
PMID:19427307
NCBI chr17:28,129,969...28,138,898
Ensembl chr17:28,129,977...28,138,896
G
Odc1
ornithine decarboxylase 1
multiple interactions increases expression
EXP
Flutamide inhibits the reaction [Testosterone Propionate results in increased expression of ODC1 mRNA]; prochloraz inhibits the reaction [Testosterone Propionate results in increased expression of ODC1 mRNA]
CTD
PMID:12377983 PMID:17688994
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
G
Osbpl3
oxysterol binding protein-like 3
decreases expression
ISO
Testosterone Propionate results in decreased expression of OSBPL3 mRNA
CTD
PMID:15601916
NCBI chr 4:79,346,583...79,523,523
Ensembl chr 4:79,350,349...79,523,393
G
Pgr
progesterone receptor
decreases expression increases expression
ISO EXP
Testosterone Propionate results in decreased expression of PGR mRNA Testosterone Propionate results in decreased expression of PGR protein Testosterone Propionate results in increased expression of PGR protein
CTD
PMID:17574608 PMID:23669243
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
G
Plagl1
PLAG1 like zinc finger 1
decreases expression
ISO
Testosterone Propionate results in decreased expression of PLAGL1 mRNA
CTD
PMID:15601916
NCBI chr 1:7,477,295...7,517,229
Ensembl chr 1:7,477,177...7,517,228
G
Pparg
peroxisome proliferator-activated receptor gamma
multiple interactions
ISO
Testosterone Propionate binds to and results in decreased activity of PPARG protein
CTD
PMID:33049310
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
G
Ptpn23
protein tyrosine phosphatase, non-receptor type 23
decreases expression
ISO
Testosterone Propionate results in decreased expression of PTPN23 mRNA
CTD
PMID:15601916
NCBI chr 8:110,360,804...110,383,271
Ensembl chr 8:110,360,804...110,383,271
G
Recql
RecQ like helicase
decreases expression
ISO
Testosterone Propionate results in decreased expression of RECQL mRNA
CTD
PMID:15601916
NCBI chr 4:175,308,337...175,332,965
Ensembl chr 4:175,304,117...175,332,945
G
Ren
renin
increases expression
EXP
Testosterone Propionate results in increased expression of REN mRNA; Testosterone Propionate results in increased expression of REN protein
CTD
PMID:1568764
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
G
Rnase9
ribonuclease A family member 9
increases expression
EXP
Testosterone Propionate results in increased expression of RNASE9 mRNA
CTD
PMID:17005942
NCBI chr15:24,259,525...24,263,079
Ensembl chr15:24,259,525...24,263,079
G
Slc12a1
solute carrier family 12 member 1
increases expression
ISO
Testosterone Propionate results in increased expression of SLC12A1 mRNA
CTD
PMID:15601916
NCBI chr 3:112,406,140...112,482,913
Ensembl chr 3:112,406,140...112,482,899
G
Slc9a2
solute carrier family 9 member A2
increases expression
ISO
Testosterone Propionate results in increased expression of SLC9A2 mRNA
CTD
PMID:15601916
NCBI chr 9:42,932,001...43,014,447
Ensembl chr 9:42,931,346...43,014,444
G
Syt6
synaptotagmin 6
increases expression
ISO
Testosterone Propionate results in increased expression of SYT6 mRNA
CTD
PMID:15601916
NCBI chr 2:191,093,009...191,152,283
Ensembl chr 2:191,093,007...191,149,956
G
Thrb
thyroid hormone receptor beta
multiple interactions
ISO
Testosterone Propionate binds to and results in increased activity of THRB protein
CTD
PMID:33049310
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
G
Tnf
tumor necrosis factor
multiple interactions
ISO
Testosterone Propionate promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF mRNA]
CTD
PMID:21745355
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Tshz2
teashirt zinc finger homeobox 2
decreases expression
ISO
Testosterone Propionate results in decreased expression of TSHZ2 mRNA
CTD
PMID:15601916
NCBI chr 3:158,405,469...158,666,915
Ensembl chr 3:158,405,423...158,850,128
G
Tuba1a
tubulin, alpha 1A
increases expression
EXP
Testosterone Propionate results in increased expression of TUBA1A mRNA
CTD
PMID:19427307
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
G
Ugt2b1
UDP glucuronosyltransferase 2 family, polypeptide B1
decreases expression
EXP
Testosterone Propionate results in decreased expression of UGT2B1 mRNA
CTD
PMID:16829708
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
G
Ugt8
UDP glycosyltransferase 8
increases expression
ISO
Testosterone Propionate results in increased expression of UGT8A mRNA
CTD
PMID:15601916
NCBI chr 2:214,264,483...214,332,769
Ensembl chr 2:214,264,483...214,332,660
G
Xrn1
5'-3' exoribonuclease 1
increases expression
EXP
Testosterone Propionate results in increased expression of XRN1 protein
CTD
PMID:25797256
NCBI chr 8:96,527,871...96,637,385
Ensembl chr 8:96,528,195...96,632,739
G
Zfp276
zinc finger protein (C2H2 type) 276
decreases expression
ISO
Testosterone Propionate results in decreased expression of ZFP276 mRNA
CTD
PMID:15601916
NCBI chr19:51,291,005...51,304,240
Ensembl chr19:51,290,777...51,304,049
G
Abhd5
abhydrolase domain containing 5, lysophosphatidic acid acyltransferase
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ABHD5 mRNA
CTD
PMID:19074003
NCBI chr 8:122,000,241...122,026,447
Ensembl chr 8:122,000,389...122,026,447
G
Ace2
angiotensin converting enzyme 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ACE2 mRNA
CTD
PMID:19074003
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
G
Adgrf5
adhesion G protein-coupled receptor F5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of ADGRF5 mRNA
CTD
PMID:19074003
NCBI chr 9:17,517,596...17,624,107
Ensembl chr 9:17,520,009...17,623,968
G
Afg1l
AFG1 like ATPase
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of AFG1L mRNA
CTD
PMID:19074003
NCBI chr20:45,798,344...45,967,997
Ensembl chr20:45,798,349...45,967,906
G
Ahctf1
AT hook containing transcription factor 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of AHCTF1 mRNA
CTD
PMID:19074003
NCBI chr13:91,481,936...91,536,391
Ensembl chr13:91,481,936...91,536,391
G
Alms1
ALMS1, centrosome and basal body associated protein
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ALMS1 mRNA
CTD
PMID:19074003
NCBI chr 4:118,125,581...118,226,005
Ensembl chr 4:118,125,607...118,226,005
G
Alpk2
alpha-kinase 2
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of ALPK2 mRNA testosterone undecanoate results in increased expression of ALPK2 mRNA
CTD
PMID:19074003
NCBI chr18:58,775,603...58,906,150
Ensembl chr18:58,775,605...58,906,258
G
Ammecr1
AMMECR nuclear protein 1
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of AMMECR1 mRNA testosterone undecanoate results in decreased expression of AMMECR1 mRNA
CTD
PMID:19074003
NCBI chr X:106,465,982...106,571,382
Ensembl chr X:106,466,699...106,571,487
G
Ampd3
adenosine monophosphate deaminase 3
increases expression
ISO
testosterone undecanoate results in increased expression of AMPD3 mRNA
CTD
PMID:19074003
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
G
Ankdd1a
ankyrin repeat and death domain containing 1A
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ANKDD1A mRNA
CTD
PMID:19074003
NCBI chr 8:66,017,571...66,043,738
Ensembl chr 8:66,017,773...66,042,651
G
Api5
apoptosis inhibitor 5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of API5 mRNA
CTD
PMID:19074003
NCBI chr 3:80,378,096...80,403,259
Ensembl chr 3:80,378,096...80,403,264
G
Arhgap23
Rho GTPase activating protein 23
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of ARHGAP23 mRNA testosterone undecanoate results in increased expression of ARHGAP23 mRNA
CTD
PMID:19074003
NCBI chr10:82,437,578...82,496,846
Ensembl chr10:82,394,648...82,496,504
G
Arl9
ADP-ribosylation factor like GTPase 9
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of ARL9 mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of ARL9 mRNA
CTD
PMID:19074003
NCBI chr14:31,157,573...31,166,803
Ensembl chr14:31,157,586...31,166,699
G
Asap1
ArfGAP with SH3 domain, ankyrin repeat and PH domain 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ASAP1 mRNA
CTD
PMID:19074003
NCBI chr 7:95,786,130...96,093,111
Ensembl chr 7:95,787,818...96,092,754
G
Azgp1
alpha-2-glycoprotein 1, zinc-binding
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of AZGP1 mRNA testosterone undecanoate results in decreased expression of AZGP1 mRNA
CTD
PMID:19074003
NCBI chr12:16,930,990...16,939,333
Ensembl chr12:16,931,024...16,939,091
G
B4galt5
beta-1,4-galactosyltransferase 5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of B4GALT5 mRNA
CTD
PMID:19074003
NCBI chr 3:156,018,056...156,033,983
Ensembl chr 3:156,018,053...156,070,074
G
Bbx
BBX high mobility group box domain containing
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of BBX mRNA
CTD
PMID:19074003
NCBI chr11:50,381,249...50,628,934
Ensembl chr11:50,381,247...50,623,251
G
Bcl2l14
Bcl2-like 14
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of BCL2L14 mRNA testosterone undecanoate results in increased expression of BCL2L14 mRNA
CTD
PMID:19074003
NCBI chr 4:167,217,561...167,258,723
Ensembl chr 4:167,219,871...167,258,086
G
Btbd3
BTB domain containing 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of BTBD3 mRNA
CTD
PMID:19074003
NCBI chr 3:125,591,427...125,621,660
Ensembl chr 3:125,591,490...125,619,038
G
Ccn3
cellular communication network factor 3
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CCN3 mRNA testosterone undecanoate results in decreased expression of CCN3 mRNA
CTD
PMID:19074003
NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019
G
Cd86
CD86 molecule
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of CD86 mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CD86 mRNA
CTD
PMID:19074003
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
G
Cdc25c
cell division cycle 25C
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CDC25C mRNA
CTD
PMID:19074003
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
G
Cdc42bpb
CDC42 binding protein kinase beta
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CDC42BPB mRNA
CTD
PMID:19074003
NCBI chr 6:130,333,712...130,416,631
Ensembl chr 6:130,333,712...130,416,377
G
Cdc42ep1
CDC42 effector protein 1
decreases expression
ISO
testosterone undecanoate results in decreased expression of CDC42EP1 mRNA
CTD
PMID:19074003
NCBI chr 7:110,395,287...110,403,203
Ensembl chr 7:110,395,332...110,403,200
G
Cdkn2d
cyclin dependent kinase inhibitor 2D
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CDKN2D mRNA
CTD
PMID:19074003
NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674
G
Cep170b
centrosomal protein 170B
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CEP170B mRNA
CTD
PMID:19074003
NCBI chr 6:131,780,935...131,806,658
Ensembl chr 6:131,778,957...131,806,658
G
Cfap65
cilia and flagella associated protein 65
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CFAP65 mRNA
CTD
PMID:19074003
NCBI chr 9:76,459,211...76,494,199
Ensembl chr 9:76,459,211...76,494,128
G
Chek2
checkpoint kinase 2
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CHEK2 mRNA testosterone undecanoate results in decreased expression of CHEK2 mRNA
CTD
PMID:19074003
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
G
Chodl
chondrolectin
decreases expression
ISO
testosterone undecanoate results in decreased expression of CHODL mRNA
CTD
PMID:19074003
NCBI chr11:17,654,137...17,676,450
Ensembl chr11:17,654,206...17,676,441
G
Chp2
calcineurin-like EF hand protein 2
decreases expression
ISO
testosterone undecanoate results in decreased expression of CHP2 mRNA
CTD
PMID:19074003
NCBI chr 1:176,757,945...176,772,443
Ensembl chr 1:176,757,876...176,772,139
G
Cimap1a
ciliary microtubule associated protein 1A
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CIMAP1A mRNA
CTD
PMID:19074003
NCBI chr 1:195,926,034...195,929,250
Ensembl chr 1:195,926,041...195,929,248
G
Cntf
ciliary neurotrophic factor
increases expression
ISO
testosterone undecanoate results in increased expression of CNTF mRNA
CTD
PMID:19074003
NCBI chr 1:209,887,854...209,889,877
Ensembl chr 1:209,887,854...209,889,877
G
Col1a1
collagen type I alpha 1 chain
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of COL1A1 mRNA
CTD
PMID:19074003
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
G
Col22a1
collagen type XXII alpha 1 chain
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of COL22A1 mRNA testosterone undecanoate results in increased expression of COL22A1 mRNA
CTD
PMID:19074003
NCBI chr 7:103,730,939...103,968,452
Ensembl chr 7:103,731,037...103,968,462
G
Corin
corin, serine peptidase
increases expression
ISO
testosterone undecanoate results in increased expression of CORIN mRNA
CTD
PMID:19074003
NCBI chr14:35,680,601...35,910,703
Ensembl chr14:35,681,304...35,909,503
G
Cpeb3
cytoplasmic polyadenylation element binding protein 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CPEB3 mRNA
CTD
PMID:19074003
NCBI chr 1:234,749,138...234,931,219
Ensembl chr 1:234,751,733...234,931,560
G
Cpxcr1
CPX chromosome region, candidate 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CPXCR1 mRNA
CTD
PMID:19074003
NCBI chr X:81,756,909...81,794,661
G
Crlf3
cytokine receptor-like factor 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CRLF3 mRNA
CTD
PMID:19074003
NCBI chr10:65,024,228...65,060,746
Ensembl chr10:65,023,388...65,060,670
G
Csmd1
CUB and Sushi multiple domains 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CSMD1 mRNA
CTD
PMID:19074003
NCBI chr16:72,218,189...73,818,380
Ensembl chr16:72,218,503...73,817,614
G
Csnk1a1
casein kinase 1, alpha 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CSNK1A1 mRNA
CTD
PMID:19074003
NCBI chr18:55,017,049...55,050,184
Ensembl chr18:55,017,055...55,049,271
G
Cxcl10
C-X-C motif chemokine ligand 10
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CXCL10 mRNA testosterone undecanoate results in increased expression of CXCL10 mRNA
CTD
PMID:19074003
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
G
Cyp17a1
cytochrome P450, family 17, subfamily a, polypeptide 1
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CYP17A1 mRNA testosterone undecanoate results in decreased expression of CYP17A1 mRNA
CTD
PMID:19074003
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
G
Dap3
death associated protein 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of DAP3 mRNA
CTD
PMID:19074003
NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461
G
Dcn
decorin
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of DCN mRNA
CTD
PMID:19074003
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
G
Ddhd1
DDHD domain containing 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of DDHD1 mRNA
CTD
PMID:19074003
NCBI chr15:18,824,389...18,891,036
Ensembl chr15:18,824,394...18,890,952
G
Dlgap2
DLG associated protein 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of DLGAP2 mRNA
CTD
PMID:19074003
NCBI chr16:74,786,771...75,496,402
Ensembl chr16:74,791,509...75,496,407
G
Dnase1l3
deoxyribonuclease 1L3
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of DNASE1L3 mRNA testosterone undecanoate results in decreased expression of DNASE1L3 mRNA
CTD
PMID:19074003
NCBI chr15:16,922,335...16,948,322
Ensembl chr15:16,922,335...16,948,317
G
Dock8
dedicator of cytokinesis 8
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of DOCK8 mRNA
CTD
PMID:19074003
NCBI chr 1:222,649,309...222,842,474
Ensembl chr 1:222,649,309...222,842,474
G
Dok5
docking protein 5
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of DOK5 mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of DOK5 mRNA
CTD
PMID:19074003
NCBI chr 3:159,515,886...159,652,811
Ensembl chr 3:159,515,893...159,652,810
G
Dsg1
desmoglein 1
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of DSG1 mRNA testosterone undecanoate results in increased expression of DSG1 mRNA
CTD
PMID:19074003
NCBI chr18:11,674,687...11,705,383
Ensembl chr18:11,674,402...11,703,443
G
Elovl5
ELOVL fatty acid elongase 5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ELOVL5 mRNA
CTD
PMID:19074003
NCBI chr 8:78,790,846...78,857,307
Ensembl chr 8:78,790,846...78,857,284
G
Eprs1
glutamyl-prolyl-tRNA synthetase 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of EPRS1 mRNA
CTD
PMID:19074003
NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966
G
Etnk1
ethanolamine kinase 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ETNK1 mRNA
CTD
PMID:19074003
NCBI chr 4:176,126,056...176,170,325
Ensembl chr 4:176,126,180...176,193,770
G
Evi2b
ecotropic viral integration site 2B
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of EVI2B mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of EVI2B mRNA
CTD
PMID:19074003
NCBI chr10:64,472,693...64,474,311
Ensembl chr10:64,471,505...64,481,560
G
Fam20a
FAM20A, golgi associated secretory pathway pseudokinase
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of FAM20A mRNA
CTD
PMID:19074003
NCBI chr10:94,638,836...94,697,814
Ensembl chr10:94,642,850...94,697,672
G
Far2
fatty acyl CoA reductase 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of FAR2 mRNA
CTD
PMID:19074003
NCBI chr 4:180,973,968...181,087,862
Ensembl chr 4:181,007,622...181,087,255
G
Fbxl20
F-box and leucine-rich repeat protein 20
decreases expression
ISO
testosterone undecanoate results in decreased expression of FBXL20 mRNA
CTD
PMID:19074003
NCBI chr10:83,080,568...83,143,680
Ensembl chr10:83,086,551...83,144,162
G
Fcrl5
Fc receptor-like 5
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of FCRL5 mRNA testosterone undecanoate results in increased expression of FCRL5 mRNA
CTD
PMID:19074003
NCBI chr 2:172,881,763...172,912,912
Ensembl chr 2:172,881,448...172,913,148
G
Fermt2
FERM domain containing kindlin 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of FERMT2 mRNA
CTD
PMID:19074003
NCBI chr15:18,682,927...18,751,959
Ensembl chr15:18,682,927...18,751,811
G
Fkbp6
FKBP prolyl isomerase family member 6
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of FKBP6 mRNA testosterone undecanoate results in increased expression of FKBP6 mRNA
CTD
PMID:19074003
NCBI chr12:21,318,251...21,390,350
Ensembl chr12:21,319,568...21,390,350
G
Fmnl3
formin-like 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of FMNL3 mRNA
CTD
PMID:19074003
NCBI chr 7:130,454,270...130,505,626
Ensembl chr 7:130,454,275...130,505,626
G
Fnbp1
formin binding protein 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of FNBP1 mRNA
CTD
PMID:19074003
NCBI chr 3:14,309,067...14,424,378
Ensembl chr 3:14,309,640...14,424,881
G
Fut1
fucosyltransferase 1
decreases expression
ISO
testosterone undecanoate results in decreased expression of FUT1 mRNA
CTD
PMID:19074003
NCBI chr 1:96,086,934...96,090,352
Ensembl chr 1:96,086,635...96,090,616
G
Gdf10
growth differentiation factor 10
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of GDF10 mRNA testosterone undecanoate results in decreased expression of GDF10 mRNA
CTD
PMID:19074003
NCBI chr16:9,237,182...9,250,537
Ensembl chr16:9,237,261...9,249,343
G
Gdpd3
glycerophosphodiester phosphodiesterase domain containing 3
increases expression
ISO
testosterone undecanoate results in increased expression of GDPD3 mRNA
CTD
PMID:19074003
NCBI chr 1:181,373,505...181,383,063
Ensembl chr 1:181,366,626...181,383,063
G
Glyr1
glyoxylate reductase 1 homolog
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of GLYR1 mRNA
CTD
PMID:19074003
NCBI chr10:10,532,036...10,567,639
Ensembl chr10:10,532,154...10,567,637
G
Gpr135
G protein-coupled receptor 135
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of GPR135 mRNA
CTD
PMID:19074003
NCBI chr 6:90,627,533...90,630,661
Ensembl chr 6:90,629,178...90,630,551
G
Greb1
growth regulating estrogen receptor binding 1
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of GREB1 mRNA testosterone undecanoate results in decreased expression of GREB1 mRNA
CTD
PMID:19074003
NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633
G
Gzmk
granzyme K
increases expression
ISO
testosterone undecanoate results in increased expression of GZMK mRNA
CTD
PMID:19074003
NCBI chr 2:44,840,811...44,848,829
Ensembl chr 2:44,840,811...44,848,894
G
Herc4
HECT and RLD domain containing E3 ubiquitin protein ligase 4
decreases expression
ISO
testosterone undecanoate results in decreased expression of HERC4 mRNA
CTD
PMID:19074003
NCBI chr20:25,329,972...25,404,657
Ensembl chr20:25,330,280...25,404,657
G
Hmmr
hyaluronan-mediated motility receptor
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of HMMR mRNA testosterone undecanoate results in increased expression of HMMR mRNA
CTD
PMID:19074003
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
G
Hnrnpa3
heterogeneous nuclear ribonucleoprotein A3
decreases expression
ISO
testosterone undecanoate results in decreased expression of HNRNPA3 mRNA
CTD
PMID:19074003
NCBI chr 3:60,578,574...60,588,755
Ensembl chr 3:60,578,673...60,588,306
G
Hoxc6
homeo box C6
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of HOXC6 mRNA testosterone undecanoate results in increased expression of HOXC6 mRNA
CTD
PMID:19074003
NCBI chr 7:134,138,017...134,148,899
Ensembl chr 7:134,135,502...134,148,392
G
Hpcal4
hippocalcin-like 4
decreases expression
ISO
testosterone undecanoate results in decreased expression of HPCAL4 mRNA
CTD
PMID:19074003
NCBI chr 5:135,454,477...135,466,417
Ensembl chr 5:135,454,540...135,466,416
G
Hpgd
15-hydroxyprostaglandin dehydrogenase
increases expression
ISO
testosterone undecanoate results in increased expression of HPGD mRNA
CTD
PMID:19074003
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
G
Hspb9
heat shock protein family B (small) member 9
increases expression
ISO
testosterone undecanoate results in increased expression of HSPB9 mRNA
CTD
PMID:19074003
NCBI chr10:85,641,284...85,641,929
Ensembl chr10:85,641,284...85,641,929
G
Htr7
5-hydroxytryptamine receptor 7
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of HTR7 mRNA
CTD
PMID:19074003
NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
G
Ice2
interactor of little elongation complex ELL subunit 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ICE2 mRNA
CTD
PMID:19074003
NCBI chr 8:70,043,419...70,085,217
Ensembl chr 8:70,043,424...70,084,995
G
Ifi30
IFI30, lysosomal thiol reductase
increases expression
ISO
testosterone undecanoate results in increased expression of IFI30 mRNA
CTD
PMID:19074003
NCBI chr16:18,675,590...18,679,655
Ensembl chr16:18,675,613...18,681,175
G
Igfbp3
insulin-like growth factor binding protein 3
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of IGFBP3 mRNA testosterone undecanoate results in increased expression of IGFBP3 mRNA
CTD
PMID:19074003
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
G
Igsf1
immunoglobulin superfamily, member 1
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of IGSF1 mRNA testosterone undecanoate results in decreased expression of IGSF1 mRNA
CTD
PMID:19074003
NCBI chr X:129,069,891...129,085,331
Ensembl chr X:129,069,896...129,085,139
G
Igsf6
immunoglobulin superfamily, member 6
increases expression
ISO
testosterone undecanoate results in increased expression of IGSF6 mRNA
CTD
PMID:19074003
NCBI chr 1:175,610,167...175,620,662
Ensembl chr 1:175,610,167...175,620,722
G
Inha
inhibin subunit alpha
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of INHA mRNA testosterone undecanoate results in decreased expression of INHA mRNA
CTD
PMID:19074003
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
G
Insl3
insulin-like 3
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of INSL3 mRNA testosterone undecanoate results in decreased expression of INSL3 mRNA
CTD
PMID:19074003
NCBI chr16:18,398,682...18,400,566
Ensembl chr16:18,384,829...18,400,560
G
Insl6
insulin-like 6
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of INSL6 mRNA
CTD
PMID:19074003
NCBI chr 1:227,069,958...227,073,493
Ensembl chr 1:227,069,958...227,073,493
G
Itih4
inter-alpha-trypsin inhibitor heavy chain 4
increases expression
ISO
testosterone undecanoate results in increased expression of ITIH4 mRNA
CTD
PMID:19074003
NCBI chr16:6,080,539...6,095,710
Ensembl chr16:6,080,539...6,095,708
G
Katnal1
katanin catalytic subunit A1 like 1
increases expression
ISO
testosterone undecanoate results in increased expression of KATNAL1 mRNA
CTD
PMID:19074003
NCBI chr12:6,094,663...6,156,114
Ensembl chr12:6,102,836...6,157,553
G
Kbtbd7
kelch repeat and BTB domain containing 7
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of KBTBD7 mRNA
CTD
PMID:19074003
NCBI chr15:54,806,878...54,811,457
Ensembl chr15:54,806,873...54,811,687
G
Kcnh7
potassium voltage-gated channel subfamily H member 7
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of KCNH7 mRNA
CTD
PMID:19074003
NCBI chr 3:47,329,338...47,822,122
Ensembl chr 3:47,338,501...47,822,195
G
Kdsr
3-ketodihydrosphingosine reductase
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of KDSR mRNA
CTD
PMID:19074003
NCBI chr13:22,862,117...22,894,118
Ensembl chr13:22,862,117...22,894,108
G
Klhl11
kelch-like family member 11
increases expression
ISO
testosterone undecanoate results in increased expression of KLHL11 mRNA
CTD
PMID:19074003
NCBI chr10:85,398,487...85,409,049
Ensembl chr10:85,398,487...85,409,049
G
Klhl28
kelch-like family member 28
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of KLHL28 mRNA
CTD
PMID:19074003
NCBI chr 6:82,987,360...83,018,971
Ensembl chr 6:82,990,945...83,016,164
G
Klhl4
kelch-like family member 4
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of KLHL4 mRNA testosterone undecanoate results in decreased expression of KLHL4 mRNA
CTD
PMID:19074003
NCBI chr X:79,429,193...79,719,482
Ensembl chr X:79,622,113...79,719,480
G
Klk13
kallikrein related-peptidase 13
increases expression
ISO
testosterone undecanoate results in increased expression of KLK13 mRNA
CTD
PMID:19074003
NCBI chr 1:94,165,381...94,177,002
Ensembl chr 1:94,165,381...94,177,002
G
Limd1
LIM domain containing 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of LIMD1 mRNA
CTD
PMID:19074003
NCBI chr 8:123,121,363...123,168,476
Ensembl chr 8:123,122,460...123,167,714
G
Lingo1
leucine rich repeat and Ig domain containing 1
increases expression
ISO
testosterone undecanoate results in increased expression of LINGO1 mRNA
CTD
PMID:19074003
NCBI chr 8:57,011,272...57,193,496
Ensembl chr 8:57,010,007...57,196,544
G
Lmntd1
lamin tail domain containing 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of LMNTD1 mRNA
CTD
PMID:19074003
NCBI chr 4:178,354,302...178,588,483
Ensembl chr 4:178,354,137...178,588,477
G
Lrig2
leucine-rich repeats and immunoglobulin-like domains 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of LRIG2 mRNA
CTD
PMID:19074003
NCBI chr 2:191,947,322...192,012,996
Ensembl chr 2:191,949,819...192,012,579
G
Man2a1
mannosidase, alpha, class 2A, member 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of MAN2A1 mRNA
CTD
PMID:19074003
NCBI chr 9:104,252,001...104,408,349
Ensembl chr 9:104,252,001...104,408,349
G
Mbnl1
muscleblind-like splicing regulator 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of MBNL1 mRNA
CTD
PMID:19074003
NCBI chr 2:144,639,819...144,814,395
Ensembl chr 2:144,670,285...144,814,368
G
Mep1b
meprin A subunit beta
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of MEP1B mRNA
CTD
PMID:19074003
NCBI chr18:12,366,126...12,392,840
Ensembl chr18:12,365,289...12,392,840
G
Midn
midnolin
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of MIDN mRNA
CTD
PMID:19074003
NCBI chr 7:9,548,100...9,559,605
Ensembl chr 7:9,549,650...9,559,752
G
Mro
maestro
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of MRO mRNA testosterone undecanoate results in decreased expression of MRO mRNA
CTD
PMID:19074003
NCBI chr18:67,450,186...67,467,593
Ensembl chr18:67,450,595...67,467,044
G
Mrps6
mitochondrial ribosomal protein S6
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of MRPS6 mRNA
CTD
PMID:19074003
NCBI chr11:31,295,358...31,348,483
Ensembl chr11:31,295,614...31,348,484
G
Mtss1
MTSS I-BAR domain containing 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of MTSS1 mRNA
CTD
PMID:19074003
NCBI chr 7:90,488,751...90,628,007
Ensembl chr 7:90,488,754...90,627,968
G
Mysm1
myb-like, SWIRM and MPN domains 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of MYSM1 mRNA
CTD
PMID:19074003
NCBI chr 5:109,761,345...109,826,652
Ensembl chr 5:109,776,286...109,819,967
G
Nacc2
NACC family member 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of NACC2 mRNA
CTD
PMID:19074003
NCBI chr 3:8,879,952...8,946,660
Ensembl chr 3:8,883,065...8,946,660
G
Ndfip1
Nedd4 family interacting protein 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of NDFIP1 mRNA
CTD
PMID:19074003
NCBI chr18:30,265,808...30,316,068
Ensembl chr18:30,250,613...30,322,311
G
Nexn
nexilin (F actin binding protein)
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of NEXN mRNA
CTD
PMID:19074003
NCBI chr 2:241,186,783...241,218,315
Ensembl chr 2:241,186,790...241,218,342
G
Nid1
nidogen 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of NID1 mRNA
CTD
PMID:19074003
NCBI chr17:86,085,133...86,158,272
Ensembl chr17:86,085,077...86,158,267
G
Nsg1
neuronal vesicle trafficking associated 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of NSG1 mRNA
CTD
PMID:19074003
NCBI chr14:72,648,771...72,670,521
Ensembl chr14:72,648,741...72,670,514
G
Olfml3
olfactomedin-like 3
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of OLFML3 mRNA testosterone undecanoate results in decreased expression of OLFML3 mRNA
CTD
PMID:19074003
NCBI chr 2:191,244,221...191,247,050
Ensembl chr 2:191,244,221...191,247,050
G
Opn5
opsin 5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of OPN5 mRNA
CTD
PMID:19074003
NCBI chr 9:18,368,393...18,416,098
Ensembl chr 9:18,368,416...18,415,476
G
Or10j2
olfactory receptor family 10 subfamily J member 2
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of OR10J1 mRNA testosterone undecanoate results in increased expression of OR10J1 mRNA
CTD
PMID:19074003
NCBI chr13:85,723,300...85,724,290
Ensembl chr13:85,719,234...85,724,767
G
Osbpl10
oxysterol binding protein-like 10
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of OSBPL10 mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of OSBPL10 mRNA
CTD
PMID:19074003
NCBI chr 8:114,661,050...114,918,664
Ensembl chr 8:114,660,743...114,918,625
G
Pak3
p21 (RAC1) activated kinase 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PAK3 mRNA
CTD
PMID:19074003
NCBI chr X:107,116,308...107,374,342
Ensembl chr X:107,260,898...107,368,314
G
Pappa
pappalysin
decreases expression multiple interactions
ISO
testosterone undecanoate results in decreased expression of PAPPA mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PAPPA mRNA
CTD
PMID:19074003
NCBI chr 5:78,497,660...78,735,873
Ensembl chr 5:78,498,300...78,730,666
G
Pard6b
par-6 family cell polarity regulator beta
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PARD6B mRNA
CTD
PMID:19074003
NCBI chr 3:156,790,540...156,811,620
Ensembl chr 3:156,790,540...156,811,622
G
Pcdh7
protocadherin 7
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PCDH7 mRNA
CTD
PMID:19074003
NCBI chr14:52,471,801...52,901,696
Ensembl chr14:52,475,610...52,902,051 Ensembl chr14:52,475,610...52,902,051
G
Pde1c
phosphodiesterase 1C
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of PDE1C mRNA
CTD
PMID:19074003
NCBI chr 4:85,300,858...85,777,948
Ensembl chr 4:85,300,858...85,863,219
G
Pkp4
plakophilin 4
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PKP4 mRNA
CTD
PMID:19074003
NCBI chr 3:43,632,364...43,835,834
Ensembl chr 3:43,631,880...43,835,474
G
Plagl1
PLAG1 like zinc finger 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PLAGL1 mRNA
CTD
PMID:19074003
NCBI chr 1:7,477,295...7,517,229
Ensembl chr 1:7,477,177...7,517,228
G
Poglut1
protein O-glucosyltransferase 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of POGLUT1 mRNA
CTD
PMID:19074003
NCBI chr11:62,198,600...62,226,446
Ensembl chr11:62,198,513...62,226,434
G
Ppp2r2c
protein phosphatase 2, regulatory subunit B, gamma
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of PPP2R2C mRNA testosterone undecanoate results in increased expression of PPP2R2C mRNA
CTD
PMID:19074003
NCBI chr14:73,846,547...73,931,489
Ensembl chr14:73,846,547...73,931,864
G
Prkab1
protein kinase AMP-activated non-catalytic subunit beta 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of PRKAB1 mRNA
CTD
PMID:19074003
NCBI chr12:40,588,140...40,598,673
Ensembl chr12:40,588,211...40,598,661
G
Prkca
protein kinase C, alpha
increases expression
ISO
testosterone undecanoate results in increased expression of PRKCA mRNA
CTD
PMID:19074003
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
G
Ptbp2
polypyrimidine tract binding protein 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PTBP2 mRNA
CTD
PMID:19074003
NCBI chr 2:207,812,659...207,874,019
Ensembl chr 2:207,812,920...207,873,506
G
Ptger2
prostaglandin E receptor 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PTGER2 mRNA
CTD
PMID:19074003
NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714
G
Ptges
prostaglandin E synthase
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PTGES mRNA testosterone undecanoate results in decreased expression of PTGES mRNA
CTD
PMID:19074003
NCBI chr 3:14,177,892...14,189,236
G
Rab11fip3
RAB11 family interacting protein 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of RAB11FIP3 mRNA
CTD
PMID:19074003
NCBI chr10:15,002,650...15,086,382
Ensembl chr10:15,002,926...15,118,479
G
Rab1a
RAB1A, member RAS oncogene family
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of RAB1A mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of RAB1A mRNA
CTD
PMID:19074003
NCBI chr14:94,422,219...94,448,799
Ensembl chr14:94,415,275...94,448,248
G
Rapgef6
Rap guanine nucleotide exchange factor 6
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of RAPGEF6 mRNA
CTD
PMID:19074003
NCBI chr10:38,655,854...38,824,227
Ensembl chr10:38,655,867...38,823,211
G
Recql
RecQ like helicase
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of RECQL mRNA
CTD
PMID:19074003
NCBI chr 4:175,308,337...175,332,965
Ensembl chr 4:175,304,117...175,332,945
G
Rftn2
raftlin family member 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of RFTN2 mRNA
CTD
PMID:19074003
NCBI chr 9:56,651,617...56,707,830
Ensembl chr 9:56,630,460...56,707,810
G
Rln1
relaxin 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of RLN1 mRNA
CTD
PMID:19074003
NCBI chr 1:227,079,960...227,082,960
Ensembl chr 1:227,079,966...227,082,882
G
Rnaseh1
ribonuclease H1
decreases expression
ISO
testosterone undecanoate results in decreased expression of RNASEH1 mRNA
CTD
PMID:19074003
NCBI chr 6:45,282,849...45,292,258
Ensembl chr 6:45,282,854...45,292,236
G
Rnf216
ring finger protein 216
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of RNF216 mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of RNF216 mRNA
CTD
PMID:19074003
NCBI chr12:11,454,752...11,576,305
Ensembl chr12:11,454,797...11,576,304
G
Rnft1
ring finger protein, transmembrane 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of RNFT1 mRNA
CTD
PMID:19074003
NCBI chr10:71,310,052...71,322,507
Ensembl chr10:71,310,104...71,323,778
G
RT1-Bb
RT1 class II, locus Bb
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of HLA-DQB1 mRNA
CTD
PMID:19074003
NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597
G
Rtn4
reticulon 4
decreases expression
ISO
testosterone undecanoate results in decreased expression of RTN4 mRNA
CTD
PMID:19074003
NCBI chr14:103,450,074...103,497,687
Ensembl chr14:103,449,930...103,497,686
G
Saraf
store-operated calcium entry-associated regulatory factor
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SARAF mRNA
CTD
PMID:19074003
NCBI chr16:58,017,231...58,035,481
Ensembl chr16:58,017,231...58,035,545
G
Scaf4
SR-related CTD-associated factor 4
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SCAF4 mRNA
CTD
PMID:19074003
NCBI chr11:29,460,479...29,521,153
Ensembl chr11:29,465,106...29,521,153
G
Senp1
SUMO specific peptidase 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SENP1 mRNA
CTD
PMID:19074003
NCBI chr 7:129,163,173...129,226,766
Ensembl chr 7:129,165,774...129,221,598
G
Serpinb3
serpin family B member 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SERPINB3 mRNA
CTD
PMID:19074003
NCBI chr13:23,274,120...23,280,660
Ensembl chr13:23,274,484...23,313,682
G
Sfrp5
secreted frizzled-related protein 5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SFRP5 mRNA
CTD
PMID:19074003
NCBI chr 1:241,006,762...241,011,224
Ensembl chr 1:241,006,762...241,011,224
G
Skic3
SKI3 subunit of superkiller complex
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SKIC3 mRNA
CTD
PMID:19074003
NCBI chr 2:5,631,544...5,783,643
Ensembl chr 2:5,631,635...5,751,626
G
Slc16a9
solute carrier family 16, member 9
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SLC16A9 mRNA testosterone undecanoate results in decreased expression of SLC16A9 mRNA
CTD
PMID:19074003
NCBI chr20:18,335,862...18,377,125
Ensembl chr20:18,335,862...18,377,022
G
Slc25a2
solute carrier family 25 member 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SLC25A2 mRNA
CTD
PMID:19074003
NCBI chr18:29,452,943...29,456,324
Ensembl chr18:29,453,582...29,460,383
G
Slc2a5
solute carrier family 2 member 5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SLC2A5 mRNA
CTD
PMID:19074003
NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106
G
Slc6a5
solute carrier family 6 member 5
increases expression
ISO
testosterone undecanoate results in increased expression of SLC6A5 mRNA
CTD
PMID:19074003
NCBI chr 1:99,645,389...99,697,016
Ensembl chr 1:99,645,389...99,697,010
G
Smyd2
SET and MYND domain containing 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SMYD2 mRNA
CTD
PMID:19074003
NCBI chr13:101,425,270...101,466,576
Ensembl chr13:101,425,273...101,466,576
G
Snrpn
small nuclear ribonucleoprotein polypeptide N
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SNRPN mRNA
CTD
PMID:19074003
NCBI chr 1:111,101,327...111,123,400
Ensembl chr 1:111,101,329...111,123,634
G
Sobp
sine oculis binding protein homolog
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SOBP mRNA
CTD
PMID:19074003
NCBI chr20:46,482,265...46,661,452
Ensembl chr20:46,482,765...46,663,541
G
Spin4
spindlin family, member 4
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SPIN4 mRNA
CTD
PMID:19074003
NCBI chr X:59,888,728...59,892,817
Ensembl chr X:59,891,581...59,892,330
G
Sptbn1
spectrin, beta, non-erythrocytic 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SPTBN1 mRNA
CTD
PMID:19074003
NCBI chr14:103,841,713...104,016,900
Ensembl chr14:103,842,684...104,008,507
G
Srgn
serglycin
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SRGN mRNA testosterone undecanoate results in decreased expression of SRGN mRNA
CTD
PMID:19074003
NCBI chr20:30,442,810...30,479,549
Ensembl chr20:30,442,813...30,457,406
G
Srp68
signal recognition particle 68
increases expression
ISO
testosterone undecanoate results in increased expression of SRP68 mRNA
CTD
PMID:19074003
NCBI chr10:101,481,213...101,508,035
Ensembl chr10:101,481,212...101,508,035
G
Stxbp5l
syntaxin binding protein 5L
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of STXBP5L mRNA testosterone undecanoate results in increased expression of STXBP5L mRNA
CTD
PMID:19074003
NCBI chr11:63,334,667...63,654,270
Ensembl chr11:63,334,667...63,657,014
G
Syt11
synaptotagmin 11
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SYT11 mRNA
CTD
PMID:19074003
NCBI chr 2:174,206,032...174,232,540
Ensembl chr 2:174,206,191...174,231,964
G
Tfdp2
transcription factor Dp-2
decreases expression
ISO
testosterone undecanoate results in decreased expression of TFDP2 mRNA
CTD
PMID:19074003
NCBI chr 8:96,760,459...96,901,466
Ensembl chr 8:96,760,504...96,896,682
G
Thpo
thrombopoietin
increases expression
ISO
testosterone undecanoate results in increased expression of THPO mRNA
CTD
PMID:19074003
Ensembl chr11:80,182,820...80,188,167
G
Tmem217
transmembrane protein 217
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of TMEM217 mRNA
CTD
PMID:19074003
NCBI chr20:7,584,177...7,619,023
Ensembl chr20:7,592,627...7,619,111 Ensembl chr20:7,592,627...7,619,111
G
Tmem225
transmembrane protein 225
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of TMEM225 mRNA
CTD
PMID:19074003
NCBI chr 8:40,497,483...40,500,041
Ensembl chr 8:40,497,483...40,500,041
G
Tmem35a
transmembrane protein 35A
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of TMEM35A mRNA testosterone undecanoate results in decreased expression of TMEM35A mRNA
CTD
PMID:19074003
NCBI chr X:97,503,350...97,514,198
Ensembl chr X:97,503,350...97,514,197
G
Tmod2
tropomodulin 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of TMOD2 mRNA
CTD
PMID:19074003
NCBI chr 8:76,316,736...76,366,003
Ensembl chr 8:76,325,667...76,365,720
G
Tnrc6b
trinucleotide repeat containing adaptor 6B
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of TNRC6B mRNA
CTD
PMID:19074003
NCBI chr 7:112,252,351...112,469,829
Ensembl chr 7:112,252,359...112,461,790
G
Tra2a
transformer 2 alpha
decreases expression multiple interactions
ISO
testosterone undecanoate results in decreased expression of TRA2A mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of TRA2A mRNA
CTD
PMID:19074003
NCBI chr 4:78,220,838...78,239,737
Ensembl chr 4:78,220,883...78,239,712
G
Trmt13
tRNA methyltransferase 13 homolog
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of TRMT13 mRNA
CTD
PMID:19074003
NCBI chr 2:204,533,630...204,547,711
Ensembl chr 2:204,533,632...204,546,843
G
Tubb2a
tubulin, beta 2A class IIa
increases expression
ISO
testosterone undecanoate results in increased expression of TUBB2A mRNA
CTD
PMID:19074003
NCBI chr17:30,796,842...30,800,713
Ensembl chr17:30,747,503...30,800,714
G
Ubap1
ubiquitin-associated protein 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of UBAP1 mRNA
CTD
PMID:19074003
NCBI chr 5:56,520,722...56,561,153
Ensembl chr 5:56,520,743...56,561,152
G
Ube2d3
ubiquitin-conjugating enzyme E2D 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of UBE2D3 mRNA
CTD
PMID:19074003
NCBI chr 2:223,868,397...223,899,606
Ensembl chr 2:223,868,730...223,898,081
G
Unc13c
unc-13 homolog C
increases expression
ISO
testosterone undecanoate results in increased expression of UNC13C mRNA
CTD
PMID:19074003
NCBI chr 8:74,247,026...74,697,629
Ensembl chr 8:74,247,899...74,673,223
G
Xiap
X-linked inhibitor of apoptosis
decreases expression
ISO
testosterone undecanoate results in decreased expression of XIAP mRNA
CTD
PMID:19074003
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
G
Xylt1
xylosyltransferase 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of XYLT1 mRNA
CTD
PMID:19074003
NCBI chr 1:171,643,925...171,929,774
Ensembl chr 1:171,643,925...171,926,783
G
Yeats2
YEATS domain containing 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of YEATS2 mRNA
CTD
PMID:19074003
NCBI chr11:80,743,134...80,829,253
Ensembl chr11:80,743,134...80,829,208
G
Zcchc7
zinc finger CCHC-type containing 7
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ZCCHC7 mRNA
CTD
PMID:19074003
NCBI chr 5:58,992,558...59,173,308
Ensembl chr 5:58,993,290...59,173,300
G
Zeb2
zinc finger E-box binding homeobox 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ZEB2 mRNA
CTD
PMID:19074003
NCBI chr 3:29,214,581...29,344,890
Ensembl chr 3:29,218,301...29,345,157
G
Zfand6
zinc finger AN1-type containing 6
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ZFAND6 mRNA
CTD
PMID:19074003
NCBI chr 1:138,581,002...138,652,052
Ensembl chr 1:138,581,002...138,651,939
G
Zfp518a
zinc finger protein 518A
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ZNF518A mRNA
CTD
PMID:19074003
NCBI chr 1:239,719,305...239,744,978
Ensembl chr 1:239,719,505...239,744,979
G
Zfp638
zinc finger protein 638
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ZNF638 mRNA
CTD
PMID:19074003
NCBI chr 4:116,355,934...116,475,051
Ensembl chr 4:116,402,428...116,479,845
G
Zfr
zinc finger RNA binding protein
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ZFR mRNA
CTD
PMID:19074003
NCBI chr 2:61,137,611...61,200,322
Ensembl chr 2:61,137,611...61,200,322
G
Zkscan7
zinc finger with KRAB and SCAN domains 7
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of ZKSCAN7 mRNA
CTD
PMID:19074003
NCBI chr 8:122,501,938...122,519,600
Ensembl chr 8:122,502,218...122,519,600
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all
Path 1
CHEBI ontology
19808
chemical entity
19806
atom
19806
nonmetal atom
19744
carbon atom
19702
organic molecular entity
19702
lipid
17957
steroid
14678
steroid ester
1295
(17Z)-3,11-dioxopregna-4,17(20)-dien-21-oic acid methyl ester
0
(24R)ergosta-7, 22E-diene-3beta, 5alpha, 6beta-triol-3-O-palmitate
0
1,2-Dihydrohelvolic acid
0
10-Hydroxyestra-1,4-dien-3-one acetate
0
11-deoxycorticosterone-21-hemisuccinate
0
11-ketofusidic acid
0
11alpha,17beta-Dihydroxyandrost-4-en-3-one diacetate
0
11alpha-hydroxyprogesterone hemisuccinate +
0
11beta,17beta-Dihydroxyandrost-4-en-3-one 17-propionate
0
15-deacetylated citreohybridone E
0
16-Dehydropregnenolone acetate
0
16-O-propionyl-16-O-deacetylhelvolic acid
0
16alpha,17alpha-Epoxy-20-oxopregn-5-en-3beta-yl acetate
0
16alpha,17beta-Dihydroxyandrost-4-en-3-one dipropionate
0
16alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate
0
16beta-fluoro-17beta-hydroxyandrost-4-en-3-one propionate
0
17-Estradiol cyclooctyl acetate
0
17-Methylandrosta-4,6-diene-3beta,17beta-diol 3-acetate
0
17-Propylestra-1,3,5(10)-triene-3,17beta-diol diacetate
0
17-[[3-(1-Pyrrolidinyl)propyl]imino]androst-5-en-3beta-ol acetate
0
17beta-(Acetylthio)estra-1,3,5(10)-trien-3-ol acetate
0
17beta-(Hydroxymethyl)androst-4-en-3-one acetate
0
17beta-Hydroxy-4-mercaptoandrost-4-en-3-one 4-acetate 17-propionate
0
17beta-Hydroxy-5alpha-androstan-3-one cyclohexanecarboxylate
0
17beta-Hydroxy-6beta-methyl-5alpha-androstan-3-one propionate
0
17beta-Hydroxy-7alpha-methylandrost-4-en-3-one propionate
0
17beta-Hydroxyandrost-4-ene-3,11-dione propionate
0
17beta-Hydroxyestr-4-en-3-one benzoate
0
17beta-Hydroxyestr-4-en-3-one cyclopentanepropionate
0
17beta-Hydroxyestr-5(10)-en-3-one acetate
0
17beta-hydroxy-5alpha-androst-1-en-3-one propionate
0
17beta-hydroxy-5alpha-androstane acetate
0
19-Chloro-3beta-hydroxyandrost-5-en-17-one acetate
0
2-Methyl-5alpha-androst-2-en-17beta-ol acetate
0
21-acetoxy-11beta,17-dihydroxy-6alpha-methylpregn-4-ene-3,20-dione
0
22:2 Campesteryl ester
0
2alpha,17beta-Dihydroxyandrost-4-en-3-one dipropionate
0
2alpha,3alpha-(Difluoromethylene)-5alpha-androstan-17beta-ol acetate
0
2alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate
0
3,17-Androstanediol glucuronide
1
3,17beta-Diacetoxyestra-1,3,5(10)-trien-6-one
0
3,3-Difluoro-5alpha-androstan-17beta-yl acetate
0
3,7-diketocephalosporin P1
0
3-(Acetyloxy)-9-mercaptoandrosta-3,5-diene-11,17-dione
0
3-Acetoxypregn-16-en-12,20-dione
0
3-Acetyl-5alpha-androstane-3beta,17beta-diol 3-acetate
0
3-Ethoxyandrosta-3,5-dien-17beta-ol propanoate
0
3-Hydroxyvecuronium
0
3-Methoxy-16-methylestra-1,3,5(10)-triene-16beta,17beta-diol 17-acetate
0
3-acetyl ergosterol 5,8-endoperoxide
0
3-cyclopentylpropanoic acid [(13S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] ester
0
3-keto Fusidic acid
0
3alpha,12alpha-dihydroxy-5beta-pregnan-20-one diacetate
0
3alpha-Hydroxy-5beta-pregn-16-ene-11,20-dione 3-acetate
0
3beta,17-Dihydroxy-5alpha-pregnane-11,20-dione 3-acetate
0
3beta,19-Dihydroxyandrost-5-en-17-one 3-acetate
0
3beta,21-Dihydroxy-pregna-5,7,9(11)-trien-20-one diacetate
0
3beta-(Acetyloxy)-5alpha-androst-16-ene-16-carboxaldehyde
0
3beta-(Acetyloxy)-5beta-methyl-6beta-chloroestr-9-en-17-one
0
3beta-Hydroxy-17-oxoandrost-5-en-19-al acetate
0
3beta-Hydroxy-5alpha-pregnan-20-one acetate
0
3beta-Linoleyloxyergosta-7,24(28)-diene
0
3beta-linoleyloxyergosta-7-ene
0
4,4-Difluoro-17beta-hydroxyandrost-5-en-3-one propionate
0
4-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate
0
4-[[(3S,10R,13S,17S)-17-acetyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4-oxobutanoic acid
0
5alpha,17alpha-Pregn-2-en-20-yn-17-ol acetate
0
5alpha-Androstan-17beta-ol propionate
0
5alpha-Androstane-2alpha-fluoro-17beta-ol-3-one acetate
0
5alpha-Androstane-2beta-fluoro-17beta-ol-3-one acetate
0
5alpha-Androstane-3beta,17beta-diol diacetate
0
6-(Dibromomethylene)-17beta-hydroxy-androst-4-en-3-one propionate
0
6-O-propionyl-6-O-deacetylhelvolic acid
0
6alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one acetate
0
6alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate
0
6alpha-fluoro-17-hydroxycorticosterone 21-acetate
0
6alpha-hydroxyandrastin B
0
6alpha-hydroxyandrastin C
0
6beta,17beta-Dihydroxyandrost-4-en-3-one diacetate
0
6beta-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate
0
6beta-hydroxyprogesterone hemisuccinate
0
7-Desacetoxyhelvolic acid
0
9-fluoro-11beta,17,21-trihydroxy-2alpha-methylpregn-4-ene-3,20-dione 21-acetate
0
Andrastone C
0
Androst-4-ene-3alpha,17beta-diol diacetate
0
Androst-4-ene-3beta,17beta-diol diacetate
0
Androstane-3,17-diol dipropionate
1
Boldenone_Undecylenate
0
Bybetaochlamysol
0
Campestanyl-16:0
0
Campesterol ester(18:2)
0
Campesteryl alpha-linolenate
0
Campesteryl caffeate
0
Campesteryl elaidate
0
Campesteryl ferulate
0
Campesteryl p-coumarate
0
Citreohybriddione A
0
Citreohybriddione B
0
Citreohybriddione C
0
Citreohybridone A
0
Citreohybridone B
0
Citreohybridone D
0
Citreohybridone E
0
Citreohybridone F
0
Citreohybridone G
0
Citreohybridone J
0
Citreohybridone K
0
Citreohybridone L
0
Citreohybridonol
0
Clostebol acetate
0
Cyclic-3,20-bis(1,2-ethanediyl acetal)-11alpha-(acetyloxy)-5alpha,6alpha-epoxypregnane-3,20-dione
0
Deoxocitreohybridonol
0
Dihydrocitreohybridonol
0
Ergosta-7,22-dien-3beta-yl palmitate
0
Ergosta-7,22-diene-3beta-yl pentadecanoa
0
Erinarol D
0
Erinarol E
0
Erinarol F
0
Estra-1,3,5(10)-triene-3,16alpha-diol dipropionate
0
Estra-1,3,5(10)-triene-3,6alpha,17beta-triol triacetate
0
Estra-1,3,5(10)-triene-3,6beta,17beta-triol triacetate
0
Estradiol 17beta-cyclopentylpropionate
4
Estradiol dipropionate
5
Estradiol mustard
0
Estradiol valerate
0
Estradiol-17-phenylpropionate
0
Estriol tripropionate
0
Favolon
0
Favolon B
0
Fusaristerol B
0
Fusidate sodium
0
Ganolucidoid A
0
Ganolucidoid B
0
Helvolinic acid
0
Isocephalosporin P1
0
Isocitreohybridone A
0
Isocitreohybridone G
0
Isocitreohybridone H
0
Isocitreohybridone I
0
Isopenicin C
0
LSM-6672
0
Leucopaxillone B
0
Metenolone enanthate
0
Methandriol dipropionate
0
Methenolone acetate
0
Monodesacetylcephalosporin-P1
0
Nandrolone cyclohexanepropionate
0
Nandrolone decanoate
20
Nandrolone furylpropionate
0
Nisterime acetate
0
Norethindrone enanthate
3
Physapubescin
0
Pipecuronium
5
Pipecuronium bromide
0
Poriaprogesterol A
0
Pregna-5,16,20-triene-3beta,20-diol diacetate
0
Pregnenolone acetate
0
Resocortol butyrate
0
Stanolone benzoate
3
Telapristone acetate
0
Testosterone decanoate
0
Testosterone isocaproate
0
Testosterone phenylpropionate
0
Testosterone propionate
63
Trenbolone acetate
0
Tricholimbrin E
0
Viridomonic acid A
0
Viridomonic acid B
0
Ximaosteroid B
0
Xylariacin B
0
[(10R,13S,17R)-17-Ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
0
[(10R,13S,17S)-10,13-Dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] propanoate
0
[(3S,5S,9S,14S)-17-Acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
0
[(8S,11R,13S,14S,17S)-17-Acetyl-11-[4-(dimethylamino)phenyl]-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
0
acetic acid (3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl) ester
0
acetic acid [(2S,3S,5R,8S,9R,10R,13R,14R,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methyl-1-piperidin-1-iumyl)-2-(1-piperidinyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] ester
0
acetic acid [(3S,5S,10S,13S)-17-acetyl-10,13-dimethyl-12-oxo-1,2,3,4,5,6,7,8,9,11,14,15-dodecahydrocyclopenta[a]phenanthren-3-yl] ester
0
acetic acid [(3S,5S,9S,14S)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methyl-1-piperidin-1-iumyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] ester
0
acetic acid [2-[(3R,5R,10S,13S,17R)-3-acetyloxy-17-hydroxy-10,13-dimethyl-11-oxo-2,3,4,5,6,7,8,9,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] ester
0
alclometasone dipropionate
10
anagestone acetate
0
androstane ester +
0
beclomethasone dipropionate
0
benzoic acid [3-hydroxy-10-(hydroxymethyl)-13-methyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] ester
0
beta-Estradiol 17-acetate
0
beta-sitosterol 3-O-acetate
0
betamethasone acetate
0
betamethasone acibutate
0
betamethasone dipropionate +
1
betamethasone valerate
9
bolandiol dipropionate
0
bolmantalate
0
cholestane ester +
0
cortancyl
0
cyproterone acetate
69
digoxigenin 3,12-diacetate
0
dromostanolone propionate
0
ergostane ester +
0
estradiol acetate
0
estradiol enanthate
0
estradiol undecylate
0
estriol acetate benzoate
0
estriol succinate
0
ethynodiol diacetate
1
etiprednol dicloacetate
0
fluorometholone acetate
0
fluticasone furoate +
0
fluticasone propionate
0
fruticoside D
0
fruticoside E
0
fruticoside F
0
gitoxigenin 3-acetate
0
hydroxyestrone diacetate
0
kidjoranin-3-O-alpha-diginopyranosyl-(1->4)-beta-cymaropyranoside
0
kidjoranin-3-O-beta-digitoxopyranoside
0
lanostane ester +
0
loteprednol etabonate
2
lucibufagin C
0
medroxyprogesterone acetate
373
megestrol acetate
21
methyl spongoate
0
methylprednisolone acetate
0
mometasone furoate
17
nandrolone cyclotate
0
norgestimate
19
oleandrigenin +
5
oleandrigenin monodigitoxoside
0
oleandrin
5
pancuronium +
11
paraminabeolide B
0
paraminabeolide C
0
pentagestrone acetate
0
pentanoic acid [(13S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] ester
0
prasterone acetate
0
pregnane ester
0
pregnenolone succinate
0
quingestanol acetate
0
rapacuronium
1
steroid acid ester +
35
steroid sulfate +
63
sterol ester +
595
stigmasterol 3-O-acetate
0
testosterone ketolaurate
0
testosterone undecanoate
182
timobesone acetate
0
trenbolone hexahydrobenzylcarbonate
0
ulipristal acetate
0
ximaosteroid c
0
zhankuic acid A methyl ester
0
Path 2
CHEBI ontology
19808
subatomic particle
19806
composite particle
19806
hadron
19806
baryon
19806
nucleon
19806
atomic nucleus
19806
atom
19806
main group element atom
19756
p-block element atom
19756
carbon group element atom
19705
carbon atom
19702
organic molecular entity
19702
organic molecule
19655
organic cyclic compound
19468
organic polycyclic compound
17225
steroid
14678
steroid ester
1295
(17Z)-3,11-dioxopregna-4,17(20)-dien-21-oic acid methyl ester
0
(24R)ergosta-7, 22E-diene-3beta, 5alpha, 6beta-triol-3-O-palmitate
0
1,2-Dihydrohelvolic acid
0
10-Hydroxyestra-1,4-dien-3-one acetate
0
11-deoxycorticosterone-21-hemisuccinate
0
11-ketofusidic acid
0
11alpha,17beta-Dihydroxyandrost-4-en-3-one diacetate
0
11alpha-hydroxyprogesterone hemisuccinate +
0
11beta,17beta-Dihydroxyandrost-4-en-3-one 17-propionate
0
15-deacetylated citreohybridone E
0
16-Dehydropregnenolone acetate
0
16-O-propionyl-16-O-deacetylhelvolic acid
0
16alpha,17alpha-Epoxy-20-oxopregn-5-en-3beta-yl acetate
0
16alpha,17beta-Dihydroxyandrost-4-en-3-one dipropionate
0
16alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate
0
16beta-fluoro-17beta-hydroxyandrost-4-en-3-one propionate
0
17-Estradiol cyclooctyl acetate
0
17-Methylandrosta-4,6-diene-3beta,17beta-diol 3-acetate
0
17-Propylestra-1,3,5(10)-triene-3,17beta-diol diacetate
0
17-[[3-(1-Pyrrolidinyl)propyl]imino]androst-5-en-3beta-ol acetate
0
17beta-(Acetylthio)estra-1,3,5(10)-trien-3-ol acetate
0
17beta-(Hydroxymethyl)androst-4-en-3-one acetate
0
17beta-Hydroxy-4-mercaptoandrost-4-en-3-one 4-acetate 17-propionate
0
17beta-Hydroxy-5alpha-androstan-3-one cyclohexanecarboxylate
0
17beta-Hydroxy-6beta-methyl-5alpha-androstan-3-one propionate
0
17beta-Hydroxy-7alpha-methylandrost-4-en-3-one propionate
0
17beta-Hydroxyandrost-4-ene-3,11-dione propionate
0
17beta-Hydroxyestr-4-en-3-one benzoate
0
17beta-Hydroxyestr-4-en-3-one cyclopentanepropionate
0
17beta-Hydroxyestr-5(10)-en-3-one acetate
0
17beta-hydroxy-5alpha-androst-1-en-3-one propionate
0
17beta-hydroxy-5alpha-androstane acetate
0
19-Chloro-3beta-hydroxyandrost-5-en-17-one acetate
0
2-Methyl-5alpha-androst-2-en-17beta-ol acetate
0
21-acetoxy-11beta,17-dihydroxy-6alpha-methylpregn-4-ene-3,20-dione
0
22:2 Campesteryl ester
0
2alpha,17beta-Dihydroxyandrost-4-en-3-one dipropionate
0
2alpha,3alpha-(Difluoromethylene)-5alpha-androstan-17beta-ol acetate
0
2alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate
0
3,17-Androstanediol glucuronide
1
3,17beta-Diacetoxyestra-1,3,5(10)-trien-6-one
0
3,3-Difluoro-5alpha-androstan-17beta-yl acetate
0
3,7-diketocephalosporin P1
0
3-(Acetyloxy)-9-mercaptoandrosta-3,5-diene-11,17-dione
0
3-Acetoxypregn-16-en-12,20-dione
0
3-Acetyl-5alpha-androstane-3beta,17beta-diol 3-acetate
0
3-Ethoxyandrosta-3,5-dien-17beta-ol propanoate
0
3-Hydroxyvecuronium
0
3-Methoxy-16-methylestra-1,3,5(10)-triene-16beta,17beta-diol 17-acetate
0
3-acetyl ergosterol 5,8-endoperoxide
0
3-cyclopentylpropanoic acid [(13S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] ester
0
3-keto Fusidic acid
0
3alpha,12alpha-dihydroxy-5beta-pregnan-20-one diacetate
0
3alpha-Hydroxy-5beta-pregn-16-ene-11,20-dione 3-acetate
0
3beta,17-Dihydroxy-5alpha-pregnane-11,20-dione 3-acetate
0
3beta,19-Dihydroxyandrost-5-en-17-one 3-acetate
0
3beta,21-Dihydroxy-pregna-5,7,9(11)-trien-20-one diacetate
0
3beta-(Acetyloxy)-5alpha-androst-16-ene-16-carboxaldehyde
0
3beta-(Acetyloxy)-5beta-methyl-6beta-chloroestr-9-en-17-one
0
3beta-Hydroxy-17-oxoandrost-5-en-19-al acetate
0
3beta-Hydroxy-5alpha-pregnan-20-one acetate
0
3beta-Linoleyloxyergosta-7,24(28)-diene
0
3beta-linoleyloxyergosta-7-ene
0
4,4-Difluoro-17beta-hydroxyandrost-5-en-3-one propionate
0
4-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate
0
4-[[(3S,10R,13S,17S)-17-acetyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4-oxobutanoic acid
0
5alpha,17alpha-Pregn-2-en-20-yn-17-ol acetate
0
5alpha-Androstan-17beta-ol propionate
0
5alpha-Androstane-2alpha-fluoro-17beta-ol-3-one acetate
0
5alpha-Androstane-2beta-fluoro-17beta-ol-3-one acetate
0
5alpha-Androstane-3beta,17beta-diol diacetate
0
6-(Dibromomethylene)-17beta-hydroxy-androst-4-en-3-one propionate
0
6-O-propionyl-6-O-deacetylhelvolic acid
0
6alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one acetate
0
6alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate
0
6alpha-fluoro-17-hydroxycorticosterone 21-acetate
0
6alpha-hydroxyandrastin B
0
6alpha-hydroxyandrastin C
0
6beta,17beta-Dihydroxyandrost-4-en-3-one diacetate
0
6beta-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate
0
6beta-hydroxyprogesterone hemisuccinate
0
7-Desacetoxyhelvolic acid
0
9-fluoro-11beta,17,21-trihydroxy-2alpha-methylpregn-4-ene-3,20-dione 21-acetate
0
Andrastone C
0
Androst-4-ene-3alpha,17beta-diol diacetate
0
Androst-4-ene-3beta,17beta-diol diacetate
0
Androstane-3,17-diol dipropionate
1
Boldenone_Undecylenate
0
Bybetaochlamysol
0
Campestanyl-16:0
0
Campesterol ester(18:2)
0
Campesteryl alpha-linolenate
0
Campesteryl caffeate
0
Campesteryl elaidate
0
Campesteryl ferulate
0
Campesteryl p-coumarate
0
Citreohybriddione A
0
Citreohybriddione B
0
Citreohybriddione C
0
Citreohybridone A
0
Citreohybridone B
0
Citreohybridone D
0
Citreohybridone E
0
Citreohybridone F
0
Citreohybridone G
0
Citreohybridone J
0
Citreohybridone K
0
Citreohybridone L
0
Citreohybridonol
0
Clostebol acetate
0
Cyclic-3,20-bis(1,2-ethanediyl acetal)-11alpha-(acetyloxy)-5alpha,6alpha-epoxypregnane-3,20-dione
0
Deoxocitreohybridonol
0
Dihydrocitreohybridonol
0
Ergosta-7,22-dien-3beta-yl palmitate
0
Ergosta-7,22-diene-3beta-yl pentadecanoa
0
Erinarol D
0
Erinarol E
0
Erinarol F
0
Estra-1,3,5(10)-triene-3,16alpha-diol dipropionate
0
Estra-1,3,5(10)-triene-3,6alpha,17beta-triol triacetate
0
Estra-1,3,5(10)-triene-3,6beta,17beta-triol triacetate
0
Estradiol 17beta-cyclopentylpropionate
4
Estradiol dipropionate
5
Estradiol mustard
0
Estradiol valerate
0
Estradiol-17-phenylpropionate
0
Estriol tripropionate
0
Favolon
0
Favolon B
0
Fusaristerol B
0
Fusidate sodium
0
Ganolucidoid A
0
Ganolucidoid B
0
Helvolinic acid
0
Isocephalosporin P1
0
Isocitreohybridone A
0
Isocitreohybridone G
0
Isocitreohybridone H
0
Isocitreohybridone I
0
Isopenicin C
0
LSM-6672
0
Leucopaxillone B
0
Metenolone enanthate
0
Methandriol dipropionate
0
Methenolone acetate
0
Monodesacetylcephalosporin-P1
0
Nandrolone cyclohexanepropionate
0
Nandrolone decanoate
20
Nandrolone furylpropionate
0
Nisterime acetate
0
Norethindrone enanthate
3
Physapubescin
0
Pipecuronium
5
Pipecuronium bromide
0
Poriaprogesterol A
0
Pregna-5,16,20-triene-3beta,20-diol diacetate
0
Pregnenolone acetate
0
Resocortol butyrate
0
Stanolone benzoate
3
Telapristone acetate
0
Testosterone decanoate
0
Testosterone isocaproate
0
Testosterone phenylpropionate
0
Testosterone propionate
63
Trenbolone acetate
0
Tricholimbrin E
0
Viridomonic acid A
0
Viridomonic acid B
0
Ximaosteroid B
0
Xylariacin B
0
[(10R,13S,17R)-17-Ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
0
[(10R,13S,17S)-10,13-Dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] propanoate
0
[(3S,5S,9S,14S)-17-Acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
0
[(8S,11R,13S,14S,17S)-17-Acetyl-11-[4-(dimethylamino)phenyl]-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
0
acetic acid (3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl) ester
0
acetic acid [(2S,3S,5R,8S,9R,10R,13R,14R,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methyl-1-piperidin-1-iumyl)-2-(1-piperidinyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] ester
0
acetic acid [(3S,5S,10S,13S)-17-acetyl-10,13-dimethyl-12-oxo-1,2,3,4,5,6,7,8,9,11,14,15-dodecahydrocyclopenta[a]phenanthren-3-yl] ester
0
acetic acid [(3S,5S,9S,14S)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methyl-1-piperidin-1-iumyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] ester
0
acetic acid [2-[(3R,5R,10S,13S,17R)-3-acetyloxy-17-hydroxy-10,13-dimethyl-11-oxo-2,3,4,5,6,7,8,9,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] ester
0
alclometasone dipropionate
10
anagestone acetate
0
androstane ester +
0
beclomethasone dipropionate
0
benzoic acid [3-hydroxy-10-(hydroxymethyl)-13-methyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] ester
0
beta-Estradiol 17-acetate
0
beta-sitosterol 3-O-acetate
0
betamethasone acetate
0
betamethasone acibutate
0
betamethasone dipropionate +
1
betamethasone valerate
9
bolandiol dipropionate
0
bolmantalate
0
cholestane ester +
0
cortancyl
0
cyproterone acetate
69
digoxigenin 3,12-diacetate
0
dromostanolone propionate
0
ergostane ester +
0
estradiol acetate
0
estradiol enanthate
0
estradiol undecylate
0
estriol acetate benzoate
0
estriol succinate
0
ethynodiol diacetate
1
etiprednol dicloacetate
0
fluorometholone acetate
0
fluticasone furoate +
0
fluticasone propionate
0
fruticoside D
0
fruticoside E
0
fruticoside F
0
gitoxigenin 3-acetate
0
hydroxyestrone diacetate
0
kidjoranin-3-O-alpha-diginopyranosyl-(1->4)-beta-cymaropyranoside
0
kidjoranin-3-O-beta-digitoxopyranoside
0
lanostane ester +
0
loteprednol etabonate
2
lucibufagin C
0
medroxyprogesterone acetate
373
megestrol acetate
21
methyl spongoate
0
methylprednisolone acetate
0
mometasone furoate
17
nandrolone cyclotate
0
norgestimate
19
oleandrigenin +
5
oleandrigenin monodigitoxoside
0
oleandrin
5
pancuronium +
11
paraminabeolide B
0
paraminabeolide C
0
pentagestrone acetate
0
pentanoic acid [(13S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] ester
0
prasterone acetate
0
pregnane ester
0
pregnenolone succinate
0
quingestanol acetate
0
rapacuronium
1
steroid acid ester +
35
steroid sulfate +
63
sterol ester +
595
stigmasterol 3-O-acetate
0
testosterone ketolaurate
0
testosterone undecanoate
182
timobesone acetate
0
trenbolone hexahydrobenzylcarbonate
0
ulipristal acetate
0
ximaosteroid c
0
zhankuic acid A methyl ester
0